US20110177011A1 - Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds - Google Patents

Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds Download PDF

Info

Publication number
US20110177011A1
US20110177011A1 US12/018,573 US1857308A US2011177011A1 US 20110177011 A1 US20110177011 A1 US 20110177011A1 US 1857308 A US1857308 A US 1857308A US 2011177011 A1 US2011177011 A1 US 2011177011A1
Authority
US
United States
Prior art keywords
mono
alkylamino
alkyl
alkoxy
alkylcarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/018,573
Inventor
Kevin S. Currie
Robert W. DeSimone
Scott A. Mitchell
Douglas A. Pippin
James W. Darrow
Xiaobing Qian
Mark Velleca
Dapeng Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/018,573 priority Critical patent/US20110177011A1/en
Publication of US20110177011A1 publication Critical patent/US20110177011A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • Certain imidazo[1,2-a]pyrazin-8-ylamine and related compounds which when appropriately substituted are inhibitors of tyrosine kinase activity, including Bruton's tyrosine kinase (Btk) activity, are provided herein. Certa in compounds provided herein are highly active and/or specific inhibitors of Btk activity. Pharmaceutical compositions comprising such compounds, and methods of using certain imidazo[1,2-a]pyrazin-8-ylamine and related compounds to treat a variety of diseases responsive to inhibition of Btk activity and/or inhibition of B-cell proliferation, are also disclosed. Additionally, methods for using such compounds as probes for the detection and/or localization of Btk in biological samples are given.
  • Protein kinases the largest family of human enzymes, encompass well over 500 proteins. Kinases play critical roles in signaling pathways controlling fundamental cellular processes such as proliferation, differentiation, and death (apoptosis). Abnormal kinase activity has been implicated in a wide range of diseases, including multiple cancers and autoimmune and inflammatory diseases. The multifaceted role of kinases in key cell signaling pathways provides a significant opportunity to identify novel drugs targeting kinases and signaling pathways. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion, and angiogenesis associated with tumor growth.
  • kinases are key regulators they are ideal drug design targets. Inhibitors of kinases are among the most important classes of pharmaceutical compounds known. Highly specific, cell-permeable inhibitors of one or more individual kinases are useful for the treatment of various kinase-implicated diseases. Kinase inhibiting compounds are additionally useful for the systematic investigation of the cellular function of one or more kinases, and thus, provide valuable tools for the identification of various kinases of therapeutic interest.
  • Bruton's Tyrosine Kinase (Btk) is a member of the Tec family of tyrosine kinases, and is a critical regulator of early B-cell development as well as mature B-cell activation, signaling and survival.
  • B-cell signaling through the B-cell receptor leads to a wide range of biological outputs, which in turn depend on the developmental stage of the B-cell.
  • the magnitude and duration of BCR signals must be precisely regulated.
  • Aberrant BCR-mediated signaling can cause disregulated B-cell proliferation and/or the formation of pathogenic auto-antibodies leading to multiple autoimmune and/or inflammatory diseases.
  • Mutation of Btk in humans results in X-linked agammaglobulinaemia (XLA). This disease is associated with the impaired maturation of B-cells, diminished immunoglobulin production, comprised T-cell-independent immune responses and marked attenuation of the sustained calcium sign upon BCR stimulation.
  • XLA X-linked agammaglobulinaemia
  • Btk-deficient mice evidence for the role of Btk in autoimmune and/or inflammatory disease has been established in Btk-deficient mouse models. For example, in standard murine preclinical models of systemic lupus erythematosus (SLE), Btk deficiency has been shown to result in a marked amelioration of disease progression. Moreover, Btk deficient mice are also resistant to developing collagen-induced arthritis and are less susceptible to Staphylococcus-induced arthritis.
  • SLE systemic lupus erythematosus
  • B-cells and the humoral immune system in the pathogenesis of autoimmune and/or inflammatory diseases.
  • Protein-based therapeutics such as Rituxan
  • Btk Because of Btk's role in B-cell activation, inhibitors of Btk are useful as inhibitors of B-cell mediated pathogenic activity (such as autoantibody production).
  • Btk is also expressed in mast cells and monocytes and has been shown to be important for the function of these cells.
  • Btk deficiency in mice is associated with impaired IgE-mediated mast cell activation (marked diminution of TNF ⁇ and other inflammatory cytokine release), and greatly reduced TNF ⁇ production by activated monocytes.
  • Btk activity is useful for the treatment of autoimmune and/or inflammatory diseases such as: SLE, rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, and asthma.
  • autoimmune and/or inflammatory diseases such as: SLE, rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, and asthma.
  • ITP idiopathic thrombocytopenic purpura
  • myasthenia gravis myasthenia gravis
  • Agents capable of inhibiting Btk kinase activity are highly desirable for the treatment of a variety of diseases, including cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
  • Specific, cell-penetrating, small molecule, non-peptide antagonists of Btk are of particular value for such therapies.
  • Such compounds are also useful for the systematic investigation of the cellular function of Btk, and thus, are valuable research tools for the identification of cell signalling proteins of therapeutic interest.
  • the present invention fulfills this need, and provides further related advantages.
  • Inhibitors of kinase activity which may generally be described as imidazo[1,2-a]pyrazin-8-ylamines and related compounds, are disclosed herein. Certain compounds provided herein are highly active and/or specific inhibitors of Btk (Bruton's tyrosine kinase) activity.
  • Btk Brunauer's tyrosine kinase
  • A is 0 or 1.
  • R 1 is phenyl or heteroaryl, each of which is optionally substituted with one of
  • L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 alkyl)(C ⁇ O)—
  • G is heterocycloalkyl, C 3 -C 7 cycloalkyl, aryl, or heteroaryl.
  • R 1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -
  • R 2 is C 1 -C 7 alkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkoxy, (heterocycloalkyl)C 0 -C 2 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 2 alkyl, or R 2 is (phenyl)C 0 -C 2 alkyl, (phenoxy)C 0 -C 2 alkyl, or (heteroaryl)C 0 -C 2 alkyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO 2 NH 2 , oxo, —COOH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 2 -C 6 alkanoyl, C 1 -C 6 hydroxyalkyl,
  • R 4 is hydrogen, or R 4 is C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl, each of which is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 6 alkylthio, (C 1 -C 6 alkoxy)C 1 -C 6 alkoxy, aminoC 1 -C 6 alkyl, mono- and di-C 1 -C 6 alkylamino, and —C(O)R 14 wherein R 14 is C 1 -C 6 alkyl, C 1 -C 3 haloalky
  • Q is phenyl or pyridyl.
  • R 3 is hydrogen, C 1 -C 7 alkyl, or halogen, or
  • R 3 is heterocycloalkyl, C 3 -C 7 cycloalkyl, or heteroaryl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO 2 NH 2 , oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 3 halooalkyl, C 1 -C 3 haloalkoxy, C 1 -C 6 alkylthio, (C 1 -C 6 -alkoxy)C 1 -C 6 alkoxy, mono- and di-C 1 -C 6 alkylamino, aminoC 1 -C 6 alkyl, and —C(O)R 14 .
  • compounds of Formula I-a which exhibit an IC 50 of 1 micromolar or less, 100 nanomolar or less, or 10 nanomolar or less in standard biochemical assay for Btk activity, such as the biochemical assay described in Example 6, are provided herein.
  • Preferred compounds described herein are highly active inhibitors of B-cell proliferation. For example certain compounds described herein exhibit an IC 50 value less than or equal to 10 micromolar, or an IC 50 value less than or equal to 1 micromolar, or an IC 50 value less than or equal to 500 nM in the tritiated thymidine incorporation assay for B-cell proliferation described in Example 8.
  • Preferred compounds described herein are specific inhibitors of B-cell proliferation, exhibiting an IC 50 value that is at least 3-fold, preferably 5-fold, and more preferably 10-fold greater for T-cell proliferation than the IC 50 for B-cell proliferation.
  • the IC 50 for T-cell proliferation may be determined via a standard assay for T-cell proliferation such as the thymidine incorporation assay of Example 9.
  • compositions comprising one or more compounds of Formula I-a, or any pharmaceutically acceptable form thereof, together with at least one pharmaceutically acceptable carrier or excipient, are provided herein.
  • kits which comprise a pharmaceutical composition, comprising one or more compounds of Formula I-a or any pharmaceutically acceptable form thereof, together with at least one pharmaceutically acceptable carrier or excipient in a container and with instructions for using the pharmaceutical composition to treat a patient.
  • the instructions are for using the pharmaceutical composition to treat a patient suffering from a disease responsive to inhibition of Btk activity.
  • Still other embodiments pertain to a method of inhibiting Btk kinase.
  • the method comprises contacting a cell or cells expressing Btk, either in vivo or in vitro, with a compound of Formula I-a or form thereof in an amount sufficient to detectably inhibit Btk activity in vitro.
  • Inhibiting Btk activity can effectively inhibit B-cell proliferation.
  • Small molecule (less than 600 amu) Btk inhibitors that are orally bioavailable, such as certain compounds and forms of Formula I-a, are particularly desirable for this purpose.
  • a method of inhibiting B-cell proliferation by contacting cells expressing Btk, either in vivo or in vitro with a compound having a molecular weight less than 600 amu in an amount sufficient to detectably inhibit the activity of Btk in vitro is provided herein.
  • the compound will be a heterocyclic compound, such as a heterocyclic compound having a bicyclic heterocyclic group.
  • the compound is a compound of Formula I-a.
  • a method of treating a mammal suffering from at least one disease responsive to inhibition of Btk activity, by administering to the mammal an effective amount of a compound that is a highly active Btk inhibitor in an in vitro assay of Btk activity is included herein.
  • the compound is also a specific inhibitor of B-cell proliferation, exhibiting an IC 50 value that is at least 3-fold, preferably 5-fold, and more preferably 10-fold greater for T-cell proliferation than the IC 50 value for B-cell proliferation.
  • Methods for treating a patient having a disease responsive to inhibition of Btk activity and/or responsive to inhibition of B-cell proliferation comprise administering to the patient an effective amount of a compound or form thereof of Formula I-a.
  • the patient may be a mammal.
  • the patient is a human patient, however methods of treating non-human patients are included herein.
  • the patient is a companion animal, such as a cat or dog, or the patient is a livestock animal, such as a horse, cow, or pig.
  • Particularly included herein are methods in which the disease responsive to Btk inhibition is cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
  • Methods of treatment include administering a compound of Formula I-a as a single active agent or administering a compound of Formula I-a in combination with one or more other active agents.
  • Formula I-a includes all subformulae thereof.
  • Formula I-a includes compounds of Formulas 1 to 9.
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium and isotopes of carbon include 11 C, 13 C, and 14 C.
  • substituted means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded.
  • substituent is oxo (i.e., ⁇ O)
  • 2 hydrogens on the atom are replaced.
  • aromatic moieties are substituted by an oxo group
  • the aromatic ring is replaced by the corresponding partially unsaturated ring.
  • a pyridyl group substituted by oxo is a pyridone.
  • Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates.
  • a stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent.
  • Suitable groups that may be present on a “substituted” position include, but are not limited to, e.g., halogen; cyano; hydroxyl; nitro; azido; alkanoyl (such as a C 2 -C 6 alkanoyl group such as acyl or the like); carboxamido; alkyl groups (typically having 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms); cycloalkyl groups, alkenyl and alkynyl groups (including groups having one or more unsaturated linkages and from 2 to about 8, or 2 to about 6 carbon atoms); alkoxy groups having one or more oxygen linkages and from 1 to about 8, or from 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those having one or more thioether linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those having one
  • a dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
  • —CHO is attached through carbon of the carbonyl (C ⁇ O) group.
  • alkyl includes both branched and straight chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms, generally from 1 to about 12 carbon atoms.
  • the term C 1 -C 7 alkyl as used herein indicates an alkyl group having from 1 to 7 carbon atoms.
  • C 0 -C n alkyl is used herein in conjunction with another group, for example, (heterocycloalkyl)C 0 -C 2 alkyl
  • the indicated group in this case heterocycloalkyl, is either directly bound by a single covalent bond (C 0 ), or attached by an alkyl chain having the specified number of carbon atoms, in this case from 1 to 2 carbon atoms.
  • alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t-butyl, n-pentyl, and sec-pentyl.
  • Alkyl groups described herein typically have from 1 to about 12 carbons atoms.
  • Preferred alkyl groups are lower alkyl groups, those alkyl groups having from 1 to about 8 carbon atoms, from 1 to about 6 carbon atoms, or from 1 to about 4 carbons atoms e.g. C 1 -C 8 , C 1 -C 6 , and C 1 -C 4 alkyl groups.
  • Alkenyl indicates a straight or branched hydrocarbon chain comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point along the chain.
  • Alkenyl groups described herein typically have from 2 to about 12 carbons atoms.
  • Preferred alkenyl groups are lower alkenyl groups, those alkenyl groups having from 2 to about 8 carbon atoms, e.g. C 2 -C 8 , C 2 -C 6 , and C 2 -C 4 alkenyl groups.
  • Examples of alkenyl groups include ethenyl, propenyl, and butenyl groups.
  • Alkynyl indicates a straight or branched hydrocarbon chain comprising one or more triple carbon-carbon bonds that may occur in any stable point along the chain, such as ethynyl and propynyl.
  • Alkynyl groups described herein typically have from 2 to about 12 carbons atoms.
  • Preferred alkynyl groups are lower alkynyl groups; those alkynyl groups having from 2 to about 8 carbon atoms, e.g. C 2 -C 8 , C 2 -C 6 , and C 2 -C 4 alkynyl groups.
  • Alkoxy indicates an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge (—O—).
  • alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.
  • (Alkoxy)alkyl alkoxy and alkyl are as defined above and the point of attachment is on the alkyl group.
  • (C 1 -C 6 alkoxy)C 1 -C 6 alkyl indicates an alkoxy group having from 1 to about 6 carbon atom attached through its oxygen atom to an alkyl group having from 1 to about 6 carbon atoms and further attached to the core molecule through a carbon atom in the C 1 -C 6 alkyl portion.
  • Alkanoyl indicates an alkyl group as defined above, attached through a keto (—(C ⁇ O)—) bridge. Alkanoyl groups have the indicated number of carbon atoms, with the carbon of the keto group being included in the numbered carbon atoms. For example a C 2 alkanoyl group is an acetyl group having the formula CH 3 (C ⁇ O)—.
  • alkylthio means alkyl-S—, where the alkyl group is an alkyl group as defined above having the defined number of carbon atoms.
  • An exemplary alkylthio group is methylthio.
  • aminoalkyl is an alkyl group as defined herein, having the indicated number of carbon atoms, and substituted with at least one amino substituent (—NH 2 ). When indicated, aminoalkyl groups, like other groups described herein, may be additionally substituted.
  • the term “mono- and/or di-alkylamino” indicates secondary or tertiary alkyl amino groups, wherein the alkyl groups are as defined above and have the indicated number of carbon atoms. The point of attachment of the alkylamino group is on the nitrogen.
  • the alkyl groups are independently chosen. Examples of mono- and/or di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino.
  • “Mono- and/or di-alkylaminoalkyl” groups are mono- and/or di-alkylamino groups attached through an alkyl linker having the specified number of carbon atoms, for example a di-methylaminoethyl group.
  • Tertiary amino substituents may by designated by nomenclature of the form N—R—N—R′, indicating that the groups R and R′ are both attached to a single nitrogen atom.
  • the term “mono- and/or di-(alkylamino)allyl” indicates a mono- and/or di-alkylamino group as defined attached through an alkyl linker having the specified number of carbon atoms.
  • “mono- and/or di-(alkylamino)alkoxy” indicates a mono- and/or di-alkylamino group as defined attached through an alkoxy linker having the specified number of carbon atoms.
  • di-alkylcarboxamide refers to groups of formula (alkyl 1 )-NH—(C ⁇ O)— and (alkyl 1 )(alkyl 2 )-N—(C ⁇ O)— in which the alkyl 1 and alkyl 2 groups are independently chosen alkyl groups as defined above having the indicated number of carbon atoms.
  • Carboxamide is a group of the formula —(C ⁇ O)NH 2 .
  • aryl indicates aromatic groups containing only carbon in the aromatic ring or rings. Such aromatic groups may be further substituted with carbon or non-carbon atoms or groups. Typical aryl groups contain 1 or 2 separate, fused, or pendant rings and from 6 to about 12 ring atoms, without heteroatoms as ring members. Where indicated, aryl groups may be substituted. Such substitution may include fusion to a 5 to 7-membered saturated cyclic group that optionally contains 1 or 2 heteroatoms independently chosen from N, O, and S, to form, for example, a 3,4-methylenedioxy-phenyl group.
  • Aryl groups include, for example, phenyl, naphthyl, including 1-naphthyl and 2-naphthyl, and bi-phenyl.
  • Cycloalkyl indicates a monocyclic or multicyclic saturated hydrocarbon ring group, having the specified number of carbon atoms, usually from 3 to about 10 ring carbon atoms. Monocyclic cycloalkyl groups typically have from 3 to about 8 carbon ring atoms or from 3 to about 7 carbon ring atoms. Multicyclic cycloalkyl groups may have 2 or 3 fused cycloalkyl rings or contain bridged or caged cycloalkyl groups. Cycloalkyl substituents may be pendant to the substituted nitrogen or carbon atom, or where a substituted carbon atom may have two substituents a cycloalkyl group may be attached as a spiro group.
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl as well as bridged or caged saturated ring groups such as norbornane or adamantane.
  • (cycloalkyl)C 0 -C 2 alkyl indicates a cycloalkyl groups as defined above either directly attached via a single covalent bond or attached through an ethylene (—CH 2 CH 2 —) or methylene (—CH 2 —) linker.
  • haloalkyl indicates both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, generally up to the maximum allowable number of halogen atoms.
  • haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.
  • Haloalkoxy indicates a haloalkyl group as defined above attached through an oxygen bridge.
  • Halo or “halogen” as used herein refers to fluoro, chloro, bromo, and/or iodo.
  • heteroaryl indicates a stable 5- to 7-membered monocyclic aromatic ring which contains from 1 to 4, or preferably from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5 to 7 membered aromatic ring which contains from 1 to 4, or preferably from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heteroaryl group is not more than 2. It is particularly preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • heteroaryl groups include, but are not limited to, oxazolyl, pyranyl, pyrazinyl, pyrazolopyrimidinyl, pyrazolyl, pyridizinyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienylpyrazolyl, thiophenyl, triazolyl, benzo[d]oxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxadiazolyl, dihydrobenzodioxynyl, furanyl, imidazolyl, indolyl, and isoxazolyl.
  • heterocycloalkyl indicates a saturated monocyclic group containing from 1 to about 3 heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a saturated bicyclic ring system having at least one N, O, or S ring atom with remaining atoms being carbon.
  • Monocyclic heterocycloalkyl groups have from 4 to about 8 ring atoms, and more typically have from 5 to 7 ring atoms.
  • Bicyclic heterocycloalkyl groups typically have from about five to about 12 ring atoms.
  • Preferred heterocycloalkyl groups include monocyclic heterocycloalkyl groups that contain from 5 to 7 ring atoms and 1 or 2 heteroatoms independently chosen from N, O, and S. Examples of heterocycloalkyl groups include morpholinyl, piperazinyl, piperidinyl, and pyrrolidinyl groups.
  • heterocycloalkyl alkyl the groups heterocycloalkyl and alkyl are as defined above and the point of attachment to the core structure is on the alkyl group.
  • hydroxyalkyl is an alkyl group as defined herein, having the indicated number of carbon atoms, and substituted with at least one hydroxyl substituent (—OH).
  • hydroxyalkyl groups like other groups described herein, may be additionally substituted.
  • hydroxyalkoxy indicates an alkoxy group as defined herein, having the indicated number of carbon atoms, and substituted with at least one hydroxyl substituent (—OH).
  • “Pharmaceutically acceptable forms” of the compounds recited herein include pharmaceutically acceptable salts, hydrates, solvates, crystal forms, polymorphs, chelates, non-covalent complexes, esters, clathrates, prodrugs, and mixtures of such compounds.
  • Pharmaceutically acceptable salts are a preferred pharmaceutically acceptable form.
  • “Pharmaceutically acceptable salts” include derivatives of the disclosed compounds wherein the parent compound is modified by making non-toxic acid or base salts thereof, and further refers to pharmaceutically acceptable solvates of such compounds and such salts.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC—(CH 2 ) n —COOH where n is 0-4, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phospho
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).
  • prodrugs includes any compounds that become compounds of Formula I-a when administered to a mammalian subject, e.g., upon metabolic processing of the prodrug.
  • prodrugs include, but are not limited to, acetate, formate and benzoate and like derivatives of functional groups (such as alcohol or amine groups) in the compounds of Formula I-a.
  • active agent is used to indicate a compound, including any pharmaceutically form thereof, or natural product, which has biological activity.
  • an “active agent” is a compound having pharmaceutical utility.
  • an active agent may be a compound of Formula I-a, or an anti-cancer or anti-inflammatory therapeutic, which is not a compound of Formula I-a.
  • an effective amount of a compound of this invention means an amount effective, when administered to a human or non-human patient, to provide a therapeutic benefit such as amelioration of symptoms, slowing of disease progression, or prevention of disease e.g., an effective amount may be an amount sufficient to decrease the symptoms of a disease responsive to Btk inhibition, and preferably is an amount sufficient to reduce cancer symptoms, the symptoms of an autoimmune and/or inflammatory disease, or the symptoms of an acute inflammatory reaction.
  • an effective amount of a compound described herein is an amount sufficient to decrease the number of detectable cancerous cells in an organism, detectably slow or stop the growth of a cancerous tumor, or more preferably an amount sufficient to shrink a cancerous tumor.
  • a therapeutically effective amount of a compound is also an amount sufficient to prevent a significant increase or significantly reduce the detectable level of cancerous cells or cancer markers in the patient's blood, serum, or tissues.
  • an effective amount may also be an amount sufficient, when administered to a patient, to detectably slow progression of the disease, or prevent the patient to whom the compound is given from presenting symptoms of the autoimmune and/or inflammatory disease, or acute inflammatory response.
  • an effective amount may also be an amount sufficient to produce a detectable decrease in the amount of a marker protein or cell type in the patient's blood or serum.
  • an effective amount is an amount of a compound described herein sufficient to significantly decrease the number of B-cells.
  • an effective amount is an amount of a compound described herein sufficient to decrease the level of anti-acetylcholine receptor antibody in a patient's blood with the disease myasthenia gravis.
  • inhibiting indicates a significant decrease in the baseline activity of a biological activity or process.
  • “Inhibition of Btk activity” refers to a decrease in Btk activity as a direct or indirect response to the presence of a compound of Formula I-a, relative to the activity of Btk in the absence of the compound.
  • the decrease in activity may be due to the direct interaction of the compound with Btk, or due to the interaction of the compound with one or more other factors that in turn affect Btk activity.
  • the presence of the compound may decrease Btk activity by directly binding to the Btk, by causing (directly or indirectly) another factor to decrease Btk activity, or by (directly or indirectly) decreasing the amount of Btk present in the cell or organism.
  • Inhibition of Btk activity also refers to observable inhibition of Btk activity in a standard biochemical assay for Btk activity, such as the ATP hydrolysis assay of Example 6.
  • Preferred inhibitors of Btk activity have an IC 50 value less than or equal to 1 micromolar, more preferably less than or equal to less than 100 nanomolar, and still more preferably less than or equal to 10 nanomolar.
  • “Inhibition of B-cell proliferation” refers to inhibition of proliferation of abnormal B-cells, such as cancerous B-cells, e.g. lymphoma B-cells and/or inhibition of normal, non-diseased B-cells.
  • the term “inhibition of B-cell proliferation” indicates any significant decrease in the number of B-cells, either in vitro or in vivo. Thus in vitro an inhibition of B-cell proliferation would be any significant decrease in the number of B-cells in an in vitro sample contacted with a compound of Formula I-a as compared to a matched sample not contacted with a compound of Formula I-a.
  • Inhibition of B-cell proliferation also refers to observable inhibition of B-cell proliferation in a standard thymidine incorporation assay for B-cell proliferation, such as the assay of Example 8.
  • Preferred inhibitors of B-cell proliferation have an IC 50 value less than or equal to 10 micromolar, more preferably less than or equal to less than 1 micromolar, and still more preferably less than or equal to 500 nanomolar.
  • significant is meant any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p ⁇ 0.05.
  • a “disease responsive to Btk inhibition” is a disease in which inhibiting Btk kinase provides a therapeutic benefit such as an amelioration of symptoms, decrease in disease progression, prevention or delay of disease onset, or inhibition of aberrant activity of certain cell-types (monocytes, B-cells, and mast cells).
  • A is 0 or 1.
  • R 1 is phenyl or heteroaryl, each of which is substituted with one of
  • L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 alkyl)(C ⁇ O)—
  • G is heterocycloalkyl, C 3 -C 7 cycloalkyl, aryl, or heteroaryl.
  • R 1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -
  • R 2 is C 1 -C 7 alkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkoxy, (heterocycloalkyl)C 0 -C 2 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 2 alkyl, or R 2 is (phenyl)C 0 -C 2 alkyl, (phenoxy)C 0 -C 2 alkyl, or (heteroaryl)C 0 -C 2 alkyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO 2 NH 2 , oxo, —COOH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 2 -C 6 alkanoyl, C 1 -C 6 hydroxyalkyl,
  • R 4 is hydrogen, or R 4 is C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl, each of which is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 6 alkylthio, (C 1 -C 6 alkoxy)C 1 -C 6 alkoxy, aminoC 1 -C 6 alkyl, mono- and di-C 1 -C 6 alkylamino, and —C(O)R 14 wherein R 14 is C 1 -C 6 alkyl, C 1 -C 3 haloalky
  • Q is phenyl or pyridyl.
  • R 3 is hydrogen, halogen, or C 1 -C 7 alkyl, or
  • R 3 is heterocycloalkyl, C 3 -C 7 cycloalkyl, or heteroaryl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO 2 NH 2 , oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 3 halooalkyl, C 1 -C 3 haloalkoxy, C 1 -C 6 alkylthio, (C 1 -C 6 -alkoxy)C 1 -C 6 alkoxy, mono- and di-C 1 -C 6 alkylamino, aminoC 1 -C 6 alkyl, and —C(O)R 14 .
  • variable R 1 satisfies one or more of the following conditions set forth in A. to O.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of
  • L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 allyl)(C ⁇ O)—
  • G is heterocycloalkyl, C 3 -C 7 cycloalkyl, aryl, or heteroaryl.
  • R 1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -
  • R 1 is phenyl or pyridyl, each of which is substituted with one of oxo, —CHO, —COOH, —CONH 2 , or —CONHOH, and R 1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of oxo, —CHO, —COOH, —CONH 2 , or —CONHOH, and R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 4 alkoxy, and mono- and di-C 1 -C 4 alkylamino.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of oxo, —CHO, —COOH, —CONH 2 , or —CONHOH, and R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C 1 -C 2 alkyl, and C 1 -C 2 alkoxy.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of (ii) C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 hydroxyalkoxy, (mono- or di-C 1 -C 6 alkylamino)C 1 -C 6 alkoxy, (C 1 -C 6 alkoxy)(C 1 -C 6 alkylamino)C 0 -C 6 alkyl, (C 1 -C 6 alkoxy)(C 1 -C 6 alkoxy)C 1 -C 6 alkoxy, heterocycloalkyl, aryl, or heteroaryl.
  • R 1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -
  • R 1 is phenyl or pyridyl, each of which is substituted with one of C 1 -C 6 hydroxyalkyl, C 1 -C 6 hydroxyalkoxy, (mono- or di-C 1 -C 6 alkylamino)C 1 -C 6 alkoxy, (C 1 -C 6 alkoxy)(C 1 -C 6 alkylamino)C 0 -C 6 alkyl, or (C 1 -C 6 alkoxy)(C 1 -C 6 alkoxy)C 1 -C 6 alkoxy, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, oxo, —COOH, —CONH 2 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -
  • R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 4 alkoxy, and mono- and di-C 1 -C 4 alkylamino.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of C 1 -C 6 hydroxyalkyl, C 1 -C 6 hydroxyalkoxy, (mono- or di-C 1 -C 6 alkylamino)C 1 -C 6 alkoxy, (C 1 -C 6 alkoxy)(C 1 -C 6 alkylamino)C 0 -C 6 alkyl, or (C 1 -C 6 alkoxy)(C 1 -C 6 alkoxy)C 1 -C 6 alkoxy.
  • R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C 1 -C 2 alkyl, and C 1 -C 2 alkoxy.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, [1,4]diazepanyl, phenyl, imidazolyl, or 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, oxo, —COOH, —CONH 2 , C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 4 alkoxycarbonyl, mono- and di-C 1 -C 4 alkylamino, and mono- and di-C 1 -C 4 alkylcar
  • R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 4 alkoxy, and mono- and di-C 1 -C 4 alkylamino.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, [1,4]diazepanyl, phenyl, imidazolyl, or 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, oxo, —COOH, —CONH 2 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, C 1 -C 4 alkoxycarbonyl, mono- and di-C 1 -C 4 alkylamino, and mono- and di-C 1 -C 4 alkylcarboxamide.
  • R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C 1 -C 2 alkyl, and C 1 -C 2 alkoxy.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of (iii) —C 1 -C 6 alkyl(C ⁇ O)OR 10 , —C 0 -C 6 alkyl(C ⁇ O)NR 10 R 11 , —C 1 -C 6 alkylNR 10 (SO 2 )R 11 , —C 0 -C 6 alkylNR 10 (C ⁇ O)R 11 , —C 0 -C 6 alkyl(SO 2 )R 10 , or —C 0 -C 6 alkylNR 10 (C ⁇ O)NR 11 R 12 where R 10 , R 11 , and R 12 are independently hydrogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 7 cycloalkyl, or heterocycloalkyl.
  • R 1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -
  • R 1 is phenyl or pyridyl, each of which is substituted with one of —C 1 -C 4 alkyl(C ⁇ O)OR 10 , —C 0 -C 4 alkyl(C ⁇ O)NR 10 R 11 , —C 1 -C 4 alkylNR 10 (SO 2 )R 11 , —C 0 -C 4 alkylNR 10 (C ⁇ O)R 11 , —C 0 -C 4 alkyl(SO 2 )R 10 , or —C 0 -C 4 alkylNR 10 (C ⁇ O)NR 11 R 12 where R 10 , R 11 , and R 12 are independently hydrogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 10 cycloalkyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, or [1,4]diazepan
  • R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C 1 -C 2 alkyl, and C 1 -C 2 alkoxy.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of (iv) -L-G, where L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 alkyl)(C ⁇ O)—, and G is heterocycloalkyl, C 3 -C 7 cycloalkyl, aryl, or heteroaryl, each of which (iv) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH 2 , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, C 1 -C 4 alkylthio, C 1 -C 2 haloalkyl, C 1 -C 2
  • R 1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -
  • R 1 is phenyl or pyridyl, each of which is substituted with one of -L-G, where L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 alkyl)(C ⁇ O)—, and G is pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, [1,4]diazepanyl, phenyl, imidazolyl, or 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, oxo, —COOH, —CONH 2 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl
  • R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 4 alkoxy, and mono- and di-C 1 -C 4 alkylamino.
  • R 1 is phenyl or pyridyl, each of which is substituted with one of -L-G, where L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 alkyl)(C ⁇ O)—, and G is pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, [1,4]diazepanyl, phenyl, imidazolyl, or 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, oxo, —COOH, —CONH 2 , C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, C 1 -C
  • R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C 1 -C 2 alkyl, and C 1 -C 2 alkoxy.
  • L is phenyl or pyridyl, each of which is substituted with one of —CH 2 —, —(C ⁇ O)—, or —(CH 2 )(C ⁇ O)—
  • G is pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, or [1,4]diazepanyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, oxo, —COOH, —CONH 2 , C 1 -C 2 alkyl, C 1 -C 2 alkoxy, C 2 -C 2 alkanoyl, C 1 -C 2 alkoxycarbonyl, mono- and di-C 1 -C 2 alkylamino, and mono- and di-C 1 -C 2 alkylcarboxamide.
  • R 1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, C 1 -C 2 alkyl, and C 1 -C 2 alkoxy.
  • R 2 may have the definition set forth for this variable in Formula I-a
  • R 2 may have the definition set forth for this variable in Formula 1
  • R 2 may have any of the values set forth for this variable in the claims, or in the subsection titled “the R 2 variable.”
  • L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 alkyl)(C ⁇ O)—
  • G is heterocycloalkyl, C 3 -C 7 cycloalkyl, aryl, or heteroaryl.
  • R A is 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • Another embodiment includes compounds and pharmaceutically acceptable forms in which R 1 is a phenyl substituted at the para position by R, and substituted at any other position by R A i.e. the invention provides compounds and pharmaceutically acceptable forms of Formula 3
  • R 2 , Z 1 , Q, and R 3 carry any of the definitions set forth herein for these variables and R and R A carry the definitions set forth for these variables for Formula 2.
  • variable R 2 satisfies one or more of the following conditions.
  • R 2 is (phenyl)C 0 -C 2 alkyl, (phenoxy)C 0 -C 2 alkyl, or (pyridyl)C 0 -C 2 alkyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO 2 NH 2 , oxo, —COOH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 2 -C 6 alkanoyl, C 1 -C 6 hydroxyalkyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, C 1 -C 6 alkylthio, (C 1 -C 6 alkoxy)C 1 -C 6 alkoxy, aminoC 1 -C 6 alkyl, mono- and di-C 1 -C 6
  • R 2 is (phenyl)C 0 -C 2 alkyl, (phenoxy)C 0 -C 2 alkyl, or (pyridyl)C 0 -C 2 alkyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, cyano, amino, halogen, —SO 2 NH 2 , oxo, —COOH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, C 1 -C 4 hydroxyalkyl, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, mono- and di-C 1 -C 6 alkylamino, mono- and di-C 1 -C 6 alkylcarboxamide, C 1 -C 4 alkoxycarbonyl, phenyl, and imidazolyl.
  • R 4 is hydrogen, C 1 -C 6 alkyl, or C 3 -C 7 cycloalkyl. In some of these embodiments R 4 is hydrogen or methyl.
  • R. R A , R 1 , R 2 , Z 1 , and R 3 carry any of the definitions set forth herein for these variables.
  • R is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 alkyl)(C ⁇ O)—
  • G is heterocycloalkyl, C 3 -C 7 cycloalkyl, aryl, or heteroaryl.
  • R A is 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • R 3 is hydrogen or methyl in certain compounds of the invention and pharmaceutically acceptable forms described herein.
  • Z 1 , R 3 and A variables carry any of the definitions set forth herein for these variables.
  • R 1 is phenyl or heteroaryl, each of which is optionally substituted with one of
  • L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 alkyl)(C ⁇ O)—
  • G is heterocycloalkyl, C 3 -C 7 cycloalkyl, aryl, or heteroaryl.
  • R 1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -
  • R 5 is isopropyl or t-butyl.
  • L is C 1 -C 2 alkyl, C 0 -C 2 alkoxy, —(C ⁇ O)—, or —(C 1 -C 2 alkyl)(C ⁇ O)—
  • G is heterocycloalkyl, C 3 -C 7 cycloalkyl, aryl, or heteroaryl.
  • R A is 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO 2 NH 2 , halogen, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkylthio, C 3 -C 7 cycloalkyl, (C 1 -C 6 alkoxy)C 0 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 6 alkyl, and C 1 -C 6 alkoxycarbonyl.
  • R 5 is isopropyl or t-butyl.
  • A, Z 1 , and R 3 may carry any of the definitions set forth above for these variables. It certain embodiments it is preferred that R 3 is hydrogen or methyl.
  • compositions comprising a compound or pharmaceutically acceptable form of Formula I-a, together with one or more pharmaceutically acceptable carriers, excipients, adjuvants, diluents, or other ingredients.
  • Pharmaceutical carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the animal being treated.
  • the carrier can be inert or it can possess pharmaceutical benefits.
  • the amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.
  • Exemplary pharmaceutically acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; synthetic oils; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; phosphate buffer solutions; emulsifiers, such as the TWEENS; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic
  • Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.
  • Effective concentrations of one or more of the compounds of the invention including pharmaceutically acceptable salts, esters or other derivatives thereof are mixed with a suitable pharmaceutical carrier, excipients, adjuvant, or vehicle.
  • a suitable pharmaceutical carrier such as dimethylsulfoxide (DMSO)
  • DMSO dimethylsulfoxide
  • surfactants such as TWEEN
  • dissolution in aqueous sodium bicarbonate such as sodium bicarbonate.
  • Derivatives of the compounds, such as salts of the compounds or prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
  • the resulting mixture may be a solution, suspension, emulsion or the like.
  • the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the chosen carrier or vehicle.
  • the effective concentration sufficient for ameliorating the symptoms of the disease treated may be empirically determined.
  • Compounds of provided herein may be administered orally, topically, parenterally, intravenously, by intramuscular injection, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage unit formulations.
  • Dosage formulations suitable for oral use include, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically elegant and palatable preparations.
  • Oral formulations contain between 0.1 and 99% of a compound of the invention and usually at least about 5% (weight %) of a compound of the present invention. Some embodiments contain from about 25% to about 50% or from 5% to 75% of a compound of invention.
  • Orally administered compositions also include liquid solutions, emulsions, suspensions, powders, granules, elixirs, tinctures, syrups, and the like.
  • the pharmaceutically acceptable carriers suitable for preparation of such compositions are well known in the art.
  • Oral formulations may contain preservatives, flavoring agents, sweetening agents, such as sucrose or saccharin, taste-masking agents, and coloring agents.
  • Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent.
  • Compounds of the invention can be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, for example. Moreover, formulations containing these compounds can be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations can contain conventional additives, such as suspending agents (e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats), emulsifying agents (e.g., lecithin, sorbitan monsoleate, or acacia), non-aqueous vehicles, which can include edible oils (e.g., almond oil, fractionated coconut oil, silyl esters, propylene glycol and ethyl alcohol), and preservatives (e.g., methyl or propyl p-hydroxybenzoate and sorbic acid).
  • suspending agents e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats
  • emulsifying agents e.g.
  • typical suspending agents include methylcellulose, sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth and sodium alginate;
  • typical wetting agents include lecithin and polysorbate 80; and
  • typical preservatives include methyl paraben and sodium benzoate.
  • Aqueous suspensions contain the active material(s) in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents; may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol substitute, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan substitute.
  • Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations.
  • These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or peanut oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, ka
  • Tablets typically comprise conventional pharmaceutically compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules (including time release and sustained release formulations) typically comprise one or more solid diluents disclosed above. The selection of carrier components often depends on secondary considerations like taste, cost, and shelf stability.
  • compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action.
  • dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methylcellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin or olive oil.
  • compositions may be in the form of a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
  • the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are useful in the preparation of injectables.
  • Compounds of the invention may be administered parenterally in a sterile medium.
  • Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrathecal injection or infusion techniques.
  • the compound or compounds of the invention depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
  • adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
  • the carrier comprises at least about 90% by weight of the total composition.
  • Preferred carriers for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil.
  • compositions may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter and polyethylene glycols.
  • Topical compositions of the present invention may be in any form including, for example, solutions, creams, ointments, gels, lotions, milks, cleansers, moisturizers, sprays, skin patches, and the like.
  • Such solutions may be formulated as 0.01%-10% isotonic solutions, pH about 5-7, with appropriate salts.
  • Compounds of the invention may also be formulated for transdermal administration as a transdermal patch.
  • Topical compositions containing the active compound can be admixed with a variety of carrier materials well known in the art, such as, for example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
  • carrier materials such as, for example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
  • compositions suitable for use in topical carriers include, for example, emollients, solvents, humectants, thickeners and powders. Examples of each of these types of materials, which can be used singly or as mixtures of one or more materials, are as follows:
  • Emollients such as stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, iso-propyl isostearate, stearic acid, iso-butyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, di-n-butyl sebacate, iso-propyl myristate, iso-propyl palmitate, iso-propyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated
  • Liposome delivery systems such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms.
  • Such compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol, and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose, and hydroxypropyl methylcellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
  • compositions for inhalation typically can be provided in the form of a solution, suspension or emulsion that can be administered as a dry powder or in the form of an aerosol using a conventional propellant (e.g., dichlorodifluoromethane or trichlorofluoromethane).
  • a conventional propellant e.g., dichlorodifluoromethane or trichlorofluoromethane.
  • compositions of the present invention may also optionally comprise an activity enhancer.
  • the activity enhancer can be chosen from a wide variety of molecules that function in different ways to enhance therapeutic effects of compounds of the invention. Particular classes of activity enhancers include skin penetration enhancers and absorption enhancers.
  • compositions of the invention may also contain additional active agents can be chosen from a wide variety of molecules, which can function in different ways to enhance the therapeutic effects of a compound of the invention. These optional other active agents, when present, are typically employed in the compositions of the invention at a level ranging from about 0.01% to about 15%. Some embodiments contain from about 0.1% to about 10% by weight of the composition. Other embodiments contain from about 0.5% to about 5% by weight of the composition.
  • the invention includes packaged pharmaceutical formulations.
  • packaged formulations include a pharmaceutical composition containing one or more compounds, salts, or other pharmaceutically acceptable forms thereof, of the invention in a container and instructions for using the composition to treat a mammal (typically a human patient).
  • the instructions are for using the pharmaceutical composition to treat a patient suffering from a disease responsive to inhibition of Btk activity and/or inhibition of B-cell proliferation.
  • the invention includes providing prescribing information; for example, to a patient or health care provider, or as a label in a packaged pharmaceutical formulation. Prescribing information may include for example efficacy, dosage and administration, contraindication and adverse reaction information pertaining to the pharmaceutical formulation.
  • the compounds of the invention can be administered alone, as mixtures, or in combination with other active agents.
  • Imidazo[1,2-a]pyrazines active as kinase inhibitors are described herein. These inhibitors are useful for treating diseases responsive to kinase inhibition, including diseases responsive to Btk inhibition and/or inhibition of B-cell proliferation, in mammals. Without wishing to be bound to any particular theory, it is believed that the interaction of the compounds of Formula I-a with Btk results in the inhibition of Btk activity and thus in the pharmaceutical utility of these compounds.
  • Other kinases that may be affected in addition to Btk include, but are not limited to, other tyrosine kinases and serine/threonine kinases.
  • the invention includes a method of treating a mammal, preferably a human, having a disease responsive to inhibition of Btk activity, comprising administrating to the mammal having such a disease, an effective amount of a compound of Formula I-a.
  • the compounds of Formula I-a may also inhibit other kinases, such that alleviation of disease, disease symptoms, preventative, and prophylactic treatment of conditions associated with these kinases is also within the scope of this invention.
  • Methods of treatment also include inhibiting Btk activity and/or inhibiting B-cell proliferation, by inhibiting ATP binding or hydrolysis by Btk or by some other mechanism, in vivo, in a patient suffering from a disease responsive to inhibition of Btk activity, by administering an effective concentration of a compound of Formula I-a to inhibit Btk activity in vitro.
  • An effective concentration may be ascertained experimentally, for example by assaying blood concentration of the compound, or theoretically, by calculating bioavailability.
  • Certain compounds described herein are useful for treating a patient suffering from a disease responsive to kinase inhibition.
  • Protein kinases the largest family of human enzymes, are now considered to be the largest druggable target class. Encompassing well over 500 proteins (2% of the human genome), kinases play critical roles in signaling pathways controlling fundamental cellular processes such as proliferation, differentiation, and death (apoptosis). Abnormal kinase activity has been implicated in a wide range of diseases, including multiple cancers, autoimmune and/or inflammatory diseases, and acute inflammatory reactions. The multifaceted role of kinases in key cell signaling pathways provides a significant opportunity to identify novel drugs targeting kinases and signaling pathways.
  • the invention includes a method of treating a patient having cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction, by administering an effective amount of a compound of Formula I-a.
  • condition responsive to inhibition of Btk activity and/or B-cell proliferation is cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
  • the conditions, diseases that can be affected using compounds and compositions according to the invention include, but are not limited to:
  • autoimmune and/or inflammatory diseases including but not limited to psoriasis, allergy, Crohn's disease, irritable bowel syndrome, Sjogren's disease, tissue graft rejection, and hyperacute rejection of transplanted organs, asthma, systemic lupus erythematosus (and associated glomerulonephritis), dermatomyositis, multiple sclerosis, scleroderma, vasculitis (ANCA-associated and other vasculitides), autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome (and associated glomerulonephritis and pulmonary hemorrhage), atherosclerosis, rheumatoid arthritis, chronic Idiopathic thrombocytopenic purpura (ITP), Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes, septic shock, myasthenia gravis, and the like, acute inflammatory reactions, including but not limited to skin sunburn, inflammatory pelvic disease,
  • Btk is a known inhibitor of apoptosis in lymphoma B-cells. Defective apoptosis contributes to the pathogenesis and drug resistance of human leukemias and lymphomas.
  • a method of promoting or inducing apoptosis in cells expressing Btk comprising contacting the cell with an agent that inhibits Btk activity is also provided herein.
  • the invention provides methods of treatment in which a compound of the invention is the only active agent given to a patient and also includes methods of treatment in which a compound of Formula I-a is given to a patient in combination with one or more additional active agent.
  • the invention provides a method of treating cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula I-a together with a second active agent, which is useful for treating an cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
  • the second agent may be an anti-inflammatory agent.
  • Treatment with the second active agent may be prior to, concomitant with, or following treatment with a compound of Formula I-a.
  • a compound of Formula I-a is combined with another active agent in a single dosage form.
  • Suitable antitumor therapeutics that may be used in combination with a compound of Formula I-a include, but are not limited to chemotherapeutic agents, for example mitomycin C, carboplatin, taxol, cisplatin, paclitaxel, etoposide, doxorubicin, or a combination comprising at least one of the foregoing chemotherapeutic agents.
  • Radiotherapeutic antitumor agents may also be used, alone or in combination with chemotherapeutic agents.
  • Btk inhibitors are useful as chemosensitizing agents, and, thus, are useful in combination with other chemotherapeutic drugs, in particular, drugs that induce apoptosis.
  • a method for increasing sensitivity of cancer cells to chemotherapy comprising administering to a patient undergoing chemotherapy a chemotherapeutic agent together with a Btk inhibitor in an amount sufficient to increase the sensitivity of cancer cells to the chemotherapeutic agent is also provided herein.
  • chemotherapeutic drugs examples include topoisomerase I inhibitors (camptothesin or topotecan), topoisomerase II inhibitors (e.g. daunomycin and etoposide), alkylating agents (e.g. cyclophosphamide, melphalan and BCNU), tubulin directed agents (e.g. taxol and vinblastine), and biological agents (e.g. antibodies such as anti CD20 antibody, IDEC 8, immunotoxins, and cytokines).
  • topoisomerase I inhibitors camptothesin or topotecan
  • topoisomerase II inhibitors e.g. daunomycin and etoposide
  • alkylating agents e.g. cyclophosphamide, melphalan and BCNU
  • tubulin directed agents e.g. taxol and vinblastine
  • biological agents e.g. antibodies such as anti CD20 antibody, IDEC 8, immunotoxins, and cytokines.
  • Anti-inflammatory agents include but are not limited to NSAIDs, non-specific and COX-2 specific cyclooxygenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor receptor (TNF) receptors antagonists, immunosuppressants and methotrexate.
  • NSAIDs include, but are not limited to ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone, sulfasalazine, tolmetin sodium, and hydroxychloroquine.
  • the anti-inflammatory agent is a salicylate.
  • Salicylates include by are not limited to acetylsalicylic acid or aspirin, sodium salicylate, and choline and magnesium salicylates.
  • the anti-inflammatory agent may also be a corticosteroid.
  • the corticosteroid may be cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, and prednisone.
  • the anti-inflammatory agent is therapeutic agent is a gold compound such as gold sodium thiomalate or auranofin.
  • the invention also includes embodiments in which the anti-inflammatory agent is a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
  • a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
  • At least one anti-inflammatory compound is an anti-C5 monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist, such as entanercept, or infliximab, which is an anti-TNF alpha monoclonal antibody.
  • an anti-C5 monoclonal antibody such as eculizumab or pexelizumab
  • TNF antagonist such as entanercept, or infliximab
  • Still other embodiments of the invention pertain to combinations in which at least one active agent is an immunosuppressant compound such as methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, or mycophenolate mofetil.
  • an immunosuppressant compound such as methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, or mycophenolate mofetil.
  • Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day).
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
  • Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most autoimmune and/or inflammatory, a dosage regimen of 4 times daily or less is preferred and a dosage regimen of 1 or 2 times daily is particularly preferred.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the patient undergoing therapy.
  • a mixture of bromoacetaldehyde diethyl acetal (51 grams (g)), 48% hydrobromic acid (HBr) (11 milliliters (mL)), and water (11 mL) is heated at 120° C. for 1 hour (hr).
  • the solution is cooled, poured into a mixture of sodium bicarbonate (NaHCO 3 ) (60 g) and isopropyl alcohol (IPA) (200 mL), and stirred for 0.5 hr.
  • the mixture is filtered, and the filtrate is treated with 3,5-dibromo-2-aminopyrazine (1) (33 g) and heated under reflux for 16 hr.
  • the suspension is cooled in ice, treated with 48% HBr (3 mL) and diethyl ether (60 mL) and filtered to afford (3) as the hydrobromide salt.
  • Tri-o-tolylphosphine (1.1 g) is added to a suspension of tris(dibenzylideneacetone)dipalladium (1.65 g) in degassed toluene (50 mL) and the mixture is stirred at room temperature for 15 minutes (min). 6,8-Dibromo-imidazo[1,2-a]pyrazine (5.0 g) is then added and the mixture is stirred at room temperature for 15 minutes more. Aniline (1.52 g) is added followed by potassium t-butoxide (2.84 g) and the mixture is stirred at room temperature for 72 hr.
  • the mixture is purified by preparative thin layer chromatography over silica gel, eluting with diethyl ether/dichloromethane (1:1) to afford 4-tert-butyl-N-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-benzamide (6) as a cream foam.
  • the bromide (8) (2.46 mmol) is dissolved in 10 mL DME (ethylene glycol, dimethyl ether) in a sealable pressure vessel and N 2 is bubbled through for 10 min. Tetrakis(triphenylphosphine)palladium (0.24 mmol) is added and N 2 is bubbled through the reaction for another 10 minutes. 3-Carboxyphenyl boronic acid (3.1 mmol) and 1N Na 2 CO 3 solution (10 mL) are then added, the vessel sealed, and the reaction heated to 95° C. for 16 hrs. with vigorous stirring. After cooling to room temperature, the reaction is acidified to pH 3 with 1N HCl and extracted with ethyl acetate (3 ⁇ 25 mL).
  • Step 1 4-(4-Nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  • Step 3 4-[4-(6-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester
  • the aqueous layer is brought to pH 6 with 3 N HCl, and the mixture is filtered to give 4- ⁇ 6-[3-(4-tert-butyl-benzoylamino)phenyl]imidazo[1,2-a]pyrazin-8-ylamino ⁇ benzoic acid (21) as a cream solid.
  • RP-HPLC is performed on an AGILENT 1100 Binary HPLC system.
  • the column is a Restek Ultra IBD 5 ⁇ m 1.0 ⁇ 30 mm (Cat. #: 9175331).
  • the Mobile Phase contains component A, 0.2% Formic Acid/Water), and component B, Acetonitrile.
  • the following Gradient is used:
  • Electrospray MS is performed on a MICROMASS LCT equipped with a LockSpray source for accurate mass measurements. Spectra are acquired in positive ion mode from 100-1000 Da at an acquisition rate of 1 spectrum/0.9 s with a 0.1 s interscan delay. The instrument is tuned for a resolution of 5000 (FWHM). Every 5 th scan is taken from the reference position of the Lockspray source. Leucine enkephalin (556.2771 [M+H] + ) is used as the reference, or lock mass.
  • the compounds disclosed in synthetic Examples 1 to 5 were tested in the Btk biochemical assay described in Example 6 and found to exhibit an IC 50 value less than or equal to 1 micromolar certain of these compounds were found to exhibit an IC 50 value less than or equal to 100 nM, and certain of these compounds exhibited an IC 50 value less than or equal to 10 nM. Some of the compounds disclosed in synthetic Examples 1 to 5 were tested in the B-cell proliferation assay of Example 8 and determined to exhibit an IC 50 value less than or equal to 10 micromolar, certain of these compounds exhibited an IC 50 value less than or equal to 1 micromolar, and certain of these compounds exhibited an IC 50 value less than or equal to 500 nM in this assay.
  • Certain of these compounds do not inhibit T-cell proliferation and have IC 50 values greater than or equal to 5 micromolar when assayed under conditions described in Example 9.
  • the compounds assayed in the Example 8 and Example 9 exhibited IC 50 values for inhibition of T-cell proliferation that were at least 3-fold, and in some instances 5-fold, or even 10-fold greater than the IC 50 values of these compounds for inhibition of B-cell proliferation.
  • a master mix minus Btk enzyme is prepared containing 1 ⁇ Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM ⁇ -glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na 3 VO 4 , 10 mM MgCl 2 ), 0.5 ⁇ M Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA.
  • a master mix plus Btk enzyme is prepared containing 1 ⁇ Cell Signaling kinase buffer, 0.5 ⁇ M PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme.
  • Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6 ⁇ His tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk. Generation of baculovirus was done based on Invitrogen's instructions detailed in its published protocol “Bac-toBac Baculovirus Expression Systems” (Cat. Nos. 10359-016 and 10608-016). Passage 3 virus was used to infect Sf9 cells to overexpress the recombinant Btk protein. The Btk protein was then purified to homogeneity using Ni-NTA column.
  • the purity of the final protein preparation was greater than 95% based on the sensitive Sypro-Ruby staining.
  • a solution of 200 ⁇ M ATP is prepared in water and adjusted to pH7.4 with 1N NaOH.
  • a quantity of 1.25 ⁇ L of compounds in 5% DMSO is transferred to a 96-well 1 ⁇ 2 area Costar polystyrene plate. Compounds are tested singly and with an 11-point dose-responsive curve (starting concentration is 10 ⁇ M; 1:2 dilution).
  • a quantity of 18.75 ⁇ L of master mix minus enzyme (as a negative control) and master mix plus enzyme is transferred to appropriate wells in 96-well 1 ⁇ 2 area costar polystyrene plate.
  • Ramos cells are incubated at a density of 0.5 ⁇ 10 7 cells/ml in the presence of test compound for 1 hr at 37° C. Cells are then stimulated by incubating with 10 ⁇ g/ml anti-human IgM F(ab) 2 for 5 minutes at 37° C. Cells are pelleted, lysed, and a protein assay is performed on the cleared lysate. Equal protein amounts of each sample are subject to SDS-PAGE and western blotting with either anti-phosphoBtk(Tyr223) antibody (Cell Signaling Technology #3531) to assess Btk autophosphorylation or an anti-Btk antibody (BD Transduction Labs #611116) to control for total amounts of Btk in each lysate.
  • B-cells are purified from spleens of 8-16 week old Balb/c mice using a B-cell isolation kit (Miltenyi Biotech, Cat # 130-090-862). Testing compounds are diluted in 0.25% DMSO and incubated with 2.5 ⁇ 10 5 purified mouse splenic B-cells for 30 min prior to addition of 10 ⁇ g/ml of an anti-mouse IgM antibody (Southern Biotechnology Associates Cat # 1022-01) in a final volume of 100 ⁇ l.
  • T cells are purified from spleens of 8-16 week old Balb/c mice using a Pan T cell isolation kit (Miltenyi Biotech, Cat # 130-090-861). Testing compounds are diluted in 0.25% DMSO and incubated with 2.5 ⁇ 10 5 purified mouse splenic T cells in a final volume of 100 ⁇ l in flat clear bottom plates precoated for 90 min at 37° C. with 10 ⁇ g/ml each of anti-CD3 (BD # 553057) and anti-CD28 (BD # 553294) antibodies.

Abstract

Compounds of Formula I-a
Figure US20110177011A1-20110721-C00001
and all pharmaceutically-acceptable forms thereof, are described herein.
The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein.
Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein.
Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction. Thus methods of treatment include administering a sufficient amount of a compound or salt as provided herein to decrease the symptoms or slow the progression of these diseases.
Other embodiments include methods of treating other animals, including livestock and domesticated companion animals, suffering from a disease responsive to inhibition of kinase activity.
Methods of treatment include administering a compound of Formula I-a as a single active agent or administering a compound of Formula I-a in combination with one or more other therapeutic agent.
A method for determining the presence of Btk in a sample, comprising contacting the sample with a compound or form thereof of Formula I-a under conditions that permit detection of Btk activity, detecting a level of Btk activity in the sample, and therefrom determining the presence or absence of Btk in the sample.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority to U.S. provisional application 60/475,634 filed Jun. 4, 2003, and U.S. provisional application 60/519,311 filed Nov. 11, 2003, which are hereby incorporated by reference in their entirety.
    • FIELD OF INVENTION
  • Certain imidazo[1,2-a]pyrazin-8-ylamine and related compounds, which when appropriately substituted are inhibitors of tyrosine kinase activity, including Bruton's tyrosine kinase (Btk) activity, are provided herein. Certa in compounds provided herein are highly active and/or specific inhibitors of Btk activity. Pharmaceutical compositions comprising such compounds, and methods of using certain imidazo[1,2-a]pyrazin-8-ylamine and related compounds to treat a variety of diseases responsive to inhibition of Btk activity and/or inhibition of B-cell proliferation, are also disclosed. Additionally, methods for using such compounds as probes for the detection and/or localization of Btk in biological samples are given.
    • BACKGROUND
  • Protein kinases, the largest family of human enzymes, encompass well over 500 proteins. Kinases play critical roles in signaling pathways controlling fundamental cellular processes such as proliferation, differentiation, and death (apoptosis). Abnormal kinase activity has been implicated in a wide range of diseases, including multiple cancers and autoimmune and inflammatory diseases. The multifaceted role of kinases in key cell signaling pathways provides a significant opportunity to identify novel drugs targeting kinases and signaling pathways. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion, and angiogenesis associated with tumor growth.
  • Because kinases are key regulators they are ideal drug design targets. Inhibitors of kinases are among the most important classes of pharmaceutical compounds known. Highly specific, cell-permeable inhibitors of one or more individual kinases are useful for the treatment of various kinase-implicated diseases. Kinase inhibiting compounds are additionally useful for the systematic investigation of the cellular function of one or more kinases, and thus, provide valuable tools for the identification of various kinases of therapeutic interest.
  • Bruton's Tyrosine Kinase (Btk) is a member of the Tec family of tyrosine kinases, and is a critical regulator of early B-cell development as well as mature B-cell activation, signaling and survival.
  • B-cell signaling through the B-cell receptor (BCR) leads to a wide range of biological outputs, which in turn depend on the developmental stage of the B-cell. The magnitude and duration of BCR signals must be precisely regulated. Aberrant BCR-mediated signaling can cause disregulated B-cell proliferation and/or the formation of pathogenic auto-antibodies leading to multiple autoimmune and/or inflammatory diseases. Mutation of Btk in humans results in X-linked agammaglobulinaemia (XLA). This disease is associated with the impaired maturation of B-cells, diminished immunoglobulin production, comprised T-cell-independent immune responses and marked attenuation of the sustained calcium sign upon BCR stimulation.
  • Evidence for the role of Btk in autoimmune and/or inflammatory disease has been established in Btk-deficient mouse models. For example, in standard murine preclinical models of systemic lupus erythematosus (SLE), Btk deficiency has been shown to result in a marked amelioration of disease progression. Moreover, Btk deficient mice are also resistant to developing collagen-induced arthritis and are less susceptible to Staphylococcus-induced arthritis.
  • A large body of evidence supports the role of B-cells and the humoral immune system in the pathogenesis of autoimmune and/or inflammatory diseases. Protein-based therapeutics (such as Rituxan) developed to deplete B-cells, represent an important approach to the treatment of a number of autoimmune and/or inflammatory diseases. Because of Btk's role in B-cell activation, inhibitors of Btk are useful as inhibitors of B-cell mediated pathogenic activity (such as autoantibody production).
  • Btk is also expressed in mast cells and monocytes and has been shown to be important for the function of these cells. For example, Btk deficiency in mice is associated with impaired IgE-mediated mast cell activation (marked diminution of TNFα and other inflammatory cytokine release), and greatly reduced TNFα production by activated monocytes.
  • Thus, inhibition of Btk activity is useful for the treatment of autoimmune and/or inflammatory diseases such as: SLE, rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, and asthma. In addition, Btk has been reported to play a role in apoptosis, thus inhibition of Btk activity is useful for the treatment of B-cell lymphoma and leukemia.
  • Agents capable of inhibiting Btk kinase activity, are highly desirable for the treatment of a variety of diseases, including cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction. Specific, cell-penetrating, small molecule, non-peptide antagonists of Btk are of particular value for such therapies. Such compounds are also useful for the systematic investigation of the cellular function of Btk, and thus, are valuable research tools for the identification of cell signalling proteins of therapeutic interest.
  • The present invention fulfills this need, and provides further related advantages.
    • SUMMARY
  • Inhibitors of kinase activity, which may generally be described as imidazo[1,2-a]pyrazin-8-ylamines and related compounds, are disclosed herein. Certain compounds provided herein are highly active and/or specific inhibitors of Btk (Bruton's tyrosine kinase) activity.
  • One embodiment provides a compound of Formula I-a
  • Figure US20110177011A1-20110721-C00002
  • or a pharmaceutically acceptable form thereof.
  • Within Formula I-a:
  • A is 0 or 1.
  • R1 is phenyl or heteroaryl, each of which is optionally substituted with one of
  • (i) oxo, —CHO, —COOH, —CONH2, or —CONHOH,
  • (ii) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, heterocycloalkyl, aryl, or heteroaryl,
  • (iii) —C1-C6alkyl(C═O)OR10, —C0-C6alkyl(C═O)NR10R11, —C1-C6alkylNR10(SO2)R11, —C0-C6alkylNR10(C═O)R11, —C0-C6alkyl(SO2)R10, or —C0-C6alkylNR10(C═O)NR11R12 where R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C10cycloalkyl, or heterocycloalkyl, or
  • (iv) -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2alkyl)(C═O)—, and G is heterocycloalkyl, C3-C7cycloalkyl, aryl, or heteroaryl.
  • Each of which (ii), (iii), and (iv) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • And, R1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • R2 is C1-C7 alkyl, (C1-C6alkoxy)C0-C6alkoxy, (heterocycloalkyl)C0-C2alkyl, (C3-C7cycloalkyl)C0-C2alkyl, or R2 is (phenyl)C0-C2alkyl, (phenoxy)C0-C2alkyl, or (heteroaryl)C0-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono- and di-C1-C6alkylamino, mono- and di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, and heteroaryl, and —(C═O)R13 wherein R13 is C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, or heteroaryl.
  • Z1 is
  • Figure US20110177011A1-20110721-C00003
  • wherein R4 is hydrogen, or R4 is C1-C6alkyl, C3-C7cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl, each of which is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono- and di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is C1-C6 alkyl, C1-C3haloalkyl, or phenyl.
  • Q is phenyl or pyridyl.
  • R3 is hydrogen, C1-C7 alkyl, or halogen, or
  • R3 is heterocycloalkyl, C3-C7cycloalkyl, or heteroaryl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3halooalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono- and di-C1-C6alkylamino, aminoC1-C6 alkyl, and —C(O)R14.
  • In certain embodiments compounds of Formula I-a, which exhibit an IC50 of 1 micromolar or less, 100 nanomolar or less, or 10 nanomolar or less in standard biochemical assay for Btk activity, such as the biochemical assay described in Example 6, are provided herein. Preferred compounds described herein are highly active inhibitors of B-cell proliferation. For example certain compounds described herein exhibit an IC50 value less than or equal to 10 micromolar, or an IC50 value less than or equal to 1 micromolar, or an IC50 value less than or equal to 500 nM in the tritiated thymidine incorporation assay for B-cell proliferation described in Example 8. Preferred compounds described herein are specific inhibitors of B-cell proliferation, exhibiting an IC50 value that is at least 3-fold, preferably 5-fold, and more preferably 10-fold greater for T-cell proliferation than the IC50 for B-cell proliferation. The IC50 for T-cell proliferation may be determined via a standard assay for T-cell proliferation such as the thymidine incorporation assay of Example 9.
  • A method for determining the presence of Btk in a sample, comprising contacting the sample with a compound or form thereof of Formula I-a under conditions that permit detection of Btk activity, detecting a level of Btk activity in the sample, and therefrom determining the presence or absence of Btk in the sample, is also provided herein.
  • Pharmaceutical compositions, comprising one or more compounds of Formula I-a, or any pharmaceutically acceptable form thereof, together with at least one pharmaceutically acceptable carrier or excipient, are provided herein.
  • Other embodiments pertain to packaged pharmaceutical compositions which comprise a pharmaceutical composition, comprising one or more compounds of Formula I-a or any pharmaceutically acceptable form thereof, together with at least one pharmaceutically acceptable carrier or excipient in a container and with instructions for using the pharmaceutical composition to treat a patient. Preferably the instructions are for using the pharmaceutical composition to treat a patient suffering from a disease responsive to inhibition of Btk activity.
  • Still other embodiments pertain to a method of inhibiting Btk kinase. In certain embodiments the method comprises contacting a cell or cells expressing Btk, either in vivo or in vitro, with a compound of Formula I-a or form thereof in an amount sufficient to detectably inhibit Btk activity in vitro.
  • Inhibiting Btk activity can effectively inhibit B-cell proliferation. Small molecule (less than 600 amu) Btk inhibitors that are orally bioavailable, such as certain compounds and forms of Formula I-a, are particularly desirable for this purpose. Thus a method of inhibiting B-cell proliferation, by contacting cells expressing Btk, either in vivo or in vitro with a compound having a molecular weight less than 600 amu in an amount sufficient to detectably inhibit the activity of Btk in vitro is provided herein. In certain embodiments the compound will be a heterocyclic compound, such as a heterocyclic compound having a bicyclic heterocyclic group. In certain embodiments the compound is a compound of Formula I-a.
  • A method of treating a mammal suffering from at least one disease responsive to inhibition of Btk activity, by administering to the mammal an effective amount of a compound that is a highly active Btk inhibitor in an in vitro assay of Btk activity is included herein. Preferably the compound is also a specific inhibitor of B-cell proliferation, exhibiting an IC50 value that is at least 3-fold, preferably 5-fold, and more preferably 10-fold greater for T-cell proliferation than the IC50 value for B-cell proliferation.
  • Methods for treating a patient having a disease responsive to inhibition of Btk activity and/or responsive to inhibition of B-cell proliferation, are provided herein. Such methods comprise administering to the patient an effective amount of a compound or form thereof of Formula I-a. The patient may be a mammal. Preferably the patient is a human patient, however methods of treating non-human patients are included herein. For example in some embodiments the patient is a companion animal, such as a cat or dog, or the patient is a livestock animal, such as a horse, cow, or pig. Particularly included herein are methods in which the disease responsive to Btk inhibition is cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
  • Methods of treatment include administering a compound of Formula I-a as a single active agent or administering a compound of Formula I-a in combination with one or more other active agents.
    • DETAILED DESCRIPTION
  • Certain terms to be used herein are provided prior to setting forth the invention in detail. Compounds of the present invention are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.
    • Chemical Description and Terminology
  • Formula I-a includes all subformulae thereof. For example Formula I-a includes compounds of Formulas 1 to 9.
  • Certain compounds are described herein using a general formula that includes variables, e.g. R1, R2, R3, Q, Z1, and A. Unless otherwise specified, each variable within such a formula is defined independently of other variables. When any variable occurs more than one time in Formula I-a, its definition on each occurrence is independent of its definition at every other occurrence.
  • In accordance with the usual meaning of “a” and “the” in patents, reference to “a” kinase or “the” kinase is inclusive of one or more kinases. Unless otherwise specified the term “compounds” includes all pharmaceutically acceptable forms of the disclosed structures.
  • In certain situations, the compounds of Formula I-a may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these compounds can additionally be mixtures of diastereomers. For compounds having asymmetric centers, it should be understood that all of the optical isomers and mixtures thereof are encompassed. In addition, compounds with carbon-carbon double bonds may occur in Z- and E-forms, with all isomeric forms of the compounds being included in the present invention. In these situations, the single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or by resolution of the racemates. Resolution of the racemates can also be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column.
  • Where a compound exists in various tautomeric forms, the invention is not limited to any one of the specific tautomers, but rather includes all tautomeric forms.
  • The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example, and without limitation, isotopes of hydrogen include tritium and deuterium and isotopes of carbon include 11C, 13C, and 14C.
  • The term “substituted”, as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded. When the substituent is oxo (i.e., ═O), then 2 hydrogens on the atom are replaced. When aromatic moieties are substituted by an oxo group, the aromatic ring is replaced by the corresponding partially unsaturated ring. For example a pyridyl group substituted by oxo is a pyridone. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent.
  • Suitable groups that may be present on a “substituted” position include, but are not limited to, e.g., halogen; cyano; hydroxyl; nitro; azido; alkanoyl (such as a C2-C6 alkanoyl group such as acyl or the like); carboxamido; alkyl groups (typically having 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms); cycloalkyl groups, alkenyl and alkynyl groups (including groups having one or more unsaturated linkages and from 2 to about 8, or 2 to about 6 carbon atoms); alkoxy groups having one or more oxygen linkages and from 1 to about 8, or from 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those having one or more thioether linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those having one or more sulfinyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfonyl groups including those having one or more sulfonyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; aminoalkyl groups including groups having one or more N atoms and from 1 to about 8, or from 1 to about 6 carbon atoms; aryl having 6 or more carbons and one or more rings, (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted aromatic); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyl being an exemplary arylalkyl group; arylalkoxy having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyloxy being an exemplary arylalkoxy group; or a saturated, unsaturated, or aromatic heterocyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O, or S atoms, e.g. coumarinyl, quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl. Such heterocyclic groups may be further substituted, e.g. with hydroxy, alkyl, alkoxy, halogen or amino.
  • A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —CHO is attached through carbon of the carbonyl (C═O) group.
  • As used herein, “alkyl” includes both branched and straight chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms, generally from 1 to about 12 carbon atoms. The term C1-C7alkyl as used herein indicates an alkyl group having from 1 to 7 carbon atoms. When C0-Cnalkyl is used herein in conjunction with another group, for example, (heterocycloalkyl)C0-C2alkyl, the indicated group, in this case heterocycloalkyl, is either directly bound by a single covalent bond (C0), or attached by an alkyl chain having the specified number of carbon atoms, in this case from 1 to 2 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t-butyl, n-pentyl, and sec-pentyl. Alkyl groups described herein typically have from 1 to about 12 carbons atoms. Preferred alkyl groups are lower alkyl groups, those alkyl groups having from 1 to about 8 carbon atoms, from 1 to about 6 carbon atoms, or from 1 to about 4 carbons atoms e.g. C1-C8, C1-C6, and C1-C4alkyl groups.
  • “Alkenyl” as used herein, indicates a straight or branched hydrocarbon chain comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point along the chain. Alkenyl groups described herein typically have from 2 to about 12 carbons atoms. Preferred alkenyl groups are lower alkenyl groups, those alkenyl groups having from 2 to about 8 carbon atoms, e.g. C2-C8, C2-C6, and C2-C4 alkenyl groups. Examples of alkenyl groups include ethenyl, propenyl, and butenyl groups.
  • “Alkynyl” as used herein, indicates a straight or branched hydrocarbon chain comprising one or more triple carbon-carbon bonds that may occur in any stable point along the chain, such as ethynyl and propynyl. Alkynyl groups described herein typically have from 2 to about 12 carbons atoms. Preferred alkynyl groups are lower alkynyl groups; those alkynyl groups having from 2 to about 8 carbon atoms, e.g. C2-C8, C2-C6, and C2-C4 alkynyl groups.
  • “Alkoxy” indicates an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge (—O—). Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.
  • In the term “(Alkoxy)alkyl” alkoxy and alkyl are as defined above and the point of attachment is on the alkyl group. For example (C1-C6alkoxy)C1-C6alkyl indicates an alkoxy group having from 1 to about 6 carbon atom attached through its oxygen atom to an alkyl group having from 1 to about 6 carbon atoms and further attached to the core molecule through a carbon atom in the C1-C6alkyl portion.
  • In the term “(Alkoxy)alkoxy” alkoxy is as defined above and the point of attachment is on the oxygen of the second listed alkoxy group. For example (C1-C6alkoxy)C1-C4alkoxy indicates an alkoxy group have from 1 to about 6 carbon atom attached through its oxygen atom to an second alkoxy group, this one having, for example, from 1 to about 4 carbon atoms, and further attached to the core molecule through an oxygen bridge. Similarly the term “(alkoxy)(alkoxy)alkoxy” refers to two such alkoxy groups attached to a third alkoxy, which is further attached to the core molecule through an oxygen bridge.
  • “Alkanoyl” indicates an alkyl group as defined above, attached through a keto (—(C═O)—) bridge. Alkanoyl groups have the indicated number of carbon atoms, with the carbon of the keto group being included in the numbered carbon atoms. For example a C2alkanoyl group is an acetyl group having the formula CH3(C═O)—.
  • As used herein, “alkylthio” means alkyl-S—, where the alkyl group is an alkyl group as defined above having the defined number of carbon atoms. An exemplary alkylthio group is methylthio.
  • As used herein the term “alkoxycarbonyl” indicates an alkoxy group, as defined above, having the indicated number of carbon atoms, attached through a keto (—(C═O)—) bridge. The alkoxy moiety of the alkoxycarbonyl group has the indicated number of carbon atoms. The carbon of the keto bridge is not included in this number. C3alkoxycarbonyl indicates for example, groups of the formula CH3(CH2)2—O—(C═O)— or (CH3)2(CH)—O—(C═O)—.
  • As used herein “aminoalkyl” is an alkyl group as defined herein, having the indicated number of carbon atoms, and substituted with at least one amino substituent (—NH2). When indicated, aminoalkyl groups, like other groups described herein, may be additionally substituted.
  • As used herein, the term “mono- and/or di-alkylamino” indicates secondary or tertiary alkyl amino groups, wherein the alkyl groups are as defined above and have the indicated number of carbon atoms. The point of attachment of the alkylamino group is on the nitrogen. The alkyl groups are independently chosen. Examples of mono- and/or di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino. “Mono- and/or di-alkylaminoalkyl” groups are mono- and/or di-alkylamino groups attached through an alkyl linker having the specified number of carbon atoms, for example a di-methylaminoethyl group. Tertiary amino substituents may by designated by nomenclature of the form N—R—N—R′, indicating that the groups R and R′ are both attached to a single nitrogen atom.
  • As used herein, the term “mono- and/or di-(alkylamino)allyl” indicates a mono- and/or di-alkylamino group as defined attached through an alkyl linker having the specified number of carbon atoms. Similarly “mono- and/or di-(alkylamino)alkoxy” indicates a mono- and/or di-alkylamino group as defined attached through an alkoxy linker having the specified number of carbon atoms.
  • As used herein the term “mono- and/or di-alkylcarboxamide” refers to groups of formula (alkyl1)-NH—(C═O)— and (alkyl1)(alkyl2)-N—(C═O)— in which the alkyl1 and alkyl2 groups are independently chosen alkyl groups as defined above having the indicated number of carbon atoms. “Carboxamide” is a group of the formula —(C═O)NH2.
  • As used herein, the term “aryl” indicates aromatic groups containing only carbon in the aromatic ring or rings. Such aromatic groups may be further substituted with carbon or non-carbon atoms or groups. Typical aryl groups contain 1 or 2 separate, fused, or pendant rings and from 6 to about 12 ring atoms, without heteroatoms as ring members. Where indicated, aryl groups may be substituted. Such substitution may include fusion to a 5 to 7-membered saturated cyclic group that optionally contains 1 or 2 heteroatoms independently chosen from N, O, and S, to form, for example, a 3,4-methylenedioxy-phenyl group. Aryl groups include, for example, phenyl, naphthyl, including 1-naphthyl and 2-naphthyl, and bi-phenyl.
  • “Cycloalkyl” as used herein, indicates a monocyclic or multicyclic saturated hydrocarbon ring group, having the specified number of carbon atoms, usually from 3 to about 10 ring carbon atoms. Monocyclic cycloalkyl groups typically have from 3 to about 8 carbon ring atoms or from 3 to about 7 carbon ring atoms. Multicyclic cycloalkyl groups may have 2 or 3 fused cycloalkyl rings or contain bridged or caged cycloalkyl groups. Cycloalkyl substituents may be pendant to the substituted nitrogen or carbon atom, or where a substituted carbon atom may have two substituents a cycloalkyl group may be attached as a spiro group. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl as well as bridged or caged saturated ring groups such as norbornane or adamantane.
  • As used herein “(cycloalkyl)C0-C2alkyl indicates a cycloalkyl groups as defined above either directly attached via a single covalent bond or attached through an ethylene (—CH2CH2—) or methylene (—CH2—) linker.
  • As used herein “haloalkyl” indicates both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, generally up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.
  • “Haloalkoxy” indicates a haloalkyl group as defined above attached through an oxygen bridge.
  • “Halo” or “halogen” as used herein refers to fluoro, chloro, bromo, and/or iodo. As used herein, “heteroaryl” indicates a stable 5- to 7-membered monocyclic aromatic ring which contains from 1 to 4, or preferably from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5 to 7 membered aromatic ring which contains from 1 to 4, or preferably from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon. When the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heteroaryl group is not more than 2. It is particularly preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl groups include, but are not limited to, oxazolyl, pyranyl, pyrazinyl, pyrazolopyrimidinyl, pyrazolyl, pyridizinyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienylpyrazolyl, thiophenyl, triazolyl, benzo[d]oxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxadiazolyl, dihydrobenzodioxynyl, furanyl, imidazolyl, indolyl, and isoxazolyl.
  • The term “heterocycloalkyl” indicates a saturated monocyclic group containing from 1 to about 3 heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a saturated bicyclic ring system having at least one N, O, or S ring atom with remaining atoms being carbon. Monocyclic heterocycloalkyl groups have from 4 to about 8 ring atoms, and more typically have from 5 to 7 ring atoms. Bicyclic heterocycloalkyl groups typically have from about five to about 12 ring atoms. Preferred heterocycloalkyl groups include monocyclic heterocycloalkyl groups that contain from 5 to 7 ring atoms and 1 or 2 heteroatoms independently chosen from N, O, and S. Examples of heterocycloalkyl groups include morpholinyl, piperazinyl, piperidinyl, and pyrrolidinyl groups.
  • In the term “(heterocycloalkyl)alkyl” the groups heterocycloalkyl and alkyl are as defined above and the point of attachment to the core structure is on the alkyl group.
  • As used herein “hydroxyalkyl” is an alkyl group as defined herein, having the indicated number of carbon atoms, and substituted with at least one hydroxyl substituent (—OH). When indicated, hydroxyalkyl groups, like other groups described herein, may be additionally substituted. Similarly the term “hydroxyalkoxy” indicates an alkoxy group as defined herein, having the indicated number of carbon atoms, and substituted with at least one hydroxyl substituent (—OH).
  • “Pharmaceutically acceptable forms” of the compounds recited herein include pharmaceutically acceptable salts, hydrates, solvates, crystal forms, polymorphs, chelates, non-covalent complexes, esters, clathrates, prodrugs, and mixtures of such compounds. Pharmaceutically acceptable salts are a preferred pharmaceutically acceptable form.
  • “Pharmaceutically acceptable salts” include derivatives of the disclosed compounds wherein the parent compound is modified by making non-toxic acid or base salts thereof, and further refers to pharmaceutically acceptable solvates of such compounds and such salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC—(CH2)n—COOH where n is 0-4, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).
  • The term “prodrugs” includes any compounds that become compounds of Formula I-a when administered to a mammalian subject, e.g., upon metabolic processing of the prodrug. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate and like derivatives of functional groups (such as alcohol or amine groups) in the compounds of Formula I-a.
  • The term “active agent” is used to indicate a compound, including any pharmaceutically form thereof, or natural product, which has biological activity. Preferably an “active agent” is a compound having pharmaceutical utility. For example an active agent may be a compound of Formula I-a, or an anti-cancer or anti-inflammatory therapeutic, which is not a compound of Formula I-a.
  • The term “effective amount” of a compound of this invention means an amount effective, when administered to a human or non-human patient, to provide a therapeutic benefit such as amelioration of symptoms, slowing of disease progression, or prevention of disease e.g., an effective amount may be an amount sufficient to decrease the symptoms of a disease responsive to Btk inhibition, and preferably is an amount sufficient to reduce cancer symptoms, the symptoms of an autoimmune and/or inflammatory disease, or the symptoms of an acute inflammatory reaction. In some embodiments an effective amount of a compound described herein is an amount sufficient to decrease the number of detectable cancerous cells in an organism, detectably slow or stop the growth of a cancerous tumor, or more preferably an amount sufficient to shrink a cancerous tumor. In certain circumstances a patient suffering from cancer may not present symptoms of being affected. Thus, a therapeutically effective amount of a compound is also an amount sufficient to prevent a significant increase or significantly reduce the detectable level of cancerous cells or cancer markers in the patient's blood, serum, or tissues. In methods described herein for treating autoimmune and/or inflammatory diseases or acute inflammatory reactions, an effective amount may also be an amount sufficient, when administered to a patient, to detectably slow progression of the disease, or prevent the patient to whom the compound is given from presenting symptoms of the autoimmune and/or inflammatory disease, or acute inflammatory response. In certain methods described herein for treating autoimmune and/or inflammatory diseases or acute inflammatory reactions, an effective amount may also be an amount sufficient to produce a detectable decrease in the amount of a marker protein or cell type in the patient's blood or serum. For example, in some embodiments an effective amount is an amount of a compound described herein sufficient to significantly decrease the number of B-cells. In another example, in some embodiments an effective amount is an amount of a compound described herein sufficient to decrease the level of anti-acetylcholine receptor antibody in a patient's blood with the disease myasthenia gravis.
  • The term “inhibition” indicates a significant decrease in the baseline activity of a biological activity or process. “Inhibition of Btk activity” refers to a decrease in Btk activity as a direct or indirect response to the presence of a compound of Formula I-a, relative to the activity of Btk in the absence of the compound. The decrease in activity may be due to the direct interaction of the compound with Btk, or due to the interaction of the compound with one or more other factors that in turn affect Btk activity. For example, the presence of the compound may decrease Btk activity by directly binding to the Btk, by causing (directly or indirectly) another factor to decrease Btk activity, or by (directly or indirectly) decreasing the amount of Btk present in the cell or organism.
  • Inhibition of Btk activity also refers to observable inhibition of Btk activity in a standard biochemical assay for Btk activity, such as the ATP hydrolysis assay of Example 6. Preferred inhibitors of Btk activity have an IC50 value less than or equal to 1 micromolar, more preferably less than or equal to less than 100 nanomolar, and still more preferably less than or equal to 10 nanomolar.
  • Without wishing to be bound to any particular theory it is believed that the inhibition of Btk activity causes an inhibition of B-cell proliferation. “Inhibition of B-cell proliferation” refers to inhibition of proliferation of abnormal B-cells, such as cancerous B-cells, e.g. lymphoma B-cells and/or inhibition of normal, non-diseased B-cells. The term “inhibition of B-cell proliferation” indicates any significant decrease in the number of B-cells, either in vitro or in vivo. Thus in vitro an inhibition of B-cell proliferation would be any significant decrease in the number of B-cells in an in vitro sample contacted with a compound of Formula I-a as compared to a matched sample not contacted with a compound of Formula I-a.
  • Inhibition of B-cell proliferation also refers to observable inhibition of B-cell proliferation in a standard thymidine incorporation assay for B-cell proliferation, such as the assay of Example 8. Preferred inhibitors of B-cell proliferation have an IC50 value less than or equal to 10 micromolar, more preferably less than or equal to less than 1 micromolar, and still more preferably less than or equal to 500 nanomolar.
  • By “significant” is meant any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p<0.05.
  • A “disease responsive to Btk inhibition” is a disease in which inhibiting Btk kinase provides a therapeutic benefit such as an amelioration of symptoms, decrease in disease progression, prevention or delay of disease onset, or inhibition of aberrant activity of certain cell-types (monocytes, B-cells, and mast cells).
    • Imidazo[1,2-β]Pyrazine Compounds
  • In addition to compounds of Formula I-a (above), compounds of Formula 1
  • Figure US20110177011A1-20110721-C00004
  • and the pharmaceutically acceptable form thereof, are also disclosed.
  • Within Formula 1:
  • A is 0 or 1.
  • R1 is phenyl or heteroaryl, each of which is substituted with one of
  • (i) oxo, —CHO, —COOH, —CONH2, or —CONHOH,
  • (ii) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, heterocycloalkyl, aryl, or heteroaryl,
  • (iii) —C1-C6alkyl(C═O)OR10, —C0-C6alkyl(C═O)NR10R11, —C1-C6alkylNR10(SO2)R11, —C0-C6alkylNR10(C═O)R11, —C0-C6alkyl(SO2)R10, or —C0-C6alkylNR10(C═O)NR11R12 where R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C10cycloalkyl, or heterocycloalkyl, or
  • (iv) -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2alkyl)(C═O)—, and G is heterocycloalkyl, C3-C7cycloalkyl, aryl, or heteroaryl.
  • Each of which (ii), (iii), and (iv) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • And, R1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • R2 is C1-C7 alkyl, (C1-C6alkoxy)C0-C6alkoxy, (heterocycloalkyl)C0-C2alkyl, (C3-C7cycloalkyl)C0-C2alkyl, or R2 is (phenyl)C0-C2alkyl, (phenoxy)C0-C2alkyl, or (heteroaryl)C0-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono- and di-C1-C6alkylamino, mono- and di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, or heteroaryl.
  • Z1 is
  • Figure US20110177011A1-20110721-C00005
  • wherein R4 is hydrogen, or R4 is C1-C6alkyl, C3-C7cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl, each of which is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono- and di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is C1-C6 alkyl, C1-C3haloalkyl, or phenyl.
  • Q is phenyl or pyridyl.
  • R3 is hydrogen, halogen, or C1-C7 alkyl, or
  • R3 is heterocycloalkyl, C3-C7cycloalkyl, or heteroaryl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3halooalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono- and di-C1-C6alkylamino, aminoC1-C6 alkyl, and —C(O)R14.
    • The Variable A
  • Also included herein are compounds of Formula 1 wherein A is 0 and compounds of Formula 1 wherein A is 1.
    • The Variable R1
  • Further provided herein are compounds of Formula 1 and pharmaceutically acceptable forms thereof, wherein the variable R1 satisfies one or more of the following conditions set forth in A. to O.
  • A. R1 is phenyl or pyridyl, each of which is substituted with one of
  • (i) oxo, —CHO, —COOH, —CONH2, or —CONHOH,
  • (ii) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, heterocycloalkyl, aryl, or heteroaryl,
  • (iii) —C1-C6alkyl(C═O)OR10, —C0-C6alkyl(C═O)NR10R11, —C1-C6alkylNR10(SO2)R11, C6alkylNR10(C═O)R11, —C0-C6alkyl(SO2)R10, or —C0-C6alkylNR10(C═O)NR11R12, where R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C10cycloalkyl, or heterocycloalkyl, or
  • (iv) -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2allyl)(C═O)—, and G is heterocycloalkyl, C3-C7cycloalkyl, aryl, or heteroaryl.
  • Each of which (ii), (iii), and (iv) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • And, R1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • B. R1 is phenyl or pyridyl, each of which is substituted with one of oxo, —CHO, —COOH, —CONH2, or —CONHOH, and R1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • C. R1 is phenyl or pyridyl, each of which is substituted with one of oxo, —CHO, —COOH, —CONH2, or —CONHOH, and R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C1-C4alkyl, C2-C4alkanoyl, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxy, and mono- and di-C1-C4alkylamino.
  • D. R1 is phenyl or pyridyl, each of which is substituted with one of oxo, —CHO, —COOH, —CONH2, or —CONHOH, and R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C1-C2alkyl, and C1-C2alkoxy.
  • E. R1 is phenyl or pyridyl, each of which is substituted with one of (ii) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, heterocycloalkyl, aryl, or heteroaryl.
  • Each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • And, R1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • F. R1 is phenyl or pyridyl, each of which is substituted with one of C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, or (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, and mono- and di-C1-C4alkylcarboxamide.
  • And, R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C1-C4alkyl, C2-C4alkanoyl, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxy, and mono- and di-C1-C4alkylamino.
  • G. R1 is phenyl or pyridyl, each of which is substituted with one of C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, or (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy.
  • And, R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C1-C2alkyl, and C1-C2alkoxy.
  • H. R1 is phenyl or pyridyl, each of which is substituted with one of pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, [1,4]diazepanyl, phenyl, imidazolyl, or 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, oxo, —COOH, —CONH2, C1-C4alkoxy, C2-C4alkanoyl, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, and mono- and di-C1-C4alkylcarboxamide.
  • And, R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C1-C4alkyl, C2-C4alkanoyl, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxy, and mono- and di-C1-C4alkylamino.
  • I. R1 is phenyl or pyridyl, each of which is substituted with one of pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, [1,4]diazepanyl, phenyl, imidazolyl, or 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, oxo, —COOH, —CONH2, C1-C4alkyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, and mono- and di-C1-C4alkylcarboxamide.
  • And, R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C1-C2alkyl, and C1-C2alkoxy.
  • J. R1 is phenyl or pyridyl, each of which is substituted with one of (iii) —C1-C6alkyl(C═O)OR10, —C0-C6alkyl(C═O)NR10R11, —C1-C6alkylNR10(SO2)R11, —C0-C6alkylNR10(C═O)R11, —C0-C6alkyl(SO2)R10, or —C0-C6alkylNR10(C═O)NR11R12 where R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C7cycloalkyl, or heterocycloalkyl. Each of which (iii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • And, R1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • K. R1 is phenyl or pyridyl, each of which is substituted with one of —C1-C4alkyl(C═O)OR10, —C0-C4alkyl(C═O)NR10R11, —C1-C4alkylNR10(SO2)R11, —C0-C4alkylNR10(C═O)R11, —C0-C4alkyl(SO2)R10, or —C0-C4alkylNR10(C═O)NR11R12 where R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C10cycloalkyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, or [1,4]diazepanyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, and mono- and di-C1-C4alkylcarboxamide.
  • And, R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C1-C2alkyl, and C1-C2alkoxy.
  • L. R1 is phenyl or pyridyl, each of which is substituted with one of (iv) -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2alkyl)(C═O)—, and G is heterocycloalkyl, C3-C7cycloalkyl, aryl, or heteroaryl, each of which (iv) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • And, R1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • M. R1 is phenyl or pyridyl, each of which is substituted with one of -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2alkyl)(C═O)—, and G is pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, [1,4]diazepanyl, phenyl, imidazolyl, or 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, and mono- and di-C1-C4alkylcarboxamide.
  • And, R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C1-C4alkyl, C2-C4alkanoyl, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxy, and mono- and di-C1-C4alkylamino.
  • N. R1 is phenyl or pyridyl, each of which is substituted with one of -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2alkyl)(C═O)—, and G is pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, [1,4]diazepanyl, phenyl, imidazolyl, or 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, oxo, —COOH, —CONH2, C1-C4alkyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, and mono- and di-C1-C4alkylcarboxamide.
  • And, R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, cyano, halogen, C1-C2alkyl, and C1-C2alkoxy.
  • O. L is phenyl or pyridyl, each of which is substituted with one of —CH2—, —(C═O)—, or —(CH2)(C═O)—, and G is pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, or [1,4]diazepanyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, oxo, —COOH, —CONH2, C1-C2alkyl, C1-C2alkoxy, C2-C2alkanoyl, C1-C2alkoxycarbonyl, mono- and di-C1-C2alkylamino, and mono- and di-C1-C2alkylcarboxamide.
  • And, R1 is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, C1-C2alkyl, and C1-C2alkoxy.
  • Also disclosed herein are compounds and pharmaceutically acceptable forms of Formula 2:
  • Figure US20110177011A1-20110721-C00006
  • Within Formula 2
  • A, R2, Z1, Q, and R3 carry any of the definitions set forth herein for these variables. For example R2 may have the definition set forth for this variable in Formula I-a, R2 may have the definition set forth for this variable in Formula 1, R2 may have any of the values set forth for this variable in the claims, or in the subsection titled “the R2 variable.”
  • R is
  • (i) oxo, —CHO, —COOH, —CONH2, or —CONHOH,
  • (ii) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, heterocycloalkyl, aryl, or heteroaryl,
  • (iii) —C1-C6alkyl(C═O)OR10, —C0-C6alkyl(C═O)NR10R11, —C1-C6alkylNR10(SO2)R11, —C0-C6alkylNR10(C═O)R11, —C0-C6alkyl(SO2)R10, or —C0-C6alkylNR10(C═O)NR11R12 where R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C10cycloalkyl, or heterocycloalkyl, or
  • (iv) -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2alkyl)(C═O)—, and G is heterocycloalkyl, C3-C7cycloalkyl, aryl, or heteroaryl. Each of which (ii), (iii), and (iv) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • RA is 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • Another embodiment includes compounds and pharmaceutically acceptable forms in which R1 is a phenyl substituted at the para position by R, and substituted at any other position by RA i.e. the invention provides compounds and pharmaceutically acceptable forms of Formula 3
  • Figure US20110177011A1-20110721-C00007
  • Within Formula 3
  • R2, Z1, Q, and R3 carry any of the definitions set forth herein for these variables and R and RA carry the definitions set forth for these variables for Formula 2.
    • The R2 Variable
  • Further provided herein are compounds of Formula 1 and pharmaceutically acceptable forms thereof, wherein the variable R2 satisfies one or more of the following conditions.
  • A. R2 is (phenyl)C0-C2alkyl, (phenoxy)C0-C2alkyl, or (pyridyl)C0-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono- and di-C1-C6 alkylamino, mono- and di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, or heteroaryl.
  • B. R2 is (phenyl)C0-C2alkyl, (phenoxy)C0-C2alkyl, or (pyridyl)C0-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C4 alkyl, C1-C4 alkoxy, C2-C4alkanoyl, C1-C4hydroxyalkyl, C1-C2haloalkyl, C1-C2haloalkoxy, mono- and di-C1-C6alkylamino, mono- and di-C1-C6alkylcarboxamide, C1-C4alkoxycarbonyl, phenyl, and imidazolyl.
    • The Z1 Variable
  • Within certain embodiments Z1 is
  • Figure US20110177011A1-20110721-C00008
  • wherein R4 is hydrogen, C1-C6alkyl, or C3-C7cycloalkyl. In some of these embodiments R4 is hydrogen or methyl.
    • The Q Variable
  • Additional embodiments, pertain to compounds and pharmaceutically acceptable forms of Formula 4 and Formula 5
  • Figure US20110177011A1-20110721-C00009
  • Within Formula 4 and 5:
  • A, R. RA, R1, R2, Z1, and R3 carry any of the definitions set forth herein for these variables.
  • In certain embodiments of Formula 5, R is
  • (i) oxo, —CHO, —COOH, —CONH2, or —CONHOH,
  • (ii) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, heterocycloalkyl, aryl, or heteroaryl,
  • (iii) —C1-C6alkyl(C═O)OR10, —C0-C6alkyl(C═O)NR10R11, —C1-C6alkylNR10(SO2)R11, —C0-C6alkylNR10(C═O)R11, —C0-C6alkyl(SO2)R10, or —C0-C6alkylNR10(C═O)NR11R12 where R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C10cycloalkyl, or heterocycloalkyl, or
  • (iv) -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2alkyl)(C═O)—, and G is heterocycloalkyl, C3-C7cycloalkyl, aryl, or heteroaryl.
  • Each of which (ii), (iii), and (iv) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • RA is 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
    • The R3 Variable
  • R3 is hydrogen or methyl in certain compounds of the invention and pharmaceutically acceptable forms described herein.
  • Additional embodiments of the invention pertain to compounds of Formula 6
  • Figure US20110177011A1-20110721-C00010
  • and the pharmaceutically acceptable forms thereof.
  • Within Formula 6
  • Z1, R3 and A variables carry any of the definitions set forth herein for these variables.
  • R1 is phenyl or heteroaryl, each of which is optionally substituted with one of
  • (i) oxo, —CHO, —COOH, —CONH2, or —CONHOH,
  • (ii) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, heterocycloalkyl, aryl, or heteroaryl,
  • (iii) —C1-C6alkyl(C═O)OR10, —C0-C6alkyl(C═O)NR10R11, —C1-C6alkylNR10(SO2)R11, —C0-C6alkylNR10(C═O)R11, —C0-C6alkyl(SO2)R10, or —C0-C6alkylNR10(C═O)NR11R12 where R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C10cycloalkyl, or heterocycloalkyl, or
  • (iv) -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2alkyl)(C═O)—, and G is heterocycloalkyl, C3-C7cycloalkyl, aryl, or heteroaryl.
  • Each of which (ii), (iii), and (iv) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • And, R1 is substituted with 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • R5 is isopropyl or t-butyl.
  • Other embodiments pertain to compounds and forms thereof of Formula 7 to Formula 9
  • Figure US20110177011A1-20110721-C00011
  • Within Formula 7 to Formula 9:
  • R is
  • (i) oxo, —CHO, —COOH, —CONH2, or —CONHOH,
  • (ii) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6hydroxyalkyl, C1-C6hydroxyalkoxy, (mono- or di-C1-C6alkylamino)C1-C6alkoxy, (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, (C1-C0alkoxy)(C1-C6alkoxy)C1-C6alkoxy, heterocycloalkyl, aryl, or heteroaryl,
  • (iii) —C1-C6alkyl(C═O)OR10, —C0-C6alkyl(C═O)NR10R11, —C1-C6alkylNR10(SO2)R11, —C0-C6alkylNR10(C═O)R11, —C0-C6alkyl(SO2)R10, or —C0-C6alkylNR10(C═O)NR11R12 where R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C10cycloalkyl, or heterocycloalkyl, or
  • (iv) -L-G, where L is C1-C2alkyl, C0-C2alkoxy, —(C═O)—, or —(C1-C2alkyl)(C═O)—, and G is heterocycloalkyl, C3-C7cycloalkyl, aryl, or heteroaryl.
  • Each of which (ii), (iii), and (iv) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono- and di-C1-C4alkylamino, mono- and di-C1-C4alkylcarboxamide, and phenyl.
  • RA is 0 or 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono- and di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
  • R5 is isopropyl or t-butyl.
  • A, Z1, and R3 may carry any of the definitions set forth above for these variables. It certain embodiments it is preferred that R3 is hydrogen or methyl.
    • Pharmaceutical Preparations
  • Compounds, salts, and any other pharmaceutically acceptable forms of the invention can be administered as the neat chemical, but are preferably administered as a pharmaceutical composition or formulation. Accordingly, the invention provides pharmaceutical formulations comprising a compound or pharmaceutically acceptable form of Formula I-a, together with one or more pharmaceutically acceptable carriers, excipients, adjuvants, diluents, or other ingredients.
  • Pharmaceutical carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the animal being treated. The carrier can be inert or it can possess pharmaceutical benefits. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.
  • Exemplary pharmaceutically acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; synthetic oils; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; phosphate buffer solutions; emulsifiers, such as the TWEENS; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.
  • Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.
  • Effective concentrations of one or more of the compounds of the invention including pharmaceutically acceptable salts, esters or other derivatives thereof are mixed with a suitable pharmaceutical carrier, excipients, adjuvant, or vehicle. In instances in which the compounds exhibit insufficient solubility, methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as salts of the compounds or prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
  • Upon mixing or addition of the compound(s) of the invention, the resulting mixture may be a solution, suspension, emulsion or the like. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the chosen carrier or vehicle. The effective concentration sufficient for ameliorating the symptoms of the disease treated and may be empirically determined.
  • Compounds of provided herein may be administered orally, topically, parenterally, intravenously, by intramuscular injection, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage unit formulations.
  • Dosage formulations suitable for oral use, include, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically elegant and palatable preparations. Oral formulations contain between 0.1 and 99% of a compound of the invention and usually at least about 5% (weight %) of a compound of the present invention. Some embodiments contain from about 25% to about 50% or from 5% to 75% of a compound of invention.
  • Orally administered compositions also include liquid solutions, emulsions, suspensions, powders, granules, elixirs, tinctures, syrups, and the like. The pharmaceutically acceptable carriers suitable for preparation of such compositions are well known in the art. Oral formulations may contain preservatives, flavoring agents, sweetening agents, such as sucrose or saccharin, taste-masking agents, and coloring agents.
  • Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent.
    • Orally Administered Liquids Formulations
  • Compounds of the invention can be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, for example. Moreover, formulations containing these compounds can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can contain conventional additives, such as suspending agents (e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats), emulsifying agents (e.g., lecithin, sorbitan monsoleate, or acacia), non-aqueous vehicles, which can include edible oils (e.g., almond oil, fractionated coconut oil, silyl esters, propylene glycol and ethyl alcohol), and preservatives (e.g., methyl or propyl p-hydroxybenzoate and sorbic acid).
    • Suspensions
  • For a suspension, typical suspending agents include methylcellulose, sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate.
  • Aqueous suspensions contain the active material(s) in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents; may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol substitute, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan substitute. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate.
  • Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
    • Emulsions
  • Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or peanut oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
    • Dispersible Powders
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.
    • Tablets and Capsules
  • Tablets typically comprise conventional pharmaceutically compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules (including time release and sustained release formulations) typically comprise one or more solid diluents disclosed above. The selection of carrier components often depends on secondary considerations like taste, cost, and shelf stability.
  • Such compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methylcellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
    • Injectable and Parenteral Formulations
  • Pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are useful in the preparation of injectables.
  • Compounds of the invention may be administered parenterally in a sterile medium. Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrathecal injection or infusion techniques. The compound or compounds of the invention, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle. In many compositions for parenteral administration the carrier comprises at least about 90% by weight of the total composition. Preferred carriers for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil.
    • Suppositories
  • Compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.
    • Topical Formulations
  • Compounds of the invention may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye. Topical compositions of the present invention may be in any form including, for example, solutions, creams, ointments, gels, lotions, milks, cleansers, moisturizers, sprays, skin patches, and the like.
  • Such solutions may be formulated as 0.01%-10% isotonic solutions, pH about 5-7, with appropriate salts. Compounds of the invention may also be formulated for transdermal administration as a transdermal patch.
  • Topical compositions containing the active compound can be admixed with a variety of carrier materials well known in the art, such as, for example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
  • Other materials suitable for use in topical carriers include, for example, emollients, solvents, humectants, thickeners and powders. Examples of each of these types of materials, which can be used singly or as mixtures of one or more materials, are as follows:
  • Emollients, such as stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, iso-propyl isostearate, stearic acid, iso-butyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, di-n-butyl sebacate, iso-propyl myristate, iso-propyl palmitate, iso-propyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, and myristyl myristate; propellants, such as propane, butane, iso-butane, dimethyl ether, carbon dioxide, and nitrous oxide; solvents, such as ethyl alcohol, methylene chloride, iso-propanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran; humectants, such as glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, and gelatin; and powders, such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, and ethylene glycol monostearate.
  • Compounds of the invention may also be topically administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
    • Other Formulations
  • Other compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms. Such compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol, and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose, and hydroxypropyl methylcellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
  • Compositions for inhalation typically can be provided in the form of a solution, suspension or emulsion that can be administered as a dry powder or in the form of an aerosol using a conventional propellant (e.g., dichlorodifluoromethane or trichlorofluoromethane).
    • Additional Components
  • The compositions of the present invention may also optionally comprise an activity enhancer. The activity enhancer can be chosen from a wide variety of molecules that function in different ways to enhance therapeutic effects of compounds of the invention. Particular classes of activity enhancers include skin penetration enhancers and absorption enhancers.
  • Pharmaceutical compositions of the invention may also contain additional active agents can be chosen from a wide variety of molecules, which can function in different ways to enhance the therapeutic effects of a compound of the invention. These optional other active agents, when present, are typically employed in the compositions of the invention at a level ranging from about 0.01% to about 15%. Some embodiments contain from about 0.1% to about 10% by weight of the composition. Other embodiments contain from about 0.5% to about 5% by weight of the composition.
    • Packaged Formulations
  • The invention includes packaged pharmaceutical formulations. Such packaged formulations include a pharmaceutical composition containing one or more compounds, salts, or other pharmaceutically acceptable forms thereof, of the invention in a container and instructions for using the composition to treat a mammal (typically a human patient). Preferably the instructions are for using the pharmaceutical composition to treat a patient suffering from a disease responsive to inhibition of Btk activity and/or inhibition of B-cell proliferation. The invention includes providing prescribing information; for example, to a patient or health care provider, or as a label in a packaged pharmaceutical formulation. Prescribing information may include for example efficacy, dosage and administration, contraindication and adverse reaction information pertaining to the pharmaceutical formulation.
  • In all of the foregoing the compounds of the invention can be administered alone, as mixtures, or in combination with other active agents.
    • Methods of Treatment
  • Imidazo[1,2-a]pyrazines active as kinase inhibitors, in particular Btk inhibitors are described herein. These inhibitors are useful for treating diseases responsive to kinase inhibition, including diseases responsive to Btk inhibition and/or inhibition of B-cell proliferation, in mammals. Without wishing to be bound to any particular theory, it is believed that the interaction of the compounds of Formula I-a with Btk results in the inhibition of Btk activity and thus in the pharmaceutical utility of these compounds. Other kinases that may be affected in addition to Btk include, but are not limited to, other tyrosine kinases and serine/threonine kinases.
  • Accordingly, the invention includes a method of treating a mammal, preferably a human, having a disease responsive to inhibition of Btk activity, comprising administrating to the mammal having such a disease, an effective amount of a compound of Formula I-a.
  • To the extent that Btk is implicated in any of the following, alleviation of the disease, disease symptoms, preventative, and prophylactic treatment is within the scope of this invention. In addition, as noted above, the compounds of Formula I-a may also inhibit other kinases, such that alleviation of disease, disease symptoms, preventative, and prophylactic treatment of conditions associated with these kinases is also within the scope of this invention.
  • Methods of treatment also include inhibiting Btk activity and/or inhibiting B-cell proliferation, by inhibiting ATP binding or hydrolysis by Btk or by some other mechanism, in vivo, in a patient suffering from a disease responsive to inhibition of Btk activity, by administering an effective concentration of a compound of Formula I-a to inhibit Btk activity in vitro. An effective concentration may be ascertained experimentally, for example by assaying blood concentration of the compound, or theoretically, by calculating bioavailability.
    • Diseases Responsive to Kinase Inhibition
  • Certain compounds described herein are useful for treating a patient suffering from a disease responsive to kinase inhibition.
  • Protein kinases, the largest family of human enzymes, are now considered to be the largest druggable target class. Encompassing well over 500 proteins (2% of the human genome), kinases play critical roles in signaling pathways controlling fundamental cellular processes such as proliferation, differentiation, and death (apoptosis). Abnormal kinase activity has been implicated in a wide range of diseases, including multiple cancers, autoimmune and/or inflammatory diseases, and acute inflammatory reactions. The multifaceted role of kinases in key cell signaling pathways provides a significant opportunity to identify novel drugs targeting kinases and signaling pathways.
    • Diseases Responsive to Btk Inhibition
  • The invention includes a method of treating a patient having cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction, by administering an effective amount of a compound of Formula I-a.
  • In a preferred embodiment, the condition responsive to inhibition of Btk activity and/or B-cell proliferation is cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
  • Preferably, the conditions, diseases that can be affected using compounds and compositions according to the invention include, but are not limited to:
  • autoimmune and/or inflammatory diseases, including but not limited to psoriasis, allergy, Crohn's disease, irritable bowel syndrome, Sjogren's disease, tissue graft rejection, and hyperacute rejection of transplanted organs, asthma, systemic lupus erythematosus (and associated glomerulonephritis), dermatomyositis, multiple sclerosis, scleroderma, vasculitis (ANCA-associated and other vasculitides), autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome (and associated glomerulonephritis and pulmonary hemorrhage), atherosclerosis, rheumatoid arthritis, chronic Idiopathic thrombocytopenic purpura (ITP), Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes, septic shock, myasthenia gravis, and the like,
    acute inflammatory reactions, including but not limited to skin sunburn, inflammatory pelvic disease, inflammatory bowel disease, urethritis, uvitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, and cholocystitis, and
    cancer, including but not limited to, B-cell lymphoma, lymphoma (including Hodgkin's and non-Hodgkins lymphoma), hairy cell leukemia, multiple myeloma, chronic and acute myelogenous leukemia, and chronic and acute lymphocytic leukemia.
  • Btk is a known inhibitor of apoptosis in lymphoma B-cells. Defective apoptosis contributes to the pathogenesis and drug resistance of human leukemias and lymphomas. Thus, a method of promoting or inducing apoptosis in cells expressing Btk comprising contacting the cell with an agent that inhibits Btk activity is also provided herein.
    • Combination Therapy
  • The invention provides methods of treatment in which a compound of the invention is the only active agent given to a patient and also includes methods of treatment in which a compound of Formula I-a is given to a patient in combination with one or more additional active agent. Thus in one embodiment the invention provides a method of treating cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula I-a together with a second active agent, which is useful for treating an cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction. For example the second agent may be an anti-inflammatory agent. Treatment with the second active agent may be prior to, concomitant with, or following treatment with a compound of Formula I-a. In certain embodiments a compound of Formula I-a is combined with another active agent in a single dosage form. Suitable antitumor therapeutics that may be used in combination with a compound of Formula I-a include, but are not limited to chemotherapeutic agents, for example mitomycin C, carboplatin, taxol, cisplatin, paclitaxel, etoposide, doxorubicin, or a combination comprising at least one of the foregoing chemotherapeutic agents. Radiotherapeutic antitumor agents may also be used, alone or in combination with chemotherapeutic agents.
  • Btk inhibitors are useful as chemosensitizing agents, and, thus, are useful in combination with other chemotherapeutic drugs, in particular, drugs that induce apoptosis.
  • A method for increasing sensitivity of cancer cells to chemotherapy, comprising administering to a patient undergoing chemotherapy a chemotherapeutic agent together with a Btk inhibitor in an amount sufficient to increase the sensitivity of cancer cells to the chemotherapeutic agent is also provided herein.
  • Examples of other chemotherapeutic drugs that can be used in combination with Btk inhibitors include topoisomerase I inhibitors (camptothesin or topotecan), topoisomerase II inhibitors (e.g. daunomycin and etoposide), alkylating agents (e.g. cyclophosphamide, melphalan and BCNU), tubulin directed agents (e.g. taxol and vinblastine), and biological agents (e.g. antibodies such as anti CD20 antibody, IDEC 8, immunotoxins, and cytokines).
  • Included herein are methods of treatment in which a compound of Formula I-a in administered in combination with an anti-inflammatory agent. Anti-inflammatory agents include but are not limited to NSAIDs, non-specific and COX-2 specific cyclooxygenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor receptor (TNF) receptors antagonists, immunosuppressants and methotrexate.
  • Examples of NSAIDs include, but are not limited to ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone, sulfasalazine, tolmetin sodium, and hydroxychloroquine. Examples of NSAIDs also include COX-2 specific inhibitors (i.e., a compound that inhibits COX-2 with an IC50 that is at least 50-fold lower than the IC50 for COX-1) such as celecoxib, valdecoxib, lumiracoxib, etoricoxib and/or rofecoxib.
  • In a further embodiment, the anti-inflammatory agent is a salicylate. Salicylates include by are not limited to acetylsalicylic acid or aspirin, sodium salicylate, and choline and magnesium salicylates.
  • The anti-inflammatory agent may also be a corticosteroid. For example, the corticosteroid may be cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, and prednisone.
  • In additional embodiments the anti-inflammatory agent is therapeutic agent is a gold compound such as gold sodium thiomalate or auranofin.
  • The invention also includes embodiments in which the anti-inflammatory agent is a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
  • Other embodiments of the invention pertain to combinations in which at least one anti-inflammatory compound is an anti-C5 monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist, such as entanercept, or infliximab, which is an anti-TNF alpha monoclonal antibody.
  • Still other embodiments of the invention pertain to combinations in which at least one active agent is an immunosuppressant compound such as methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, or mycophenolate mofetil.
    • Dosage Levels
  • Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
  • Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most autoimmune and/or inflammatory, a dosage regimen of 4 times daily or less is preferred and a dosage regimen of 1 or 2 times daily is particularly preferred.
  • It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the patient undergoing therapy.
    • EXAMPLES Example 1 Exemplary Synthesis of Certain Imidazo[1,2-a]Pyrazin-8-Ylamines
  • Step 1. 6,8-dibromoimidazo[1,2-a]pyrazine (3)
  • Figure US20110177011A1-20110721-C00012
  • A mixture of bromoacetaldehyde diethyl acetal (51 grams (g)), 48% hydrobromic acid (HBr) (11 milliliters (mL)), and water (11 mL) is heated at 120° C. for 1 hour (hr). The solution is cooled, poured into a mixture of sodium bicarbonate (NaHCO3) (60 g) and isopropyl alcohol (IPA) (200 mL), and stirred for 0.5 hr. The mixture is filtered, and the filtrate is treated with 3,5-dibromo-2-aminopyrazine (1) (33 g) and heated under reflux for 16 hr. The suspension is cooled in ice, treated with 48% HBr (3 mL) and diethyl ether (60 mL) and filtered to afford (3) as the hydrobromide salt.
  • Step 2. (6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-phenyl-amine (4)
  • Figure US20110177011A1-20110721-C00013
  • Tri-o-tolylphosphine (1.1 g) is added to a suspension of tris(dibenzylideneacetone)dipalladium (1.65 g) in degassed toluene (50 mL) and the mixture is stirred at room temperature for 15 minutes (min). 6,8-Dibromo-imidazo[1,2-a]pyrazine (5.0 g) is then added and the mixture is stirred at room temperature for 15 minutes more. Aniline (1.52 g) is added followed by potassium t-butoxide (2.84 g) and the mixture is stirred at room temperature for 72 hr. Water (150 mL) is added and the mixture is extracted with ethyl acetate (3×150 mL), the extracts are washed with water (1×100 mL) and brine (1×100 mL), dried over MgSO4, and evaporated in vacuo to afford a gum. Trituration with diethyl ether affords (6-bromo-imidazo[1,2-a]pyrazin-8-yl)-phenyl-amine (4) as a brown solid.
  • Step 3. [6-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-phenyl-amine (5)
  • Figure US20110177011A1-20110721-C00014
  • A mixture of (6-bromo-imidazo[1,2-a]pyrazin-8-yl)-phenyl-amine (4) (1.9 g), 3-aminophenylboronic acid hemisulfate (1.35 g), tetrakis(triphenylphosphine) palladium (380 mg), 1M aqueous sodium carbonate (20 mL), and 1,2-dimethoxyethane (40 mL) is heated at 90° for 16 hr. The mixture is cooled to room temperature, treated with water (50 mL) and extracted with ethyl acetate (3×80 mL). The extracts are washed with water (1×50 mL) and brine (1×50 mL), dried over MgSO4, and evaporated in vacuo to afford a gum which is purified by flash chromatography over silica gel, eluting with ethyl acetate, to afford [6-(3-amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-phenyl-amine (5) as a light brown solid.
  • Step 4. 4-tert-Butyl-N-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-benzamide (6)
  • Figure US20110177011A1-20110721-C00015
  • A solution of [6-(3-amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-phenyl-amine (5) (50 mg), 4-tert-butyl-benzoyl chloride (0.83 mL of a 0.2M solution in toluene), and triethylamine (0.034 mL) in toluene (1 mL) and N,N,-dimethylformamide (1 mL) is stirred at room temperature for 16 hr. The mixture is purified by preparative thin layer chromatography over silica gel, eluting with diethyl ether/dichloromethane (1:1) to afford 4-tert-butyl-N-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-benzamide (6) as a cream foam.
    • Example 2 Synthesis of N-(4-Tert-Butyl-Phenyl)-3-{8-[4-(Morpholin-4-Carbonyl)-Phenylamino]-Imidazo[1,2-a]Pyrazin-6-Yl}-Benzamide
  • Step. 1. 4-(6-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid (7)
  • Figure US20110177011A1-20110721-C00016
  • A mixture of 4-(6-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester (30 mmol), 1N aqueous sodium hydroxide (50 mL), and ethanol (80 mL) is heated at reflux for 1.5 hr. The mixture is cooled and the ethanol removed in vacuo. The residue is diluted with 1N sodium hydroxide (30 mL) and washed with ethyl acetate (2×100 mL) The aqueous layer is brought to pH 6 with 3N HCl, and the mixture filtered to give 4-(6-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid (7) as a light orange solid.
  • Step 2. [4-(6-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-phenyl]-morpholin-4-yl-methanone (8)
  • Figure US20110177011A1-20110721-C00017
  • A mixture of 4-(6-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid (7) (0.16 mmol), benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (0.16 mmol), and N′N-diisopropylethylamine (0.48 mmol) is stirred at room temperature for 20 min. under N2. Morpholine (0.48 mmol) is added and the mixture is stirred at room temperature for 16 hr. Water (10 mL) is added and the mixture extracted with ethyl acetate (2×70 mL). The extracts are subsequently washed with water (2×30 mL) and brine (1×30 mL), dried over sodium sulfate, and concentrated in vacuo. The residue is triturated with diethyl ether to give [4-(6-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-phenyl]-morpholin-4-yl-methanone (8) as a cream solid.
  • Step 3. 3-{8-[4-(Morpholine-4-carbonyl)-phenylamino]-imidazo[1, 2-a]pyrazin-6-yl}-benzoic acid (9)
  • Figure US20110177011A1-20110721-C00018
  • The bromide (8) (2.46 mmol) is dissolved in 10 mL DME (ethylene glycol, dimethyl ether) in a sealable pressure vessel and N2 is bubbled through for 10 min. Tetrakis(triphenylphosphine)palladium (0.24 mmol) is added and N2 is bubbled through the reaction for another 10 minutes. 3-Carboxyphenyl boronic acid (3.1 mmol) and 1N Na2CO3 solution (10 mL) are then added, the vessel sealed, and the reaction heated to 95° C. for 16 hrs. with vigorous stirring. After cooling to room temperature, the reaction is acidified to pH 3 with 1N HCl and extracted with ethyl acetate (3×25 mL). The pooled ethyl acetate layers are washed with brine, dried over sodium sulfate, and the solvent removed in vacuo. The resulting solid is then dissolved in a minimal volume of CH2Cl2 and precipitated out as a whitish-tan solid by slow addition of ethyl acetate (5 mL) followed by hexanes (30 mL) to yield 3-{8-[4-(Morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-benzoic acid (9).
  • Step 4. N-(4-tert-Butyl-phenyl)-3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-benzamide (10)
  • Figure US20110177011A1-20110721-C00019
  • A mixture of 3-{8-[4-(Morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-benzoic acid (9) (0.23 mmol), benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate reagent (0.23 mmol) and N,N′-diisopropylethylamine (0.77 mmol) is stirred under N2 for 15 min. in 1 mL DMF. 4-tert-Butyl-phenylamine (0.37 mmol) is added and the reaction stirred at rt for 8 hrs. The reaction is partitioned between ethyl acetate (15 mL) and water (15 mL) and the ethyl acetate layer washed with water (2×15 mL) and brine (1×15 mL). The organic layer is dried over sodium sulfate and the solvent removed in vacuo. The resulting crude oil is dissolved in 1 ml CH2Cl2 and clean yellow solid is precipitated by slow addition of diethyl ether, yielding the final product, (10) N-(4-tert-Butyl-phenyl)-3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-benzamide.
    • Example 3 Synthesis of N-(3-{8-[4-(4-Acetyl-Piperazin-1-Yl)-Phenylamino]-Imidazo[1,2-a]Pyrazin-6-Yl}-Phenyl)-4-Tert-Butyl-Benzamide
  • Step 1. 4-(4-Nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  • Figure US20110177011A1-20110721-C00020
  • A mixture of 1-fluoro-4-nitrobenzene (20.4 mmol), piperazine-1-carboxylic acid tert-butyl ester (20.4 mmol), potassium carbonate (40.8 mmol), and N′N-dimethylformamide (80 mL) is heated at 60° C. for 3 hrs. The mixture is cooled to room temperature, treated with water (100 mL), extracted with ethyl acetate (3×80 mL). The extracts are washed with water (3×60 mL) and brine (1×75 ml), dried over magnesium sulfate, and concentrated in vacuo to give 4-(4-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (11) as a yellow solid.
  • Step 2. 4-(4-Amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  • Figure US20110177011A1-20110721-C00021
  • A mixture of 4-(4-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (11) (18.9 mmol), 10% palladium-on-carbon (600 mg), ethanol (100 mL), and ethyl acetate (100 mL) is hydrogenated at room temperature and 40 psi for 2 hrs. The mixture is filtered through celite, washing with ethyl acetate (2×100 mL), and concentrated in vacuo to give 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (12) as a brown oil.
  • Step 3. 4-[4-(6-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester
  • Figure US20110177011A1-20110721-C00022
  • A mixture of 6,8-dibromoimidazo[1,2-a]pyrazine (12.5 mmol), 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (12) (13.1 mmol), potassium carbonate (25 mmol), acetonitrile (50 mL) and N,N-dimethylacetamide (20 mL) is heated at 65° C. for 16 hrs. The mixture is cooled to room temperature, treated water (100 mL), and extracted with ethyl acetate (3×80 mL). The extracts are washed with water (3×60 mL) and brine (1×60 mL), dried over magnesium sulfate, and concentrated in vacuo. The residue is chromatographed over silica gel, eluting with ethyl acetate, to give 4-[4-(6-bromo-imidazo[1,2-a]pyrazin-8-ylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (13) as a light brown foam.
  • Step 4. 4-{4-[6-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (14)
  • Figure US20110177011A1-20110721-C00023
  • A mixture of 4-(6-bromoimidazo[1,2-a]pyrazin-8-ylamino)benzoic acid ethyl ester (13) (4.33 mmol), 3-aminophenylboronic acid hemisulfate (5.63 mmol), tetrakis(triphenylphosphine)palladium (0.2 mmol), 1N aqueous sodium carbonate solution (13 mL), and dimethoxyethane (70 mL) is heated at 95° C. for 2 days. The mixture is allowed to cool, treated with water (100 mL), and extracted with ethyl acetate (3×80 mL). The extracts are washed with water (2×75 mL) and brine (1×75 mL), dried over magnesium sulfate, and evaporated in vacuo. The residue is chromatographed over silica gel, eluting with ethyl acetate, to give 4-{4-[6-(3-amino-phenyl)-imidazo[1,2-a]pyrazin-8-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (14) as a cream solid.
  • Step 5. 4-(4-{6-[3-(4-tert-Butyl-benzoylamino)-phenyl]-imidazo[1,2-a]pyrazin-8-ylamino}-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (15)
  • Figure US20110177011A1-20110721-C00024
  • An ice-cold solution of 4-{4-[6-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (14) (2.35 mmol), triethylamine (3.53 mmol), and tetrahydrofuran (20 mL) is treated dropwise with a solution of 4-t-butylbenzoyl chloride (2.35 mmol) in tetrahydrofuran (10 mL). The mixture is stirred at room temperature for 1 hr. Water (50 mL) is added and the mixture extracted with ethyl acetate (3×70 mL). The extracts are washed with water (2×50 mL) and brine (1×50 mL), dried over magnesium sulfate, and evaporated in vacuo. The residue is triturated with diethyl ether to give 4-(4-{6-[3-(4-tert-butyl-benzoylamino)-phenyl]-imidazo[1,2-a]pyrazin-8-ylamino}-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (15) as a cream solid.
  • Step 6. 4-tert-Butyl-N-{3-[8-(4-piperazin-1-yl-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-benzamide (16)
  • Figure US20110177011A1-20110721-C00025
  • A mixture of 4-(4-{6-[3-(4-tert-butyl-benzoylamino)-phenyl]-imidazo[1,2-a]pyrazin-8-ylamino}-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (15) (2.0 mmol), 1M HCl in diethyl ether (20 mL), and dioxane (60 mL) is stirred at room temperature for 16 hr. Water (100 mL) is added and the pH brought to 11 with 1N NaOH. The mixture is extracted with ethyl acetate (3×80 mL), the extracts washed with water (2×70 mL) and brine (1×70 mL), dried over magnesium sulfate, and concentrated in vacuo. The residue is slurried with diethyl ether and filtered to give 4-tert-butyl-N-{3-[8-(4-piperazin-1-yl-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-benzamide (16) as a cream solid.
  • Step 7. N-(3-{8-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-4-tert-butyl-benzamide (17)
  • Figure US20110177011A1-20110721-C00026
  • A mixture of 4-tert-butyl-N-{3-[8-(4-piperazin-1-yl-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-benzamide (16) (0.55 mmol), triethylamine (1.1 mmol), acetic anhydride (0.60 mmol), and dichloromethane (10 mL) is stirred at room temperature for 1 hr. Water (30 mL) is added, the mixture extracted with dichloromethane (2×50 mL), the extracts washed with water (2×30 mL) and brine (1×30 mL), dried over magnesium sulfate, and concentrated in vacuo. The residue is triturated with diethyl ether and ethyl acetate to give N-(3-{8-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-imidazo [1,2-a]pyrazin-6-yl}-phenyl)-4-tert-butyl-benzamide (17) as a cream solid.
    • Example 4 Synthesis of 4-Tert-Butyl-N-(3-{8-[4-(Morpholine-4-Carbonyl)-Phenylamino]-Imidazo[1,2-A]Pyrazin-6-Yl}-Phenyl)-Benzamide
  • Step 1. 4-(6-Bromo-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester (18)
  • Figure US20110177011A1-20110721-C00027
  • A mixture of 6,8-dibromoimidazo[1,2-a]pyrazine (0.18 mol), 4-aminobenzoic acid ethyl ester (2) (0.18 mol), and N,N-dimethylacetamide (30 mL) is heated at 160° C. for 30 min. The mixture is cooled to room temperature, treated with ethyl acetate (150 mL), stirred, and filtered to afford an orange/brown solid. This solid is slurried with ethyl acetate and saturated sodium bicarbonate solution to give 4-(6-bromoimidazo[1,2-a]pyrazin-8-ylamino)benzoic acid ethyl ester (18) freebase.
  • Step 2. 4-[6-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-ylamino]-benzoic acid ethyl ester (19)
  • Figure US20110177011A1-20110721-C00028
  • A mixture of 4-(6-bromoimidazo[1,2-a]pyrazin-8-ylamino)benzoic acid ethyl ester (18) (55.3 mmol), 3-aminophenylboronic acid hemisulfate (72 mmol), tetrakis(triphenylphosphine)palladium (2.8 mmol), 1N aqueous sodium carbonate solution (166 mmol), and dimethoxyethane (200 mL) is heated at reflux for 4 days. The mixture is allowed to cool, treated with water (200 mL), and extracted with ethyl acetate (4×100 mL). The extracts are washed with water (2×150 mL) and brine (1×100 mL), dried over magnesium sulfate, and evaporated in vacuo. The residue is triturated with dichloromethane and diethyl ether to give 4-[6-(3-aminophenyl)imidazo[1,2-a]pyrazin-8-ylamino]benzoic acid ethyl ester (19) as a yellow solid.
  • Step 3. 4-{6-[3-(4-tert-Butyl-benzoylamino)-phenyl]imidazo[1,2-a]pyrazin-8-ylamino}-benzoic acid ethyl ester (20)
  • Figure US20110177011A1-20110721-C00029
  • An ice-cold solution of 4-[6-(3-aminophenyl)imidazo[1,2-a]pyrazin-8-ylamino]benzoic acid ethyl ester (19) (44.2 mmol), triethylamine (66.4 mmol), and tetrahydrofuran (140 mL) is treated dropwise with a solution of 4-t-butylbenzoyl chloride (44.2 mmol) in tetrahydrofuran (60 mL) and the mixture is stirred at room temperature for 1 hr. Water (100 mL) is added and the mixture extracted with ethyl acetate (3×100 mL), the extracts are washed with water (2×100 mL) and brine (1×100 mL), dried over magnesium sulfate and evaporated in vacuo. The residue is triturated with dichloromethane to give 4-{6-[3-(4-tert-butyl-benzoylamino)phenyl]imidazo[1,2-a]pyrazin-8-ylamino}benzoic acid ethyl ester (20) as a pale orange solid.
  • Step 4. 4-{6-[3-(4-tert-Butyl-benzoylamino)-phenyl]-imidazo[1,2-a]pyrazin-8-ylamino}-benzoic acid (21)
  • Figure US20110177011A1-20110721-C00030
  • A mixture of 4-{6-[3-(4-tert-butyl-benzoylamino)phenyl]imidazo[1,2-a]pyrazin-8-ylamino}benzoic acid ethyl ester (20) (30 mmol), 1N aqueous sodium hydroxide (50 mL), and ethanol (80 mL) is heated at reflux for 1.5 hrs. The mixture is cooled and the ethanol removed in vacuo. The residue is diluted with 1N sodium hydroxide (30 mL) and washed with ethyl acetate (2×100 mL). The aqueous layer is brought to pH 6 with 3 N HCl, and the mixture is filtered to give 4-{6-[3-(4-tert-butyl-benzoylamino)phenyl]imidazo[1,2-a]pyrazin-8-ylamino}benzoic acid (21) as a cream solid.
  • Step 5. 4-tert-Butyl-N-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide (22)
  • Figure US20110177011A1-20110721-C00031
  • A mixture of 4-{6-[3-(4-tert-butyl-benzoylamino)phenyl]imidazo[1,2-a]pyrazin-8-ylamino}benzoic acid (21) (0.16 mmol), benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (0.16 mmol), and N′N-diisopropylethylamine (0.48 mmol) is stirred at room temperature for 20 min. Morpholine (0.48 mmol) is added and the mixture is stirred at room temperature or 16 hrs. Water (10 mL) is added and the mixture extracted with ethyl acetate (2×70 mL), the extracts are washed with water (2×30 mL) and brine (1×30 mL), dried over magnesium sulfate, and concentrated in vacuo. The residue is triturated with diethyl ether to give 4-tert-B\butyl-N-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]imidazo[1,2-a]pyrazin-6-yl}-phenyl)benzamide (22) as a cream solid.
    • Example 5 Additional Imidazo[1,2-a]Pyrazin-8-Ylamines
  • The following compounds are synthesized via the procedure set forth in Examples 1 to 4. In some instances changes in starting materials and reaction conditions that will be readily apparent to those skilled in the art of organic synthesis may be required.
  • LC-MS data reported in this example is obtained as follows:
  • LC conditions: RP-HPLC is performed on an AGILENT 1100 Binary HPLC system. The column is a Restek Ultra IBD 5 μm 1.0×30 mm (Cat. #: 9175331). The Mobile Phase contains component A, 0.2% Formic Acid/Water), and component B, Acetonitrile. The following Gradient is used:
  • Flow Rate
    Time (min.) % B (μl/min)
    0 10 500
    1.8 60 500
    2.0 95 500
    2.2 95 500
    2.4 10 500
  • MS conditions: Electrospray MS is performed on a MICROMASS LCT equipped with a LockSpray source for accurate mass measurements. Spectra are acquired in positive ion mode from 100-1000 Da at an acquisition rate of 1 spectrum/0.9 s with a 0.1 s interscan delay. The instrument is tuned for a resolution of 5000 (FWHM). Every 5th scan is taken from the reference position of the Lockspray source. Leucine enkephalin (556.2771 [M+H]+) is used as the reference, or lock mass.
  • TABLE I
    Cmp. Name and MS
    # Structure Molecular Formula MW m/z (M+ 1)
    23
    Figure US20110177011A1-20110721-C00032
         		4-tert-Butyl-N-[3-(8- phenylamino- imidazo[1,2-a]pyrazin- benzamide MF = C29H27N5O 461.22 462.21
    24
    Figure US20110177011A1-20110721-C00033
         		4-Isopropyl-N-[3-(8- phenylamino- imidazo[1,2-a]pyrazin- 6-yl)-phenyl]- benzamide MF = C28H25N5O 447.21 448.21
    25
    Figure US20110177011A1-20110721-C00034
         		4-tert-Butyl-N-{3-[8- (pyridin-3-ylamino)- imidazo[1,2-a]pyrazin- 6-yl]-phenyl}- benzamide MF = C28H26N6O 462.21 463.07
    26
    Figure US20110177011A1-20110721-C00035
         		4-tert-Butyl-N-{3-[8- (4-methoxy- phenylamino)- imidazo[1,2-a]pyrazin- 6-yl]-phenyl}- benzamide MF = C30H29N5O2 491.23 492.10
    27
    Figure US20110177011A1-20110721-C00036
         		4-tert-Butyl-N-{3-[8- (pyridin-4-ylamino)- imidazo[1,2-a]pyrazin- 6-yl]-phenyl}- benzamide MF = C28H26N6O 462.22 463.19
    28
    Figure US20110177011A1-20110721-C00037
         		4-tert-Butyl-N-{3-[8- (4-fluoro- phenylamino)- imidazo[1,2-a]pyrazin- 6-yl]-phenyl}- benzamide MF = C29H26FN5O 479.21 480.10
    29
    Figure US20110177011A1-20110721-C00038
         		4-tert-Butyl-N-{3-[8- (3-fluoro- phenylamino)- imidazo[1,2-a]pyrazin- 6-yl]-phenyl}- benzamide MF = C29H26FN5O 479.21 480.10
    30
    Figure US20110177011A1-20110721-C00039
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin- 8-ylamino}-benzoic acid MF = C30H27N5O3 505.21 506.08
    31
    Figure US20110177011A1-20110721-C00040
         		4-tert-Butyl-N-{3-[8- (3-methoxy- phenylamino)- imidazo[1,2-a]pyrazin- 6-yl]-phenyl}- benzamide MF = C30H29N5O2 491.23 492.08
    32
    Figure US20110177011A1-20110721-C00041
         		4-tert-Butyl-N-{3-[8- (6-methoxy-pyridin-3- ylamino)-imidazo[1,2- a]pyrazin-6-yl]- phenyl}-benzamide MF = C29H28N6O2 492.22 493.08
    33
    Figure US20110177011A1-20110721-C00042
         		3-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin- 8-ylamino}-benzoic acid MF = C30H27N5O3 505.21 506.25
    34
    Figure US20110177011A1-20110721-C00043
         		4-(6-[3-(4-Isopropyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin- 8-ylamino}-benzoic acid MF = C29H25N5O3 491.19 492.19
    35
    Figure US20110177011A1-20110721-C00044
         		4-tert-Butyl-N-{3-[8- (4-cyano-phenylamino)- imidazo[1,2-a]pyrazin- 6-yl]-phenyl}- benzamide MF = C30H26N6O 486.22 487.28
    36
    Figure US20110177011A1-20110721-C00045
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin- 8-ylamino}-benzamide MF = C30H28N6O2 504.22 505.21
  • TABLE II
    Cmp. MS
    # Structure NAME MW m/z (M+1)
    37
    Figure US20110177011A1-20110721-C00046
         		4-tert-Butyl-N-{3-[8-(4- morpholin-4-yl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C33H34N6O2 546.27 547.11
    38
    Figure US20110177011A1-20110721-C00047
         		3-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzoic acid C30H27N5O3 505.21 506.25
    39
    Figure US20110177011A1-20110721-C00048
         		4-tert-Butyl-N-{3-[8-(3- fluoro-4-methoxy- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C30H28FN5O2 509.22 510.26
    40
    Figure US20110177011A1-20110721-C00049
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzoic N-Methyl amide C31H30N6O2 518.24 519.21
    41
    Figure US20110177011A1-20110721-C00050
         		4-tert-Butyl-N-{3-[8-(4- piperazin-1-yl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C33H35N7O 545.29 546.19
    42
    Figure US20110177011A1-20110721-C00051
         		4-tert-Butyl-N-[3-(8-m- tolylamino-imidazo[1,2- a]pyrazin-6-yl)-phenyl]- benzamide C30H29N5O 475.23 476.22
    43
    Figure US20110177011A1-20110721-C00052
         		(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-phenyl)-acetic acid methyl ester C32H31N5O3 533.24 534.22
    44
    Figure US20110177011A1-20110721-C00053
         		(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-phenyl)-acetic acid C31H29N5O3 519.22 520.22
    45
    Figure US20110177011A1-20110721-C00054
         		4-tert-Butyl-N-(3-{8-[4- (piperazine-1-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H35N7O2 573.28 574.85
    46
    Figure US20110177011A1-20110721-C00055
         		4-tert-Butyl-N-(3-{8-[4-(2- methoxy-ethoxymethoxy)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C33H35N5O4 565.26 566.25
    47
    Figure US20110177011A1-20110721-C00056
         		4-tert-Butyl-N-(3-[8-(4- hydroxy-phenylamino)- imidazo[1,2-a]pyrazin-6-yl]- phenyl}-benzamide C29H27N5O2 477.22 478.22
    48
    Figure US20110177011A1-20110721-C00057
         		4-tert-Butyl-N-{3-[8-(6- piperazin-1-yl-pyridin-3- ylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C32H34N8O 546.28 547.24
    49
    Figure US20110177011A1-20110721-C00058
         		4-tert-Butyl-N-(3-{8-[4-(4- methyl-piperazin-1-yl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H37N7O 559.31 560.26
    50
    Figure US20110177011A1-20110721-C00059
         		4-tert-Butyl-N-{3-[8-(4- [1,4]diazepan-1-yl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C34H37N7O 559.31 561.17
    51
    Figure US20110177011A1-20110721-C00060
         		4-tert-Butyl-N-(3-{8-[4-(4- oxo-piperidin-1-yl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H34N6O2 558.27 559.22
    52
    Figure US20110177011A1-20110721-C00061
         		(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzoylamino)- acetic acid methyl ester C33H32N6O4 576.24 577.29
    53
    Figure US20110177011A1-20110721-C00062
         		(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzoylamino)- acetic acid C32H30N6O4 562.23 563.26
    54
    Figure US20110177011A1-20110721-C00063
         		N-(3-{8-[4-(4-Acetyl- piperazin-1-yl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)-4- tert-butyl-benzamide C35H37N7O2 587.3 588.31
    55
    Figure US20110177011A1-20110721-C00064
         		4-tert-Butyl-N-(3-{8-[4-(3- methyl-piperazin-1-yl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H37N7O 559.31 560.35
    56
    Figure US20110177011A1-20110721-C00065
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzoic hydroxyl amide C30H28N6O3 520.22 521.26
    57
    Figure US20110177011A1-20110721-C00066
         		4-tert-Butyl-N-{3-[8-(4- hydroxymethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C30H29N5O2 491.23 492.28
    58
    Figure US20110177011A1-20110721-C00067
         		4-tert-Butyl-N-{3-[8-(4- piperazin-1-ylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C34H37N7O 559.31 560.37
    59
    Figure US20110177011A1-20110721-C00068
         		4-{6-[3-(4-Bromo-3-methyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzoic acid C27H20BrN5O3 541.07 542.14
    60
    Figure US20110177011A1-20110721-C00069
         		4-tert-Butyl-N-{3-[8-(3- methyl-4-piperazin-1-yl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C34H37N7O 559.31 560.35
    61
    Figure US20110177011A1-20110721-C00070
         		4-tert-Butyl-N-(3-{8-[4-(3- methyl-piperazin-1-yl)- phenylamino}-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H37N7O 559.31 560.26
    62
    Figure US20110177011A1-20110721-C00071
         		4-tert-Butyl-N-{3-[8-(3- hydroxymethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C30H29N5O2 491.23 492.28
    63
    Figure US20110177011A1-20110721-C00072
         		4-tert-Butyl-N-(3-{8-[3-(3- methyl-piperazin-1- ylmethyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C35H39N7O 573.32 574.4
    64
    Figure US20110177011A1-20110721-C00073
         		4-tert-Butyl-N-(3-{8-[3-(3- methyl-piperazin-1- ylmethyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C35H39N7O 573.32 574.35
    65
    Figure US20110177011A1-20110721-C00074
         		4-tert-Butyl-N-(3-{8-[3-(3,5- dimethyl-piperazin-1- ylmethyl)-phenylamino]- imidazo[1,2-a]pyrazin- 6-yl}-phenyl)-benzamide C36H41N7O 587.33 588.39
    66
    Figure US20110177011A1-20110721-C00075
         		4-tert-Butyl-N-(3-{8-[4-3,5- dimethyl-piperazin-1-yl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}- phenyl)-benzamide C35H39N7O 573.32 574.42
    67
    Figure US20110177011A1-20110721-C00076
         		4-({6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-methyl)-benzoic acid C31H29N5O3 519.22 520.4
    68
    Figure US20110177011A1-20110721-C00077
         		4-tert-Butyl-N-(3-{8-[4-(3- methyl-piperazin-1-yl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H37N7O 559.3 560.47
    69
    Figure US20110177011A1-20110721-C00078
         		4-(1-Hydroxy-1-methyl- ethyl)-N-[3-(8-phenylamino- imidazo[1,2-a]pyrazin-6-yl)- phenyl]-benzamide C28H25N5O2 463.2 464.36
    70
    Figure US20110177011A1-20110721-C00079
         		(3-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-phenyl)-acetic acid C31H29N5O3 519.22 520.4
    71
    Figure US20110177011A1-20110721-C00080
         		N-[3-(8-Phenylamino- imidazo[1,2-a]pyrazin-6-yl)- phenyl]-terephthalamic acid methyl ester C27H21N5O3 463.16 464.32
    72
    Figure US20110177011A1-20110721-C00081
         		N-[3-(8-Phenylamino- imidazo[1,2-a]pyrazin-6-yl)- phenyl]-terephthalamic acid C26H19N5O3 449.14 450.36
    73
    Figure US20110177011A1-20110721-C00082
         		2-(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino)-phenyl)-propionic acid ethyl ester C34H35N5O3 561.27 562.45
    74
    Figure US20110177011A1-20110721-C00083
         		2-(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-phenyl)-propionic acid C32H31N5O3 533.24 534.43
    75
    Figure US20110177011A1-20110721-C00084
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-2-methoxy- benzoic acid methyl ester C32H31N5O4 549.23 550.42
    76
    Figure US20110177011A1-20110721-C00085
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-2-methoxy- benzoic acid C31H29N5O4 535.22 536.42
    77
    Figure US20110177011A1-20110721-C00086
         		4-tert-Butyl-N-{3-[8-(3- methylcarbamoylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C32H32N6O2 532.26 533.4
    78
    Figure US20110177011A1-20110721-C00087
         		4-tert-Butyl-N-{3-[8-(4- methylcarbamoylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C32H32N6O2 532.25 533.41
    79
    Figure US20110177011A1-20110721-C00088
         		4-tert-Butyl-N-{3-[8-(4- cyclooctylcarbamoylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C39H44N6O2 628.35 629.51
    80
    Figure US20110177011A1-20110721-C00089
         		4-tert-Butyl-N-[3-(8-{4- [(diisopropylcarbamoyl)- methyl]-phenylamino}- imidazo[1,2-a]pyrazin-6-yl)- phenyl]-benzamide C37H42N6O2 602.34 603.49
    81
    Figure US20110177011A1-20110721-C00090
         		4-tert-Butyl-N-{3-[8-(4- carbamoylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C31H30N6O2 518.24 519.48
    82
    Figure US20110177011A1-20110721-C00091
         		3-(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-phenyl)-propionic acid C32H31N5O3 533.24 534.22
    83
    Figure US20110177011A1-20110721-C00092
         		4-tert-Butyl-N-(3-{8-[4-(2- hydroxy-ethyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C31H31N5O2 505.25 506.4
    84
    Figure US20110177011A1-20110721-C00093
         		4-tert-Butyl-N-(3-{8-[4-(2- methylamino-ethyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C32H34N6O 518.3 519.45
    85
    Figure US20110177011A1-20110721-C00094
         		4-tert-Butyl-N-{3-[8-(4- methylaminomethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C31H32N6O 504.26 505.43
    86
    Figure US20110177011A1-20110721-C00095
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-2-hydroxy-benzoic acid C30H27N5O4 521.2 522.31
    87
    Figure US20110177011A1-20110721-C00096
         		4-tert-Butyl-N-(3-{8-[4-(1- hydroxy-1-methyl-ethyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C32H33N5O2 519.26 520.27
    88
    Figure US20110177011A1-20110721-C00097
         		4-tert-Butyl-N-(3-{8-[4-(2- hydroxy-ethoxy)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C31H31N5O3 521.24 522.25
    89
    Figure US20110177011A1-20110721-C00098
         		4-tert-Butyl-N-(3-{8-[4-(4- methyl-piperazine-1- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C35H37N7O2 587.3 588.28
    90
    Figure US20110177011A1-20110721-C00099
         		4-tert-Butyl-N-(3-{8-[4-(2- methylamino-ethoxy)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C32H34N6O2 534.27 535.27
    91
    Figure US20110177011A1-20110721-C00100
         		4-tert-Butyl-N-(3-{8-[4-(2- dimethylamino-ethoxy)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C33H36N6O2 548.28 549.28
    92
    Figure US20110177011A1-20110721-C00101
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzoic methoxy amide C31H30N6O3 534.23 535.25
    93
    Figure US20110177011A1-20110721-C00102
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzoic hyrdoxyl methyl amide C31H30N6O3 534.23 535.25
    94
    Figure US20110177011A1-20110721-C00103
         		4-tert-Butyl-N-(3-{8-[4- ([1,4]diazepane-1-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C35H37N7O2 587.3 588.27
    95
    Figure US20110177011A1-20110721-C00104
         		4-tert-Butyl-N-(3-{8-[4- (pyrrolidine-1-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H34N6O2 558.27 559.25
    96
    Figure US20110177011A1-20110721-C00105
         		4-tert-Butyl-N-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H34N6O3 574.26 575.24
    97
    Figure US20110177011A1-20110721-C00106
         		4-tert-Butyl-N-(3-{8-[4- (ethoxyamine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C33H34N6O3 548.25 549.22
    98
    Figure US20110177011A1-20110721-C00107
         		4-tert-Butyl-N-(3-{8-[4- (dimethylamine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C32H32N6O2 532.25 533.22
    99
    Figure US20110177011A1-20110721-C00108
         		4-tert-Butyl-N-(3-{8-[4- (methylethylamine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C33H34N6O2 546.27 547.24
    100
    Figure US20110177011A1-20110721-C00109
         		4-tert-Butyl-N-(3-{8-[4-(3- oxo-piperazine-1-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H33N7O3 587.26 588.28
    101
    Figure US20110177011A1-20110721-C00110
         		4-tert-Butyl-N-(3-{8- [N,N,N′-Trimethyl-ethane- 1,2-diamine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C35H39N7O2 589.31 590.35
    102
    Figure US20110177011A1-20110721-C00111
         		4-tert-Butyl-N-(3-{8-[4-(4- methyl-[1,4]diazepane-1- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C36H39N7O2 601.31 602.32
    103
    Figure US20110177011A1-20110721-C00112
         		4-tert-Butyl-N-(3-{8-[4-(N- methyl ethoxyamine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C33H34N6O3 562.26 563.29
    104
    Figure US20110177011A1-20110721-C00113
         		4-tert-Butyl-N-(3-{8-[4-(4- ethyl-piperazine-1- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C36H39N7O2 601.31 602.38
    105
    Figure US20110177011A1-20110721-C00114
         		4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzoic benzyl amide C37H34N6O2 595.26 596.32
    106
    Figure US20110177011A1-20110721-C00115
         		4-tert-Butyl-N-(3-{8-[4-(4- methyl-piperazin-1- ylmethyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C35H39N7O 573.32 574.39
    107
    Figure US20110177011A1-20110721-C00116
         		4-tert-Butyl-N-(3-{8-[4-(4- ethyl-piperazin-1-ylmethyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C36H41N7O 587.33 588.42
    108
    Figure US20110177011A1-20110721-C00117
         		4-tert-Butyl-N-{3-[8-(4- [1,4]diazepan-1-ylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C35H39N7O 573.32 574.39
    109
    Figure US20110177011A1-20110721-C00118
         		4-tert-Butyl-N-(3-{8-[4-(3- methyl-piperazin-1- ylmethyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C35H39N7O 573.32 574.38
    110
    Figure US20110177011A1-20110721-C00119
         		4-tert-Butyl-N-{3-[8-(4- dimethylaminomethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C32H34N6O 518.27 519.33
    111
    Figure US20110177011A1-20110721-C00120
         		4-tert-Butyl-N-[3-(8-{4- [(ethyl-methyl-amino)- methyl]-phenylamino}- imidazo[1,2-a]pyrazin-6-yl)- phenyl]-benzamide C33H36N6O 532.29 533.33
    112
    Figure US20110177011A1-20110721-C00121
         		4-tert-Butyl-N-{3-[8-(4- {[(2-methoxy-ethyl)-methyl- amino]-methyl}- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C34H38N6O2 562.31 563.33
    113
    Figure US20110177011A1-20110721-C00122
         		4-tert-Butyl-N-[3-(8-{4-[(2- methoxy-ethylamino)- methyl]-phenylamino}- imidazo[1,2-a]pyrazin-6-yl)- phenyl]-benzamide C33H36N6O2 548.28 549.32
    114
    Figure US20110177011A1-20110721-C00123
         		4-tert-Butyl-N-{3-[8-(4- {[(2-dimethylamino-ethyl)- methyl-amino]-methyl}- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C35H41N7O 575.33 576.39
    115
    Figure US20110177011A1-20110721-C00124
         		N-(3-{8-[4-(4-Acetyl- piperazine-1-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)-4- tert-butyl-benzamide C36H37N7O3 615.29 616.31
    116
    Figure US20110177011A1-20110721-C00125
         		4-tert-Butyl-N-{3-[8-(4- {[(2-hydroxy-ethyl)-methyl- amino]-methyl}- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C33H36N6O2 548.28 549.32
    117
    Figure US20110177011A1-20110721-C00126
         		4-tert-Butyl-N-[3-(8-{4-[(2- hydroxy-ethylamino)- methyl]-phenylamino}- imidazo[1,2-a]pyrazin-6-yl)- phenyl]-benzamide C32H34N6O2 534.27 535.32
    118
    Figure US20110177011A1-20110721-C00127
         		4-tert-Butyl-N-(3-{8-[4-(4- methyl-[1,4]diazepan-1- ylmethyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C36H41N7O 587.33 588.37
    119
    Figure US20110177011A1-20110721-C00128
         		N-[3-(8-{4-[2-(Acetyl- methyl-amino)-ethoxy]- phenylamino}-imidazo[1,2- a]pyrazin-6-yl)-phenyl]-4- tert-butyl-benzamide C34H36N6O3 576.28 577.32
    120
    Figure US20110177011A1-20110721-C00129
         		4-(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-phenyl)- piperazine-1-carboxylic acid ethyl ester C36H39N7O3 617.31 618.31
    121
    Figure US20110177011A1-20110721-C00130
         		N-(3-{8-[4-(4-Acetyl- piperazin-1-ylmethyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl)-phenyl)-4- tert-butyl-benzamide C36H39N7O2 601.31 602.26
    122
    Figure US20110177011A1-20110721-C00131
         		4-tert-Butyl-N-{3-[8-(4- imidazol-1-ylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C33H31N7O 541.25 542.27
    123
    Figure US20110177011A1-20110721-C00132
         		4-tert-Butyl-N-{3-[8-(4- pyrrolidin-1-ylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C34H36N6O 544.29 545.3
    124
    Figure US20110177011A1-20110721-C00133
         		N-[3-(8-{4-[(Acetyl-methyl- amino)-methyl]- phenylamino}-imidazo[1,2- a]pyrazin-6-yl)-phenyl]-4- tert-butyl-benzamide C33H34N6O2 546.27 547.33
    125
    Figure US20110177011A1-20110721-C00134
         		4-tert-Butyl-N-[3-(8-{4- [(methanesulfonyl-methyl- amino)-methyl]- phenylamino}-imidazo[1,2- a]pyrazin-6-yl)-phenyl]- benzamide C32H34N6O3S 582.24 583.27
    126
    Figure US20110177011A1-20110721-C00135
         		4-tert-Butyl-N-(3-{8-[4-(3- isopropyl-1-methyl- ureidomethyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C35H39N7O2 589.31 590.35
    127
    Figure US20110177011A1-20110721-C00136
         		4-Isopropyl-N-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C33H32N6O3 560.25 561.28
    128
    Figure US20110177011A1-20110721-C00137
         		N-{3-[8-(4-{[(2-Hydroxy- ethyl)-methyl-amino]- carbonyl}-phenylamino)- imidazo[1,2-a]pyrazin-6-yl]- phenyl}-4-isopropyl- benzamide C32H32N6O3 548.25 549.25
    129
    Figure US20110177011A1-20110721-C00138
         		N-(3-{8-[4-(Morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C30H26N6O3 518.2 519.22
    130
    Figure US20110177011A1-20110721-C00139
         		4-Methyl-N-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C31H28N6O3 532.22 533.17
    131
    Figure US20110177011A1-20110721-C00140
         		4-Ethyl-N-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C32H30N6O3 546.23 547.17
    132
    Figure US20110177011A1-20110721-C00141
         		4-Fluoro-N-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C30H25FN6O3 536.19 537.21
    133
    Figure US20110177011A1-20110721-C00142
         		N-(3-{8-[4-(Morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-4-trifluoromethyl- benzamide C31H25F3N6O3 586.19 587.2
    134
    Figure US20110177011A1-20110721-C00143
         		4-tert-Butyl-N-(3-{8-[4-(5,6- dihydro-8H-imidazo[1,2- a]pyrazine-7-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C36H34N8O2 610.28 611.21
    135
    Figure US20110177011A1-20110721-C00144
         		4-tert-Butyl-N-(3-{8-[4-(3- oxo-piperazin-1-ylmethyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C34H35N7O2 573.28 574.18
    136
    Figure US20110177011A1-20110721-C00145
         		1-(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzyl)- pyrrolidine-2-carboxylic acid methyl ester C36H38N6O3 602.3 603.39
    137
    Figure US20110177011A1-20110721-C00146
         		N-(3-{8-[4-(Morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-terephthalamic acid methyl ester C32H28N6O5 576.21 577.36
    138
    Figure US20110177011A1-20110721-C00147
         		N-(3-{8-[4-(Morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-terephthalamic acid C31H26N6O5 562.19 563.33
    139
    Figure US20110177011A1-20110721-C00148
         		N-(3-{8-[4-(4-Acetyl- piperazin-1-yl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)-4- ethyl-benzamide C33H33N7O2 559.26 560.25
    140
    Figure US20110177011A1-20110721-C00149
         		N-(3-{8-[4-(4-Acetyl- piperazin-1-yl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)-4- trifluoromethyl-benzamide C32H28F3N7O2 599.22 600.22
    141
    Figure US20110177011A1-20110721-C00150
         		4-tert-Butyl-N-(3-{8-[4-(3- methyl-5,6-dihydro-8H- [1,2,4]triazolo[4,3-a]pyrazin- 7-ylmethyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C36H37N9O 611.31 612.41
    142
    Figure US20110177011A1-20110721-C00151
         		4-tert-Butyl-N-(3-{8-{4-(3- methyl-5,6-dihydro-8H- [1,2,4]triazolo[4,3- a]pyrazine-7-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C36H35N9O2 625.29 626.4
    143
    Figure US20110177011A1-20110721-C00152
         		N-(3-{8-[4-(4-Acetyl- piperazin-1-yl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)-4- isopropyl-benzamide C34H35N7O2 573.28 574.38
    144
    Figure US20110177011A1-20110721-C00153
         		N-(3-{8-[4-(4-Acetyl- piperazine-1-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)-4- isopropyl-benzamide C35H35N7O3 601.28 602.27
    145
    Figure US20110177011A1-20110721-C00154
         		1-(4-{6-[3-(4-tert-Butyl- benzoylamino)-phenyl]- imidazo[1,2-a]pyrazin-8- ylamino}-benzyl)- pyrrolidine-2-carboxylic acid C35H36N6O3 588.28 589.25
    146
    Figure US20110177011A1-20110721-C00155
         		4-Isopropyl-N-(3-{8-[4-(3- methyl-5,6-dihydro-8H- [1,2,4]triazolo[4,3- a]pyrazine-7-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C35H33N9O2 611.27 612.26
    147
    Figure US20110177011A1-20110721-C00156
         		N-(3-{8-[4-(5,6-Dihydro- 8H-imidazo[1,2-a]pyrazine- 7-carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-4-isopropyl- benzamide C35H32N8O2 596.26 597.26
    148
    Figure US20110177011A1-20110721-C00157
         		4-Isopropyl-N-(3-{8-[4-(3- oxo-piperazine-1-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C33H31N7O3 573.24 574.27
    149
    Figure US20110177011A1-20110721-C00158
         		4-Isopropyl-N-(3-{8-[4-(4- methyl-piperazine-1- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C34H35N7O2 573.28 574.29
    150
    Figure US20110177011A1-20110721-C00159
         		4-Isopropyl-N-(3-{8-[4-(3- oxo-piperazin-1-ylmethyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C33H33N7O2 559.26 560.29
    151
    Figure US20110177011A1-20110721-C00160
         		N-(3-{8-[4-(4-Acetyl- piperazin-1-ylmethyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)-4- isopropyl-benzamide C35H37N7O2 587.3 588.31
    152
    Figure US20110177011A1-20110721-C00161
         		N-(3-{8-[4-(Morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-isonicotinamide C29H25N7O3 519.2 520.2
    153
    Figure US20110177011A1-20110721-C00162
         		N-(3-{8-[4-(Morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-nicotinamide C29H25N7O3 519.2 520.19
    154
    Figure US20110177011A1-20110721-C00163
         		4-tert-Butyl-N-(3-{8-[4-(2- morpholin-4-yl-2-oxo- ethyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C35H36N6O3 588.28 589.28
    155
    Figure US20110177011A1-20110721-C00164
         		4-tert-Butyl-N-(3-{8-[3-(2- morpholin-4-yl-2-oxo- ethyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C35H36N6O3 588.28 589.29
    156
    Figure US20110177011A1-20110721-C00165
         		4-Isopropyl-N-{3-[8-(4- morpholin-4-ylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C33H34N6O2 546.27 547.28
    157
    Figure US20110177011A1-20110721-C00166
         		4-tert-Butyl-N-{3-[8-(4- morpholin-4-ylmethyl- phenylamino)-imidazo[1,2- a]pyrazin-6-yl]-phenyl}- benzamide C34H36N6O2 560.28 561.43
    158
    Figure US20110177011A1-20110721-C00167
         		N-(3-{8-[4-(Morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-2-phenyl-acetamide C31H28N6O3 532.22 533.21
    159
    Figure US20110177011A1-20110721-C00168
         		N-(4-tert-Butyl-phenyl)-3- {8-[4-(morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- benzamide C34H34N6O3 574.27 575.23
    160
    Figure US20110177011A1-20110721-C00169
         		N-(3-Chloro-benzyl)-3-{8- [4-(morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-benzamide C31H27ClN6O3 566.18 567.17
    161
    Figure US20110177011A1-20110721-C00170
         		4-Cyano-N-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C31H25N7O3 543.2 544.32
    162
    Figure US20110177011A1-20110721-C00171
         		6-Dimethylamino-N-(3-{8- [4-(morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- nicotinamide C31H30N8O3 562.24 563.26
    163
    Figure US20110177011A1-20110721-C00172
         		N-Methyl-N′-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- terephthalamide C32H29N7O4 575.22 576.25
    164
    Figure US20110177011A1-20110721-C00173
         		N,N-Dimethyl-N′-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- terephthalamide C33H31N7O4 589.24 590.26
    165
    Figure US20110177011A1-20110721-C00174
         		4-Acetyl-N-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- benzamide C32H28N6O4 560.21 561.25
    166
    Figure US20110177011A1-20110721-C00175
         		4-(1H-Imidazol-2-yl)-N-(3- {8-[4-(morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-benzamide C33H28N8O3 584.22 585.31
    167
    Figure US20110177011A1-20110721-C00176
         		2-(3-Isopropyl-phenoxy)-N- (3-{8-[4-(morpholine-4- carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}- phenyl)-acetamide C34H34N6O4 590.26 591.32
    168
    Figure US20110177011A1-20110721-C00177
         		6-tert-Butyl-N-(3-{8-[4- (morpholine-4-carbonyl)- phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)- nicotinamide C33H33N7O3 575.26 576.24
    169
    Figure US20110177011A1-20110721-C00178
         		4-(6-{3-[(6-tert-Butyl- pyridine-3-carbonyl)- amino]-phenyl}- imidazo[1,2a] pyrazin-8-ylamino)-benzoic acid C29H26N6O3 506.2 507.21
  • The compounds disclosed in synthetic Examples 1 to 5 were tested in the Btk biochemical assay described in Example 6 and found to exhibit an IC50 value less than or equal to 1 micromolar certain of these compounds were found to exhibit an IC50 value less than or equal to 100 nM, and certain of these compounds exhibited an IC50 value less than or equal to 10 nM. Some of the compounds disclosed in synthetic Examples 1 to 5 were tested in the B-cell proliferation assay of Example 8 and determined to exhibit an IC50 value less than or equal to 10 micromolar, certain of these compounds exhibited an IC50 value less than or equal to 1 micromolar, and certain of these compounds exhibited an IC50 value less than or equal to 500 nM in this assay. Certain of these compounds do not inhibit T-cell proliferation and have IC50 values greater than or equal to 5 micromolar when assayed under conditions described in Example 9. The compounds assayed in the Example 8 and Example 9 exhibited IC50 values for inhibition of T-cell proliferation that were at least 3-fold, and in some instances 5-fold, or even 10-fold greater than the IC50 values of these compounds for inhibition of B-cell proliferation.
    • Example 6 Biochemical Btk Assay
  • A generalized procedure for one standard biochemical Btk Kinase Assay used to test compounds disclosed in this application is as follows.
  • A master mix minus Btk enzyme is prepared containing 1× Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM β-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 μM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1× Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6×His tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk. Generation of baculovirus was done based on Invitrogen's instructions detailed in its published protocol “Bac-toBac Baculovirus Expression Systems” (Cat. Nos. 10359-016 and 10608-016). Passage 3 virus was used to infect Sf9 cells to overexpress the recombinant Btk protein. The Btk protein was then purified to homogeneity using Ni-NTA column. The purity of the final protein preparation was greater than 95% based on the sensitive Sypro-Ruby staining. A solution of 200 μM ATP is prepared in water and adjusted to pH7.4 with 1N NaOH. A quantity of 1.25 μL of compounds in 5% DMSO is transferred to a 96-well ½ area Costar polystyrene plate. Compounds are tested singly and with an 11-point dose-responsive curve (starting concentration is 10 μM; 1:2 dilution). A quantity of 18.75 μL of master mix minus enzyme (as a negative control) and master mix plus enzyme is transferred to appropriate wells in 96-well ½ area costar polystyrene plate. 5 μL of 200 μM ATP is added to that mixture in the 96-well ½ area Costar polystyrene plate for final ATP concentration of 40 μM. The reaction is allowed to incubate for 1 hour at room temperature. The reaction is stopped with Perkin Elmer 1× detection buffer containing 30 mM EDTA, 20 nM SA-APC, and 1 nM PT66 Ab. The plate is read using time-resolved fluorescence with a Perkin Elmer Envision using excitation filter 330 nm, emission filter 665 nm, and 2nd emission filter 615 nm. IC50 values are subsequently calculated.
    • Example 7 Ramos Cell Btk Assay
  • Another generalized procedure for a standard cellular Btk Kinase Assay used to test compounds disclosed in this application is as follows.
  • Ramos cells are incubated at a density of 0.5×107 cells/ml in the presence of test compound for 1 hr at 37° C. Cells are then stimulated by incubating with 10 μg/ml anti-human IgM F(ab)2 for 5 minutes at 37° C. Cells are pelleted, lysed, and a protein assay is performed on the cleared lysate. Equal protein amounts of each sample are subject to SDS-PAGE and western blotting with either anti-phosphoBtk(Tyr223) antibody (Cell Signaling Technology #3531) to assess Btk autophosphorylation or an anti-Btk antibody (BD Transduction Labs #611116) to control for total amounts of Btk in each lysate.
    • Example 8 B-Cell Proliferation Assay
  • B-cells are purified from spleens of 8-16 week old Balb/c mice using a B-cell isolation kit (Miltenyi Biotech, Cat # 130-090-862). Testing compounds are diluted in 0.25% DMSO and incubated with 2.5×105 purified mouse splenic B-cells for 30 min prior to addition of 10 μg/ml of an anti-mouse IgM antibody (Southern Biotechnology Associates Cat # 1022-01) in a final volume of 100 μl. Following 24 hr incubation, 1 μCi3H-thymidine is added and plates are incubated an additional 36 hr prior to harvest using the manufacturer's protocol for SPA[3H] thymidine uptake assay system (Amersham Biosciences # RPNQ 0130). SPA-bead based fluorescence is counted in a microbeta counter (Wallace Triplex 1450, Perkin Elmer).
    • Example 9 T Cell Proliferation Assay
  • T cells are purified from spleens of 8-16 week old Balb/c mice using a Pan T cell isolation kit (Miltenyi Biotech, Cat # 130-090-861). Testing compounds are diluted in 0.25% DMSO and incubated with 2.5×105 purified mouse splenic T cells in a final volume of 100 μl in flat clear bottom plates precoated for 90 min at 37° C. with 10 μg/ml each of anti-CD3 (BD # 553057) and anti-CD28 (BD # 553294) antibodies. Following 24 hr incubation, 1 μCi 3H-thymidine is added and plates incubated an additional 36 hr prior to harvest using the manufacturer's protocol for SPA[3H] thymidine uptake assay system (Amersham Biosciences # RPNQ 0130). SPA-bead based fluorescence was counted in a microbeta counter (Wallace Triplex 1450, Perkin Elmer).

Claims (16)

1-86. (canceled)
87. A pharmaceutical composition, comprising at least one pharmaceutically acceptable carrier or excipient and a compound of Formula 1
Figure US20110177011A1-20110721-C00179
or a pharmaceutically acceptable salt, hydrate or diastereomer thereof, wherein
A is 0 or 1;
R1 is
substituted phenyl wherein the substituent is
hydroxy,
CHO,
—COOH,
—CONH2,
—CONHOH,
C2-C6 alkenyl,
mono-, di- or tri-substituted C2-C6 alkenyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C2-C6 alkynyl,
mono-, di- or tri-substituted C2-C6 alkynyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C1-C6hydroxyalkyl,
mono-, di- or tri-substituted C1-C6hydroxyalkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C1-C6hydroxyalkoxy,
mono-, di- or tri-substituted C1-C6hydroxyalkoxy, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
(mono-C1-C6alkylamino)C1-C6alkoxy,
mono-, di- or tri-substituted (mono-C1-C6alkylamino)C1-C6alkoxy, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
(di-C1-C6alkylamino)C1-C6alkoxy,
mono-, di- or tri-substituted (di-C1-C6alkylamino)C1-C6alkoxy, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
(C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl,
mono-, di- or tri-substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
(C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy,
mono-, di- or tri-substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
heterocycloalkyl,
mono-, di- or tri-substituted heterocycloalkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
aryl,
mono-, di- or tri-substituted aryl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
heteroaryl,
mono-, di- or tri-substituted heteroaryl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C1-C6alkyl(C═O)OR10,
mono-, di- or tri-substituted-C1-C6alkyl(C═O)OR10, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C0-C6alkyl(C═O)NR10R11,
mono-, di- or tri-substituted-C0-C6alkyl(C═O)NR10R11, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C1-C6alkylNR10(SO2)R11,
mono-, di- or tri-substituted-C1-C6alkylNR10(SO2)R11, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C0-C6alkylNR10(C═O)R11,
mono-, di- or tri-substituted-C0-C6alkylNR10(C═O)R11, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C0-C6alkyl(SO2)R10,
mono-, di- or tri-substituted-C0-C6alkyl(SO2)R10, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C0-C6alkylNR10(C═O)NR11R12,
mono-, di- or tri-substituted-C0-C6alkylNR10(C═O)NR11R12, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
-L-G, where
L is
C1-C2alkylene,
mono-, di- or tri-substituted C1-C2alkylene, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C0-C2alkylene-O—,
mono-, di- or tri-substituted C0-C2alkylene-O—, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—(C═O)—,
—(C1-C2alkylene)(C═O)—,
mono-, di- or tri-substituted —(C1-C2alkylene)(C═O)—, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
G is
heterocycloalkyl,
mono-, di- or tri-substituted heterocycloalkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C3-C7cycloalkyl,
mono-, di- or tri-substituted C3-C7cycloalkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
aryl,
mono-, di- or tri-substituted aryl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
heteroaryl,
mono-, di- or tri-substituted heteroaryl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
or
substituted heteroaryl wherein the substituent is
oxo,
—CHO,
—COOH,
—CONH2,
—CONHOH,
C2-C6 alkenyl,
mono-, di- or tri-substituted C2-C6 alkenyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C2-C6 alkynyl,
mono-, di- or tri-substituted C2-C6 alkynyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C1-C6hydroxyalkyl,
mono-, di- or tri-substituted C1-C6hydroxyalkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C1-C6hydroxyalkoxy,
mono-, di- or tri-substituted C1-C6hydroxyalkoxy, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
(mono-C1-C6alkylamino)C1-C6alkoxy,
mono-, di- or tri-substituted (mono-C1-C6alkylamino)C1-C6alkoxy, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
(di-C1-C6alkylamino)C1-C6alkoxy,
mono-, di- or tri-substituted (di-C1-C6alkylamino)C1-C6alkoxy, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
(C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl,
mono-, di- or tri-substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
(C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy,
mono-, di- or tri-substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
heterocycloalkyl,
mono-, di- or tri-substituted heterocycloalkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
aryl,
mono-, di- or tri-substituted aryl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
heteroaryl,
mono-, di- or tri-substituted heteroaryl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C1-C6alkyl(C═O)OR10,
mono-, di- or tri-substituted-C1-C6alkyl(C═O)OR10, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C0-C6alkyl(C═O)NR10R11,
mono-, di- or tri-substituted-C0-C6alkyl(C═O)NR10R11, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C1-C6alkylNR10(SO2)R11,
mono-, di- or tri-substituted-C1-C6alkylNR10(SO2)R11, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C0-C6alkylNR10(C═O)R11,
mono-, di- or tri-substituted-C0-C6alkylNR10(C═O)R11, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C0-C6alkyl(SO2)R10,
mono-, di- or tri-substituted-C0-C6alkyl(SO2)R10, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—C0-C6alkylNR10(C═O)NR11R12,
mono-, di- or tri-substituted-C0-C6alkylNR10(C═O)NR11R12, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
-L-G, where
L is
C1-C2alkylene,
mono-, di- or tri-substituted C1-C2alkylene, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C0-C2alkylene-O—,
mono-, di- or tri-substituted C0-C2alkylene-O—, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
—(C═O)—,
—(C1-C2alkylene)(C═O)—,
mono-, di- or tri-substituted —(C1-C2alkylene)(C═O)—, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
G is
heterocycloalkyl,
mono-, di- or tri-substituted heterocycloalkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
C3-C7cycloalkyl,
mono-, di- or tri-substituted C3-C7cycloalkyl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
aryl,
mono-, di- or tri-substituted aryl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
heteroaryl,
mono-, di- or tri-substituted heteroaryl, wherein the substituents are independently halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, or phenyl,
R10, R11, and R12 are independently hydrogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C3-C10cycloalkyl, or heterocycloalkyl,
R1 is optionally further substituted with 1 or more substituents which are independently hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono-C1-C6 alkylamino)C0-C6 alkyl, (di-C1-C6 alkylamino)C0-C6 alkyl, or
C1-C6alkoxycarbonyl;
R2 is
C1-C7 alkyl,
(C1-C6alkoxy)C0-C6alkoxy,
(heterocycloalkyl) C0-C2alkyl,
(C3-C7cycloalkyl)C0-C2alkyl,
(phenyl)C0-C2alkyl,
mono-, di-, or tri-substituted (phenyl)C0-C2alkyl, wherein the substituents are independently hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6alkylamino, di-C1-C6alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, or —(C═O)R13 wherein R13 is C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, or heteroaryl;
(phenoxy)C0-C2alkyl,
mono-, di-, or tri-substituted (phenoxy)C0-C2alkyl, wherein the substituents are independently hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6alkylamino, di-C1-C6alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, or —(C═O)R13 wherein R13 is C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, or heteroaryl;
(heteroaryl)C0-C2alkyl,
mono-, di-, or tri-substituted (heteroaryl)C0-C2alkyl, wherein the substituents are independently hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6alkylamino, di-C1-C6alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, or —(C═O)R13 wherein R13 is C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, or heteroaryl;
Z1 is
Figure US20110177011A1-20110721-C00180
R4 is
Hydrogen,
C1-C6alkyl,
substituted C1-C6alkyl wherein the substituent is hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or —C(O)R14 wherein R14 is C1-C6 alkyl, C1-C3haloalkyl, or phenyl;
C3-C7cycloalkyl,
substituted C3-C7cycloalkyl, wherein the substituent is hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or —C(O)R14 wherein R14 is C1-C6 alkyl, C1-C3haloalkyl, or phenyl;
heterocycloalkyl,
substituted heterocycloalkyl, wherein the substituent is hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or —C(O)R14 wherein R14 is C1-C6 alkyl, C1-C3haloalkyl, or phenyl;
phenyl,
substituted phenyl, wherein the substituent is hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or —C(O)R14 wherein R14 is C1-C6 alkyl, C1-C3haloalkyl, or phenyl;
heteroaryl,
substituted heteroaryl, wherein the substituent is hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or —C(O)R14 wherein R14 is C1-C6 alkyl, C1-C3haloalkyl, or phenyl;
Q is phenyl or pyridyl;
R3 is
hydrogen,
halogen,
C1-C7 alkyl,
heterocycloalkyl,
mono-, di-, or tri-substituted heterocycloalkyl, wherein the substituents are independently hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono-C1-C6alkylamino, di-C1-C6alkylamino, aminoC1-C6 alkyl, or —C(O)R14,
C3-C7cycloalkyl,
mono-, di-, or tri-substituted C3-C7cycloalkyl, wherein the substituents are independently hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono-C1-C6alkylamino, di-C1-C6alkylamino, aminoC1-C6 alkyl, or —C(O)R14,
heteroaryl,
mono-, di-, or tri-substituted heteroaryl, wherein the substituents are independently hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono-C1-C6alkylamino, di-C1-C6alkylamino, aminoC1-C6 alkyl, or —C(O)R14.
88. A pharmaceutical composition of claim 87, wherein the composition is formulated as an injectable fluid, an aerosol, a cream, a gel, a tablet, a pill, a capsule, a syrup, ophthalmic solution, or a transdermal patch.
89. A packaged pharmaceutical composition, comprising
a pharmaceutical composition in a container; and instructions for using the composition to treat a patient suffering from an disease responsive to Btk inhibition, wherein the pharmaceutical composition comprises
(a) at least one pharmaceutically acceptable carrier or excipient and
(b) the compound of Formula I-a
Figure US20110177011A1-20110721-C00181
or a pharmaceutically acceptable salt, hydrate or diastereomer thereof, wherein
A is chosen from 0 and 1;
R1 is chosen from
phenyl substituted with a group chosen from
hydroxy,
—CHO,
—COOH,
—CONH2,
—CONHOH,
C2-C6 alkenyl,
substituted C2-C6 alkenyl chosen from mono-, di-, and tri-substituted C2-C6 alkenyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C2-C6 alkynyl,
substituted C2-C6 alkynyl chosen from mono-, di-, and tri-substituted C2-C6 alkynyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkyl,
substituted C1-C6hydroxyalkyl chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkoxy,
substituted C1-C6hydroxyalkoxy chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(mono-C1-C6alkylamino)C1-C6alkoxy,
substituted (mono-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (mono-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(di-C1-C6alkylamino)C1-C6alkoxy,
substituted (di-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (di-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl,
substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy,
substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl,
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkyl(C═O)OR10,
substituted —C1-C6alkyl(C═O)OR10 chosen from mono-, di-, and tri-substituted —C1-C6alkyl(C═O)OR10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(C═O)NR10R11,
substituted —C0-C6alkyl(C═O)NR10R11 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(C═O)NR10R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkylNR10(SO2)R11,
substituted —C1-C6alkylNR10(SO2)R11 chosen from mono-, di-, and tri-substituted —C1-C6alkylNR10(SO2)R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)R11,
substituted —C0-C6alkylNR10(C═O)R11 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)R11, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(SO2)R10,
substituted —C0-C6alkyl(SO2)R10 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(SO2)R10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)NR11R12,
substituted —C0-C6alkylNR10(C═O)NR11R12 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)NR11R12, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
-L-G, where
L is chosen from
C1-C2alkylene,
substituted C1-C2alkylene chosen from mono-, di-, and tri-substituted C1-C2alkylene wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C0-C2alkylene-O—,
substituted C0-C2alkylene-O— chosen from mono-, di-, and tri-substituted C0-C2alkylene-O— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—(C═O)—,
—(C1-C2alkylene)(C═O)—, and
substituted —(C1-C2alkylene)(C═O)— chosen from mono-, di-, and tri-substituted —(C1-C2alkylene)(C═O)— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
G is chosen from
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C3-C7cycloalkyl,
substituted C3-C7cycloalkyl chosen from mono-, di-, and tri-substituted C3-C7cycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl, and
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
heteroaryl substituted with a group chosen from
hydroxy,
—CHO,
—COOH,
—CONH2,
—CONHOH,
C2-C6 alkenyl,
substituted C2-C6 alkenyl chosen from mono-, di-, and tri-substituted C2-C6 alkenyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C2-C6 alkynyl,
substituted C2-C6 alkynyl chosen from mono-, di-, and tri-substituted C2-C6 alkynyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkyl,
substituted C1-C6hydroxyalkyl chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkoxy,
substituted C1-C6hydroxyalkoxy chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(mono-C1-C6alkylamino)C1-C6alkoxy,
substituted (mono-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (mono-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(di-C1-C6alkylamino)C1-C6alkoxy,
substituted (di-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (di-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl,
substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy,
substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl,
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkyl(C═O)OR10,
substituted —C1-C6alkyl(C═O)OR10 chosen from mono-, di-, and tri-substituted —C1-C6alkyl(C═O)OR10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(C═O)NR10R11,
substituted —C0-C6alkyl(C═O)NR10R11 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(C═O)NR10R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkylNR10(SO2)R11,
substituted —C1-C6alkylNR10(SO2)R11 chosen from mono-, di-, and tri-substituted —C1-C6alkylNR10(SO2)R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)R11,
substituted —C0-C6alkylNR10(C═O)R11 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)R11, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(SO2)R10,
substituted —C0-C6alkyl(SO2)R10 chosen from mono-, di-, and tri-substituted-C0-C6alkyl(SO2)R10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)NR11R12,
substituted —C0-C6alkylNR10(C═O)NR11R12 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)NR11R12, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
-L-G, where
L is chosen from
C1-C2alkylene,
substituted C1-C2alkylene chosen from mono-, di-, and tri-substituted C1-C2alkylene wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C0-C2alkylene-O—,
substituted C0-C2alkylene-O— chosen from mono-, di-, and tri-substituted C0-C2alkylene-O— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—(C═O)—,
—(C1-C2alkylene)(C═O)—, and
substituted —(C1-C2alkylene)(C═O)— chosen from mono-, di-, and tri-substituted —(C1-C2alkylene)(C═O)— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
G is chosen from
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C3-C7cycloalkyl,
substituted C3-C7cycloalkyl chosen from mono-, di-, and tri-substituted C3-C7cycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl, and
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
R1 is optionally further substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono-C1-C6 alkylamino)C0-C6 alkyl, (di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl;
R2 is chosen from
C1-C7 alkyl,
(C1-C6alkoxy)C0-C6alkoxy,
(heterocycloalkyl)C0-C2alkyl,
(C3-C7cycloalkyl)C0-C2alkyl,
(phenyl)C0-C2alkyl,
substituted (phenyl)C0-C2alkyl chosen from mono-, di-, and tri-substituted (phenyl)C0-C2alkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6alkylamino, di-C1-C6alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is chosen from C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, and heteroaryl,
(phenoxy)C0-C2alkyl,
substituted (phenoxy)C0-C2alkyl chosen from mono-, di-, and tri-substituted (phenoxy)C0-C2alkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6alkylamino, di-C1-C6alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is chosen from C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, and heteroaryl,
(heteroaryl)C0-C2alkyl, and
substituted (heteroaryl)C0-C2alkyl chosen from mono-, di-, and tri-substituted (heteroaryl)C0-C2alkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6alkylamino, di-C1-C6alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is chosen from C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, and heteroaryl;
Z1 is chosen from
Figure US20110177011A1-20110721-C00182
wherein
R4 is chosen from
hydrogen,
C1-C6alkyl,
C1-C6alkyl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
C3-C7cycloalkyl,
C3-C7cycloalkyl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
heterocycloalkyl,
heterocycloalkyl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
phenyl,
phenyl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
heteroaryl,
heteroaryl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
Q is chosen from phenyl and pyridyl; and
R3 is chosen from
hydrogen,
halogen,
C1-C7 alkyl,
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono —C1-C6alkylamino, di-C1-C6alkylamino, aminoC1-C6 alkyl, and —C(O)R14,
C3-C7cycloalkyl,
substituted C3-C7cycloalkyl chosen from mono-, di-, and tri-substituted C3-C7cycloalkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono —C1-C6alkylamino, di-C1-C6alkylamino, aminoC1-C6 alkyl, and —C(O)R14,
heteroaryl, and
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono —C1-C6alkylamino, di-C1-C6alkylamino, aminoC1-C6 alkyl, and −C(O)R14.
90. A packaged pharmaceutical composition, comprising a pharmaceutical composition of claim 87 in a container; and instructions for using the composition to treat a patient suffering from an disease responsive to Btk inhibition.
91. The packaged pharmaceutical composition of claim 89 wherein the disease responsive to Btk inhibition is cancer.
92. The packaged pharmaceutical composition of claim 89 wherein the disease responsive to Btk inhibition is an autoimmune disease, an inflammatory disease, or an acute inflammatory reaction.
93. A method for treating a patient having a disease responsive to inhibition of Btk activity, comprising administering to the patient an effective amount of the compound of Formula I-a
Figure US20110177011A1-20110721-C00183
or a pharmaceutically acceptable salt, hydrate or diastereomer thereof, wherein
A is chosen from 0 and 1;
R1 is chosen from
phenyl substituted with a group chosen from
hydroxy,
—CHO,
—COOH,
—CONH2,
—CONHOH,
C2-C6 alkenyl,
substituted C2-C6 alkenyl chosen from mono-, di-, and tri-substituted C2-C6 alkenyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C2-C6 alkynyl,
substituted C2-C6 alkynyl chosen from mono-, di-, and tri-substituted C2-C6 alkynyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkyl,
substituted C1-C6hydroxyalkyl chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkoxy,
substituted C1-C6hydroxyalkoxy chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(mono-C1-C6alkylamino)C1-C6alkoxy,
substituted (mono-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (mono-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(di-C1-C6alkylamino)C1-C6alkoxy,
substituted (di-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (di-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl,
substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy,
substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl,
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkyl(C═O)OR10,
substituted —C1-C6alkyl(C═O)OR10 chosen from mono-, di-, and tri-substituted —C1-C6alkyl(C═O)OR10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(C═O)NR10R11,
substituted —C0-C6alkyl(C═O)NR10R11 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(C═O)NR10R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkylNR10(SO2)R11,
substituted —C1-C6alkylNR10(SO2)R11 chosen from mono-, di-, and tri-substituted —C1-C6alkylNR10(SO2)R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)R11,
substituted —C0-C6alkylNR10(C═O)R11 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)R11, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(SO2)R10,
substituted —C0-C6alkyl(SO2)R10 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(SO2)R10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)NR11R12,
substituted —C0-C6alkylNR10(C═O)NR11R12 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)NR11R12, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
-L-G, where
L is chosen from
C1-C2alkylene,
substituted C1-C2alkylene chosen from mono-, di-, and tri-substituted C1-C2alkylene wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C0-C2alkylene-O—,
substituted C0-C2alkylene-O— chosen from mono-, di-, and tri-substituted C0-C2alkylene-O— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—(C═O)—,
—(C1-C2alkylene)(C═O)—, and
substituted —(C1-C2alkylene)(C═O)— chosen from mono-, di-, and tri-substituted —(C1-C2alkylene)(C═O)— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
G is chosen from
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C3-C7cycloalkyl,
substituted C3-C7cycloalkyl chosen from mono-, di-, and tri-substituted C3-C7cycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl, and
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
heteroaryl substituted with a group chosen from hydroxy,
—CHO,
—COOH,
—CONH2,
—CONHOH,
C2-C6 alkenyl,
substituted C2-C6 alkenyl chosen from mono-, di-, and tri-substituted C2-C6 alkenyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C2-C6 alkynyl,
substituted C2-C6 alkynyl chosen from mono-, di-, and tri-substituted C2-C6 alkynyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkyl,
substituted C1-C6hydroxyalkyl chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkoxy,
substituted C1-C6hydroxyalkoxy chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(mono-C1-C6alkylamino)C1-C6alkoxy,
substituted (mono-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (mono-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(di-C1-C6alkylamino)C1-C6alkoxy,
substituted (di-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (di-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl,
substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy,
substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl,
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkyl(C═O)OR10,
substituted —C1-C6alkyl(C═O)OR10 chosen from mono-, di-, and tri-substituted —C1-C6alkyl(C═O)OR10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(C═O)NR10R11,
substituted —C0-C6alkyl(C═O)NR10R11 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(C═O)NR10R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkylNR10(SO2)R11,
substituted —C1-C6alkylNR10(SO2)R11 chosen from mono-, di-, and tri-substituted —C1-C6alkylNR10(SO2)R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)R11,
substituted —C0-C6alkylNR10(C═O)R11 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)R11, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(SO2)R10,
substituted —C0-C6alkyl(SO2)R10 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(SO2)R10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)NR11R12,
substituted —C0-C6alkylNR10(C═O)NR11R12 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)NR11R12, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
-L-G, where
L is chosen from
C1-C2alkylene,
substituted C1-C2alkylene chosen from mono-, di-, and tri-substituted C1-C2alkylene wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C0-C2alkylene-O—,
substituted C0-C2alkylene-O— chosen from mono-, di-, and tri-substituted C0-C2alkylene-O— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—(C═O)—,
—(C1-C2alkylene)(C═O)—, and
substituted —(C1-C2alkylene)(C═O)— chosen from mono-, di-, and tri-substituted —(C1-C2alkylene)(C═O)— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
G is chosen from
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C3-C7cycloalkyl,
substituted C3-C7cycloalkyl chosen from mono-, di-, and tri-substituted C3-C7cycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl, and
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
R1 is optionally further substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono-C1-C6 alkylamino)C0-C6 alkyl, (di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl;
R2 is chosen from
C1-C7 alkyl,
(C1-C6alkoxy)C0-C6alkoxy,
(heterocycloalkyl)C0-C2alkyl,
(C3-C7cycloalkyl)C0-C2alkyl,
(phenyl)C0-C2alkyl,
substituted (phenyl)C0-C2alkyl chosen from mono-, di-, and tri-substituted (phenyl)C0-C2alkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6alkylamino, di-C1-C6alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is chosen from C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, and heteroaryl,
(phenoxy)C0-C2alkyl,
substituted (phenoxy)C0-C2alkyl chosen from mono-, di-, and tri-substituted (phenoxy)C0-C2alkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6alkylamino, di-C1-C6alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is chosen from C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, and heteroaryl,
(heteroaryl)C0-C2alkyl, and
substituted (heteroaryl)C0-C2alkyl chosen from mono-, di-, and tri-substituted (heteroaryl)C0-C2alkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6alkylamino, di-C1-C6alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is chosen from C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, and heteroaryl
Z1 is chosen from
Figure US20110177011A1-20110721-C00184
wherein
R4 is chosen from
hydrogen,
C1-C6alkyl,
C1-C6alkyl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
C3-C7cycloalkyl,
C3-C7cycloalkyl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
heterocycloalkyl,
heterocycloalkyl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
phenyl,
phenyl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
heteroaryl,
heteroaryl substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6 alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and —C(O)R14 wherein R14 is chosen from C1-C6 alkyl, C1-C3haloalkyl, and phenyl;
Q is chosen from phenyl and pyridyl; and
R3 is chosen from
hydrogen,
halogen,
C1-C7 alkyl,
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono —C1-C6alkylamino, di-C1-C6alkylamino, aminoC1-C6 alkyl, and —C(O)R14,
C3-C7cycloalkyl,
substituted C3-C7cycloalkyl chosen from mono-, di-, and tri-substituted C3-C7cycloalkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono —C1-C6alkylamino, di-C1-C6alkylamino, aminoC1-C6 alkyl, and —C(O)R14,
heteroaryl, and
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6-alkoxy)C1-C6 alkoxy, mono —C1-C6alkylamino, di-C1-C6alkylamino, aminoC1-C6 alkyl, and —C(O)R14
94. A method for treating a patient having a disease responsive to inhibition of Btk activity, comprising administering an effective amount of the pharmaceutical composition according to claim 87 to the patient.
95. A method for increasing sensitivity of cancer cells to chemotherapy, comprising administering to a patient undergoing chemotherapy with a chemotherapeutic agent an amount of the pharmaceutical composition of claim 87, sufficient to increase the sensitivity of cancer cells to the chemotherapeutic agent.
96. A pharmaceutical composition of claim 87, wherein in the compound of formula I, A is 0.
97. A pharmaceutical composition of claim 87, wherein in the compound of formula I, A is 1.
98. A pharmaceutical composition of claim 87, wherein in the compound of formula I,
R1 is chosen from
phenyl substituted with
hydroxy,
—CHO,
—COOH,
—CONH2,
—CONHOH,
C2-C6 alkenyl,
substituted C2-C6 alkenyl chosen from mono-, di-, and tri-substituted C2-C6 alkenyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C2-C6 alkynyl,
substituted C2-C6 alkynyl chosen from mono-, di-, and tri-substituted C2-C6 alkynyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkyl,
substituted C1-C6hydroxyalkyl chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkoxy,
substituted C1-C6hydroxyalkoxy chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(mono-C1-C6alkylamino)C1-C6alkoxy,
substituted (mono-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (mono-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(di-C1-C6alkylamino)C1-C6alkoxy,
substituted (di-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (di-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl,
substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy,
substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl,
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkyl(C═O)OR10,
substituted —C1-C6alkyl(C═O)OR10 chosen from mono-, di-, and tri-substituted —C1-C6alkyl(C═O)OR10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(C═O)NR10R11,
substituted —C0-C6alkyl(C═O)NR10R11 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(C═O)NR10R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkylNR10(SO2)R11,
substituted —C1-C6alkylNR10(SO2)R11 chosen from mono-, di-, and tri-substituted —C1-C6alkylNR10(SO2)R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)R11,
substituted —C0-C6alkylNR10(C═O)R11 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)R11, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(SO2)R10,
substituted —C0-C6alkyl(SO2)R10 chosen from mono-, di-, and tri-substituted-C0-C6alkyl(SO2)R10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)NR11R12,
substituted —C0-C6alkylNR10(C═O)NR11R12 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)NR11R12, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
-L-G, where
L is chosen from
C1-C2alkylene,
substituted C1-C2alkylene chosen from mono-, di-, and tri-substituted C1-C2alkylene wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C0-C2alkylene-O—,
substituted C0-C2alkylene-O— chosen from mono-, di-, and tri-substituted C0-C2alkylene-O— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—(C═O)—,
—(C1-C2alkylene)(C═O)—, and
substituted —(C1-C2alkylene)(C═O)— chosen from mono-, di-, and tri-substituted —(C1-C2alkylene)(C═O)— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
G is chosen from
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C3-C7cycloalkyl,
substituted C3-C7cycloalkyl chosen from mono-, di-, and tri-substituted C3-C7cycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl,
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
pyridyl substituted with
hydroxy,
—CHO,
—COOH,
—CONH2,
—CONHOH,
C2-C6 alkenyl,
substituted C2-C6 alkenyl chosen from mono-, di-, and tri-substituted C2-C6 alkenyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C2-C6 alkynyl,
substituted C2-C6 alkynyl chosen from mono-, di-, and tri-substituted C2-C6 alkynyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkyl,
substituted C1-C6hydroxyalkyl chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C1-C6hydroxyalkoxy,
substituted C1-C6hydroxyalkoxy chosen from mono-, di-, and tri-substituted C1-C6hydroxyalkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(mono-C1-C6alkylamino)C1-C6alkoxy,
substituted (mono-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (mono-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(di-C1-C6alkylamino)C1-C6alkoxy,
substituted (di-C1-C6alkylamino)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (di-C1-C6alkylamino)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl,
substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkylamino)C0-C6alkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
(C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy,
substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy chosen from mono-, di-, and tri-substituted (C1-C6alkoxy)(C1-C6alkoxy)C1-C6alkoxy wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl,
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkyl(C═O)OR10,
substituted —C1-C6alkyl(C═O)OR10 chosen from mono-, di-, and tri-substituted —C1-C6alkyl(C═O)OR10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(C═O)NR10R11,
substituted —C0-C6alkyl(C═O)NR10R11 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(C═O)NR10R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C1-C6alkylNR10(SO2)R11,
substituted —C1-C6alkylNR10(SO2)R11 chosen from mono-, di-, and tri-substituted —C1-C6alkylNR10(SO2)R11 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)R11,
substituted —C0-C6alkylNR10(C═O)R11 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)R11, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkyl(SO2)R10,
substituted —C0-C6alkyl(SO2)R10 chosen from mono-, di-, and tri-substituted —C0-C6alkyl(SO2)R10 wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—C0-C6alkylNR10(C═O)NR11R12)
substituted —C0-C6alkylNR10(C═O)NR11R12 chosen from mono-, di-, and tri-substituted —C0-C6alkylNR10(C═O)NR11R12, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
-L-G, where
L is chosen from
C1-C2alkylene,
substituted C1-C2alkylene chosen from mono-, di-, and tri-substituted C1-C2alkylene wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C0-C2alkylene-O—,
substituted C0-C2alkylene-O— chosen from mono-, di-, and tri-substituted C0-C2alkylene-O— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
—(C═O)—,
—(C1-C2alkylene)(C═O)—, and
substituted —(C1-C2alkylene)(C═O)— chosen from mono-, di-, and tri-substituted —(C1-C2alkylene)(C═O)— wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
G is chosen from
heterocycloalkyl,
substituted heterocycloalkyl chosen from mono-, di-, and tri-substituted heterocycloalkyl, wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
C3-C7cycloalkyl,
substituted C3-C7cycloalkyl chosen from mono-, di-, and tri-substituted C3-C7cycloalkyl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
aryl,
substituted aryl chosen from mono-, di-, and tri-substituted aryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl,
heteroaryl,
substituted heteroaryl chosen from mono-, di-, and tri-substituted heteroaryl wherein the substituents are independently selected from halogen, hydroxy, amino, oxo, —COOH, —CONH2, C1-C4alkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, C1-C4alkylthio, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C4alkoxycarbonyl, mono-C1-C4alkylamino, di-C1-C4alkylamino, mono-C1-C4alkylcarboxamide, di-C1-C4alkylcarboxamide, and phenyl, and
wherein R1 is optionally further substituted with 1 or more substituents independently chosen from hydroxy, nitro, cyano, amino, —SO2NH2, halogen, C1-C6 alkyl, C2-C6alkanoyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C6 alkylthio, C3-C7cycloalkyl, (C1-C6 alkoxy)C0-C6alkyl, (mono-C1-C6 alkylamino)C0-C6 alkyl, (di-C1-C6 alkylamino)C0-C6 alkyl, and C1-C6alkoxycarbonyl.
99. A pharmaceutical composition of claim 87, wherein in the compound of formula I,
R2 is chosen from
(phenyl)C0-C2alkyl,
substituted (phenyl)C0-C2alkyl chosen from mono-, di-, and tri-substituted (phenyl)C0-C2alkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is chosen from C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, and heteroaryl,
(phenoxy)C0-C2alkyl,
substituted (phenoxy)C0-C2alkyl chosen from mono-, di-, and tri-substituted (phenoxy)C0-C2alkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is chosen from C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, and heteroaryl,
(pyridyl)C0-C2alkyl, and
substituted (pyridyl)C0-C2alkyl chosen from mono-, di-, and tri-substituted (pyridyl)C0-C2alkyl wherein the substituents are independently chosen from hydroxy, nitro, cyano, amino, halogen, —SO2NH2, oxo, —COOH, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6 alkoxy, C2-C6alkanoyl, C1-C6hydroxyalkyl, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C6 alkylthio, (C1-C6 alkoxy)C1-C6 alkoxy, aminoC1-C6alkyl, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, mono-C1-C6alkylcarboxamide, di-C1-C6alkylcarboxamide, C1-C6alkoxycarbonyl, phenyl, heteroaryl, and —(C═O)R13 wherein R13 is chosen from C1-C6alkyl, (C3-C7cycloalkyl)C0-C2alkyl, C1-C3haloalkyl, heterocycloalkyl, phenyl, and heteroaryl.
100. A pharmaceutical composition of claim 87, wherein in the compound of formula I,
Z1 is chosen from
Figure US20110177011A1-20110721-C00185
and
R4 is chosen from hydrogen, C1-C6alkyl, and C3-C7cycloalkyl.
101. A pharmaceutical composition of claim 87, wherein in the compound of formula I, R3 is chosen from hydrogen and methyl.
US12/018,573 2003-06-04 2008-01-23 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds Abandoned US20110177011A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/018,573 US20110177011A1 (en) 2003-06-04 2008-01-23 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47563403P 2003-06-04 2003-06-04
US51931103P 2003-11-11 2003-11-11
US10/861,791 US7405295B2 (en) 2003-06-04 2004-06-04 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US12/018,573 US20110177011A1 (en) 2003-06-04 2008-01-23 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/861,791 Division US7405295B2 (en) 2003-06-04 2004-06-04 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds

Publications (1)

Publication Number Publication Date
US20110177011A1 true US20110177011A1 (en) 2011-07-21

Family

ID=34138527

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/861,791 Active 2024-12-29 US7405295B2 (en) 2003-06-04 2004-06-04 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US12/018,573 Abandoned US20110177011A1 (en) 2003-06-04 2008-01-23 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/861,791 Active 2024-12-29 US7405295B2 (en) 2003-06-04 2004-06-04 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds

Country Status (2)

Country Link
US (2) US7405295B2 (en)
WO (1) WO2005014599A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041677A1 (en) * 2006-09-22 2010-02-18 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20100101977A1 (en) * 2008-06-05 2010-04-29 United Comb & Novelty Corporation Stackable Packaging For Lipped Containers
US20110224235A1 (en) * 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8754090B2 (en) 2010-06-03 2014-06-17 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (Btk)
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
WO2015083008A1 (en) 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
WO2016024231A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
WO2016024230A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
US9533991B2 (en) 2014-08-01 2017-01-03 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US9540385B2 (en) 2012-11-15 2017-01-10 Pharmacyclics Llc Pyrrolopyrimidine compounds as kinase inhibitors
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US9655857B2 (en) 2015-03-03 2017-05-23 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
WO2017122175A1 (en) 2016-01-13 2017-07-20 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2020150681A1 (en) * 2019-01-18 2020-07-23 Xibin Liao Bruton's tyrosine kinase inhibitors
EP3747472A1 (en) 2015-09-15 2020-12-09 Acerta Pharma B.V. Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022562A1 (en) * 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
WO2004072080A1 (en) * 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
US20060183746A1 (en) * 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
MX2007005643A (en) * 2004-11-10 2008-03-13 Cgi Pharmaceuticals Inc Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity.
JP2008526988A (en) * 2005-01-14 2008-07-24 シージーアイ ファーマシューティカルズ，インコーポレーテッド 1,3-Diaryl-substituted ureas as kinase activity modulators
EP1858877B1 (en) 2005-01-14 2014-03-12 Gilead Connecticut, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
WO2006099075A2 (en) * 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
US7777040B2 (en) * 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
TW200800213A (en) 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
AU2006336506B2 (en) * 2006-01-13 2012-06-28 Pharmacyclics Llc Inhibitors of tyrosine kinases and uses thereof
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
PE20080839A1 (en) * 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc CERTAIN AMIDAS SUBSTITUTED, METHOD OF PREPARATION AND METHOD OF USE OF THE SAME
US20100160292A1 (en) * 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
CA3001152A1 (en) * 2007-03-28 2008-10-09 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CL2008002793A1 (en) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
JP5485178B2 (en) 2008-02-25 2014-05-07 エフ．ホフマン−ラ ロシュ アーゲー Pyrrolopyrazine kinase inhibitor
PE20100851A1 (en) 2008-06-24 2011-01-31 Hoffmann La Roche PYRIDIN-2-ONAS AND PYRIDAZIN-3-ONAS SUBSTITUTED AS Btk INHIBITORS
JP5318952B2 (en) 2008-07-15 2013-10-16 エフ．ホフマン−ラ ロシュ アーゲー Novel phenyl-imidazopyridines and pyridazines
AU2009272838B2 (en) * 2008-07-18 2014-04-10 F. Hoffmann-La Roche Ag Novel phenylimidazopyrazines
US8476430B2 (en) 2008-07-24 2013-07-02 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
SG171991A1 (en) 2008-12-08 2011-07-28 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
CN102307581B (en) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 Imidazopyrazine SYK inhibitors
KR20110098827A (en) 2008-12-19 2011-09-01 브리스톨-마이어스 스큅 컴퍼니 Carbazole carboxamide compounds useful as kinase inhibitors
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
JP5656976B2 (en) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド Pyrrolotriazine compounds
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EA020847B1 (en) 2009-10-30 2015-02-27 Янссен Фармацевтика Нв IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
CA2792769C (en) 2010-03-11 2018-05-22 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
AR082590A1 (en) 2010-08-12 2012-12-19 Hoffmann La Roche INHIBITORS OF THE TIROSINA-QUINASA DE BRUTON
JO3438B1 (en) * 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
JP6115962B2 (en) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ．ベー． 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline derivatives
WO2013010136A2 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
LT2734522T (en) 2011-07-19 2019-02-11 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
EP2751080B1 (en) * 2011-08-31 2015-10-28 Amakem NV Novel soft rock inhibitors
UA111756C2 (en) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг HETEROARYLPYRIDONE AND AZAPIRIDONE COMPOUNDS AS BRUTON TYROSINKINASE INHIBITORS
EP2773639B1 (en) 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylated piperazine compounds as inhibitors of btk activity
CN104203937A (en) 2011-11-03 2014-12-10 霍夫曼-拉罗奇有限公司 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity
BR112014010391A2 (en) 2011-11-03 2017-04-18 Hoffmann La Roche compound, pharmaceutical composition, process of producing a pharmaceutical composition, method of treatment, kit and use of a pharmaceutical composition
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
AU2013208087B2 (en) 2012-01-09 2017-11-23 X-Chem, Inc. Tryptoline derivatives having kinase inhibitory activity and uses thereof
CN104411312B (en) 2012-06-26 2018-03-06 詹森药业有限公司 The combination for being used in treatment neurological or dysbolism use including PDE2 the inhibitor such as methyl of 1 aryl 4 [1,2,4] triazole [4,3 A] quinoxaline compounds and PDE10 inhibitor
RU2667058C2 (en) 2012-07-09 2018-09-14 Янссен Фармацевтика Нв Inhibitors of phosphodiesterase 10 enzyme
NZ706739A (en) 2012-10-15 2018-11-30 Epizyme Inc Substituted benzene compounds
EP2948458B1 (en) * 2013-01-23 2019-05-01 Merck Sharp & Dohme Corp. Btk inhibitors
NZ711540A (en) 2013-04-25 2018-08-31 Beigene Ltd Fused heterocyclic compounds as protein kinase inhibitors
AR096721A1 (en) 2013-06-25 2016-01-27 Bristol Myers Squibb Co TETRAHYDROCARBAZOL AND CARBAZOL CARBOXAMIDA SUBSTITUTED COMPOUNDS
CN105473573B (en) 2013-06-25 2018-03-16 百时美施贵宝公司 Carbazole carboxamide compounds useful as kinase inhibitor
KR101815360B1 (en) 2013-07-03 2018-01-04 에프. 호프만-라 로슈 아게 Heteroaryl pyridone and aza-pyridone amide compounds
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
US9382256B2 (en) 2013-07-30 2016-07-05 Gilead Connecticut, Inc. Formulation of Syk inhibitors
EA029281B1 (en) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. POLYMORPH OF Syk INHIBITORS
EP4130044A1 (en) 2013-09-13 2023-02-08 BeiGene Switzerland GmbH Anti-pd1 antibodies and their use as therapeutics and diagnostics
KR20160062103A (en) 2013-09-30 2016-06-01 파마싸이클릭스 엘엘씨 Inhibitors of bruton's tyrosine kinase
CN111265531B (en) 2013-10-25 2023-11-10 药品循环有限责任公司 Methods for treating and preventing graft versus host disease
JP6298539B2 (en) 2013-12-04 2018-03-20 ギリアード サイエンシーズ， インコーポレイテッド How to treat cancer
EP3077384B1 (en) 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
EP3082811B1 (en) 2013-12-20 2020-01-15 Merck Sharp & Dohme Corp. Btk inhibitors
EP3082809B1 (en) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk inhibitors
TWI662037B (en) 2013-12-23 2019-06-11 美商基利科學股份有限公司 Syk inhibitors
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
TWI726608B (en) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
NZ726365A (en) 2014-07-14 2018-06-29 Gilead Sciences Inc Combinations for treating cancers
EP3209656B1 (en) 2014-10-24 2020-04-01 Bristol-Myers Squibb Company Indole carboxamides compounds useful as kinase inhibitors
MX2017005060A (en) 2014-10-24 2017-07-05 Bristol Myers Squibb Co Tricyclic atropisomer compounds.
PL3209651T3 (en) 2014-10-24 2020-03-31 Bristol-Myers Squibb Company Carbazole derivatives
TW201702218A (en) 2014-12-12 2017-01-16 美國杰克森實驗室 Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
WO2016106628A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106629A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017087777A1 (en) 2015-11-19 2017-05-26 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2018007774A (en) 2015-12-22 2018-11-09 Incyte Corp Heterocyclic compounds as immunomodulators.
KR20200118507A (en) 2016-02-29 2020-10-15 에프. 호프만-라 로슈 아게 Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
ES2906460T3 (en) 2016-05-06 2022-04-18 Incyte Corp Heterocyclic compounds as immunomodulators
TW201808902A (en) 2016-05-26 2018-03-16 美商英塞特公司 Heterocyclic compounds as immunomodulators
IL263825B (en) 2016-06-20 2022-08-01 Incyte Corp Heterocyclic compounds as immunomodulators
AU2017293423B2 (en) 2016-07-05 2023-05-25 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
CN109563099B (en) 2016-08-16 2023-02-03 百济神州有限公司 Crystal form of compound, preparation and application thereof
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
EP3515414B1 (en) 2016-09-19 2022-11-30 MEI Pharma, Inc. Combination therapy
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
ES2899402T3 (en) 2016-12-22 2022-03-11 Incyte Corp Pyridine derivatives as immunomodulators
CA3047986A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN110709702A (en) 2017-03-24 2020-01-17 豪夫迈·罗氏有限公司 Methods of treating autoimmune and inflammatory diseases
JOP20180040A1 (en) 2017-04-20 2019-01-30 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
AU2018290532A1 (en) 2017-06-26 2019-11-21 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
CN109384782A (en) * 2017-08-04 2019-02-26 厦门大学 Substituted five-membered and hexa-member heterocycle class compound, preparation method, pharmaceutical composition and application thereof
CN110997677A (en) 2017-08-12 2020-04-10 百济神州有限公司 Btk inhibitors with improved dual selectivity
KR20220070056A (en) 2017-08-25 2022-05-27 길리애드 사이언시즈, 인코포레이티드 Polymorphs of syk inhibitors
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
RS64055B1 (en) 2018-03-30 2023-04-28 Incyte Corp Heterocyclic compounds as immunomodulators
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP4219492A1 (en) 2018-05-11 2023-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
CN112118845B (en) 2018-05-14 2023-06-13 吉利德科学公司 MCL-1 inhibitors
ES2962674T3 (en) 2018-07-13 2024-03-20 Gilead Sciences Inc PD-1/PD-L1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP2022521413A (en) 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Solid form of condensed pyrazine as a SYK inhibitor
JP2022544189A (en) 2019-08-09 2022-10-17 インサイト・コーポレイション Salts of PD-1/PD-L1 inhibitors
CA3155852A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
JP2023500395A (en) 2019-11-11 2023-01-05 インサイト・コーポレイション Salts and Crystal Forms of PD-1/PD-L1 Inhibitors
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
KR20230117573A (en) 2020-11-06 2023-08-08 인사이트 코포레이션 Methods for preparing PD-1 and PD-L1 inhibitors and salts and crystalline forms thereof
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
AU2022290855A1 (en) 2021-06-11 2023-12-07 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
CN113480543B (en) * 2021-07-07 2022-05-17 无锡市第二人民医院 2,6, 8-polysubstituted imidazo [1,2-a ] pyrazine and synthetic method and application thereof
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028605A (en) * 1986-05-12 1991-07-02 L'universite De Montpellier I 8-alkylaminoimidazo(1,2-a)pyrazines and derivatives, their preparation and their application in therapy
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5658857A (en) * 1993-02-15 1997-08-19 Bayer Aktiengesellschaft Imidazoazines
US5738576A (en) * 1995-07-21 1998-04-14 Nec Corporation Lapping tape with abrasive liquid for forming a convex tip on a workpiece
US20030212073A1 (en) * 2002-04-19 2003-11-13 Currie Kevin S. Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US20040063715A1 (en) * 2002-09-23 2004-04-01 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
US20040067951A1 (en) * 2002-09-09 2004-04-08 Desimone Robert W. 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof
US20040072835A1 (en) * 2002-09-23 2004-04-15 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
US20040220189A1 (en) * 2003-02-20 2004-11-04 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors
US20050009832A1 (en) * 2003-02-20 2005-01-13 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20050054649A1 (en) * 2003-02-10 2005-03-10 Currie Kevin S. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity
US20050085484A1 (en) * 2003-08-11 2005-04-21 Mitchell Scott A. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US20050101604A1 (en) * 2003-06-30 2005-05-12 Currie Kevin S. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds
US20050288295A1 (en) * 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE4337609A1 (en) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Novel pyrazinecarboxamide derivatives, their preparation and their use in medicines
DE4337611A1 (en) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg New benzoylguanidines, their preparation and their use in medicines
FR2711993B1 (en) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Drugs containing 7H-imidazol [1,2-a] pyrazine-8-one derivatives, new compounds and their preparation.
FR2723373B1 (en) 1994-08-02 1996-09-13 Rhone Poulenc Rorer Sa PURIFIED FORM OF STREPTOGRAMINS, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO1996034866A1 (en) 1995-05-01 1996-11-07 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors
SE9704404D0 (en) 1997-11-28 1997-11-28 Astra Ab New compounds
DE19948434A1 (en) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substance library containing bicyclic imidazo-5-amines and / or bicyclic imidazo-3-amines
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (en) 2000-10-13 2002-04-18 Gruenenthal Gmbh Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
US7304336B2 (en) * 2003-02-13 2007-12-04 Massachusetts Institute Of Technology FinFET structure and method to make the same
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028605A (en) * 1986-05-12 1991-07-02 L'universite De Montpellier I 8-alkylaminoimidazo(1,2-a)pyrazines and derivatives, their preparation and their application in therapy
US5658857A (en) * 1993-02-15 1997-08-19 Bayer Aktiengesellschaft Imidazoazines
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5738576A (en) * 1995-07-21 1998-04-14 Nec Corporation Lapping tape with abrasive liquid for forming a convex tip on a workpiece
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
US20030212073A1 (en) * 2002-04-19 2003-11-13 Currie Kevin S. Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US6919340B2 (en) * 2002-04-19 2005-07-19 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US20040067951A1 (en) * 2002-09-09 2004-04-08 Desimone Robert W. 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof
US20040072835A1 (en) * 2002-09-23 2004-04-15 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
US20040063715A1 (en) * 2002-09-23 2004-04-01 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
US6919341B2 (en) * 2002-09-23 2005-07-19 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US20050054649A1 (en) * 2003-02-10 2005-03-10 Currie Kevin S. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity
US20050054648A1 (en) * 2003-02-10 2005-03-10 Mitchell Scott A. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US20040220189A1 (en) * 2003-02-20 2004-11-04 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors
US20050009832A1 (en) * 2003-02-20 2005-01-13 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20050101604A1 (en) * 2003-06-30 2005-05-12 Currie Kevin S. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds
US20050085484A1 (en) * 2003-08-11 2005-04-21 Mitchell Scott A. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US20050288295A1 (en) * 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409911B2 (en) 2006-09-22 2016-08-09 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US9206189B2 (en) 2006-09-22 2015-12-08 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US20100254905A1 (en) * 2006-09-22 2010-10-07 Lee Honigberg Inhibitors of bruton's tyrosine kinase
US9266893B2 (en) 2006-09-22 2016-02-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US9193735B2 (en) 2006-09-22 2015-11-24 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US8476284B2 (en) 2006-09-22 2013-07-02 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8497277B2 (en) 2006-09-22 2013-07-30 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8501751B2 (en) 2006-09-22 2013-08-06 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8552010B2 (en) 2006-09-22 2013-10-08 Pharmacyclics, Inc. Inhibitors of Bruton'S tyrosine kinase
US8563563B2 (en) 2006-09-22 2013-10-22 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8658653B2 (en) 2006-09-22 2014-02-25 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8691546B2 (en) 2006-09-22 2014-04-08 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8697711B2 (en) 2006-09-22 2014-04-15 Pharmacyclics, Inc. Inhibitors of bruton'S tyrosine kinase
US8703780B2 (en) 2006-09-22 2014-04-22 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8735403B2 (en) 2006-09-22 2014-05-27 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8735404B2 (en) 2006-09-22 2014-05-27 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8741908B2 (en) 2006-09-22 2014-06-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8883435B2 (en) 2006-09-22 2014-11-11 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8748439B2 (en) 2006-09-22 2014-06-10 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8754091B2 (en) 2006-09-22 2014-06-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20100041677A1 (en) * 2006-09-22 2010-02-18 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8759516B2 (en) 2006-09-22 2014-06-24 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US20110039868A1 (en) * 2006-09-22 2011-02-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9181257B2 (en) 2006-09-22 2015-11-10 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US8748438B2 (en) 2006-09-22 2014-06-10 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US9133202B2 (en) 2006-09-22 2015-09-15 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8952015B2 (en) 2006-09-22 2015-02-10 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8957079B2 (en) 2006-09-22 2015-02-17 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8975266B2 (en) 2006-09-22 2015-03-10 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US9133201B2 (en) 2006-09-22 2015-09-15 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US9133198B2 (en) 2006-09-22 2015-09-15 Pharmacyclics Llc Inhibitors of bruton'S tyrosine kinase
US9127012B2 (en) 2006-09-22 2015-09-08 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9212185B2 (en) 2006-09-22 2015-12-15 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US9079908B2 (en) 2007-03-28 2015-07-14 Pharmacyclics, Inc. Inhibitors of Bruton'S tyrosine kinase
US9556182B2 (en) 2007-03-28 2017-01-31 Pharmacylics LLC Inhibitors of Bruton's tyrosine kinase
US8940750B2 (en) 2007-03-28 2015-01-27 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9139591B2 (en) 2007-03-28 2015-09-22 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US9181263B2 (en) 2007-03-28 2015-11-10 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US20100101977A1 (en) * 2008-06-05 2010-04-29 United Comb & Novelty Corporation Stackable Packaging For Lipped Containers
US9107924B2 (en) 2008-07-16 2015-08-18 Pharmacyclics, Inc. Inhibitors of Bruton'S tyrosine kinase for the treatment of solid tumors
US9795605B2 (en) 2008-07-16 2017-10-24 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
US20110224235A1 (en) * 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US9278100B2 (en) 2008-07-16 2016-03-08 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8883803B2 (en) 2008-07-16 2014-11-11 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
US9814721B2 (en) 2010-06-03 2017-11-14 Pharmacyclics Llc Use of inhibitors of bruton'S tyrosine kinase (BTK)
US8999999B2 (en) 2010-06-03 2015-04-07 Pharmacyclics, Inc. Use of inhibitors of Bruton's tyrosine kinase (Btk)
US11672803B2 (en) 2010-06-03 2023-06-13 Pharmacyclics Llc Use of inhibitors of Brutons tyrosine kinase (Btk)
US10751342B2 (en) 2010-06-03 2020-08-25 Pharmacyclics Llc Use of inhibitors of Bruton's tyrosine kinase (Btk)
US10653696B2 (en) 2010-06-03 2020-05-19 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (BTK)
US10478439B2 (en) 2010-06-03 2019-11-19 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (Btk)
US10016435B2 (en) 2010-06-03 2018-07-10 Pharmacyclics Llc Use of inhibitors of Bruton's tyrosine kinase (Btk)
US10004746B2 (en) 2010-06-03 2018-06-26 Pharmacyclics Llc Use of inhibitors of Bruton's tyrosine kinase (Btk)
US10004745B2 (en) 2010-06-03 2018-06-26 Pharmacyclics Llc Use of inhibitors of Bruton'S tyrosine kinase (Btk)
US8754090B2 (en) 2010-06-03 2014-06-17 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (Btk)
US9801881B2 (en) 2010-06-03 2017-10-31 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (BTK)
US9125889B2 (en) 2010-06-03 2015-09-08 Pharmacyclics, Inc. Use of inhibitors of Bruton's tyrosine kinase (Btk)
US9801883B2 (en) 2010-06-03 2017-10-31 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (Btk)
US10106548B2 (en) 2012-06-04 2018-10-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10294232B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9540382B2 (en) 2012-06-04 2017-01-10 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10961251B1 (en) 2012-06-04 2021-03-30 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10752634B2 (en) 2012-06-04 2020-08-25 Pharmacyclics Llc Crystalline forms of a brutons tyrosine kinase inhibitor
US10294231B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10266540B2 (en) 2012-06-04 2019-04-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10125140B1 (en) 2012-06-04 2018-11-13 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10065968B2 (en) 2012-06-04 2018-09-04 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US9828383B1 (en) 2012-06-04 2017-11-28 Pharmacyclic s LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9713617B2 (en) 2012-06-04 2017-07-25 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9725455B1 (en) 2012-06-04 2017-08-08 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
US9540385B2 (en) 2012-11-15 2017-01-10 Pharmacyclics Llc Pyrrolopyrimidine compounds as kinase inhibitors
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
US10016434B2 (en) 2013-08-12 2018-07-10 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
US9724349B2 (en) 2013-08-12 2017-08-08 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
WO2015083008A1 (en) 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9533991B2 (en) 2014-08-01 2017-01-03 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
WO2017025814A1 (en) 2014-08-07 2017-02-16 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
US20180028537A1 (en) 2014-08-07 2018-02-01 Pharmacyclics Llc Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
WO2016024230A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
WO2016024231A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
WO2016024228A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
US10828259B2 (en) 2015-03-03 2020-11-10 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US9655857B2 (en) 2015-03-03 2017-05-23 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10213386B2 (en) 2015-03-03 2019-02-26 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10010507B1 (en) 2015-03-03 2018-07-03 Pharmacyclics Llc Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
EP3747472A1 (en) 2015-09-15 2020-12-09 Acerta Pharma B.V. Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
WO2017122175A1 (en) 2016-01-13 2017-07-20 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
WO2020150681A1 (en) * 2019-01-18 2020-07-23 Xibin Liao Bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
US7405295B2 (en) 2008-07-29
US20050090499A1 (en) 2005-04-28
WO2005014599A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
US7405295B2 (en) Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton&#39;s tyrosine kinase by such compounds
US20060183746A1 (en) Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton&#39;s tyrosine kinase by such compounds
US7393848B2 (en) Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton&#39;s tyrosine kinase by such compounds
US7838523B2 (en) Certain substituted amides, method of making, and method of use thereof
US20060178367A1 (en) Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US8426424B2 (en) Certain substituted amides, method of making, and method of use thereof
EP2079726B1 (en) Substituted amides, method of making, and method of use thereof
US20080125417A1 (en) Certain pyrimidines, method of making, and method of use thereof
US7947835B2 (en) Certain substituted amides, method of making, and method of use thereof
US8058446B2 (en) Certain substituted amides, method of making, and method of use thereof
US7884108B2 (en) Certain substituted pyrazinones
US7259164B2 (en) Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US8697699B2 (en) Imidazopyrazine SYK inhibitors
US8318723B2 (en) Pyrazine compounds, their use and methods of preparation
US20100160292A1 (en) Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
WO2010068810A2 (en) Certain substituted amides, method of making, and method of use thereof
WO2010068788A1 (en) Heterocyclic amides as btk inhibitors
US11078182B2 (en) Heteroaromatic compounds as Vanin inhibitors
US20230174481A1 (en) Kinase inhibitors

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION